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Abstract 
The progression of breast cancer is driven by the interplay between cancer cells and 
their microenvironment. The interaction between cancer cells and stromal cells results 
in stromal cells with a cancer-associated phenotype. Examples of this are the cancer-
associated fibroblast (CAF) and the tumour-associated macrophage (TAM), which are 
important players in the tumour microenvironment. CAFs and TAMs play a role in all 
stages of tumour progression, from epithelial-to-mesenchymal transition (EMT) and 
cancer cell proliferation, to metastasis and treatment resistance. 
 
Caveolin-1 (CAV1) is the structural protein of caveolae, 60-80 nm diameter 
invaginations of the cell membrane. Caveolae play a role in clathrin-independent 
endocytosis, cholesterol homeostasis, cellular signalling, and mechanosensing.  
 
The role of CAV1 in breast cancer is a complex one. CAV1 has been described as an 
oncogene, as well as a tumour suppressor in breast cancer cells. The loss of CAV1 
expression in the tumour microenvironment of breast cancer patients has been shown 
to correlate with a reduction in progression-free survival. In addition, CAV1 
expression has been proposed as a marker of CAFs, and the downregulation of CAV1 
in fibroblasts has been shown to promote tumour progression, in vivo. However, 
conflicting with these findings, other studies have indicated that CAV1 expression in 
the tumour microenvironment is associated with cancer progression and that low 
fibroblastic CAV1 levels are suppressive of breast cancer. 
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The mechanisms behind the regulation of CAV1 expression in cancer-associated 
fibroblasts are unclear. This study describes fibroblastic CAV1 expression in a cell 
culture model that includes major cell types in the tumour microenvironment:  
the cancer cell, the fibroblast and the macrophage.  
 
The non-contact co-culture of primary human breast fibroblasts with human breast 
cancer cells did not result in significant changes in fibroblastic CAV1 levels. 
However, the introduction of differentiated monocytes into the co-culture system 
resulted in a decrease of CAV1 expression by fibroblasts.  
 
Similar to the non-contact co-culture system, the contact co-culture of primary human 
breast fibroblasts with breast cancer cells did not result in changes in fibroblastic 
CAV1 expression. Conversely, the contact co-culture of fibroblasts with monocytes 
decreased fibroblastic CAV1 levels. 
 
The reduction of fibroblastic CAV1 levels after non-contact co-culture suggests that 
fibroblastic CAV1 expression is regulated by the secretion of a soluble factor. This 
study measured the levels of several cytokines in the conditioned medium from non-
contact and contact co-cultures of fibroblasts, cancer cells and differentiated and 
undifferentiated monocytes. The secretion profiles of fibroblast and cancer cell co-
cultures were markedly different from the secretion profiles of co-cultures of 
fibroblast with differentiated monocytes. The inclusion of differentiated monocytes in 
the fibroblast and cancer cell co-cultures resulted in the increased secretion of CAF-
associated cytokines. Additionally, co-cultures that contain fibroblasts, cancer cells, 
and differentiated monocytes resulted in the increased secretion of cytokines that are 
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known to drive the polarization of macrophages to a tumour-associated macrophage 
(TAM) phenotype, compared to co-cultures of fibroblasts and differentiated 
monocytes alone. Several cytokines, some of which have been previously implicated 
in the regulation of CAV1 expression, were secreted in increased amounts in co-
cultures with decreased fibroblastic CAV1 levels. The cytokine profiles generated by 
this study provide candidates to be investigated further for their ability to regulate 
CAV1 levels in fibroblasts. 
 
The effect of the decrease of fibroblastic CAV1 levels on their ability to induce EMT 
in breast cancer cells was investigated using fibroblasts transfected with CAV1 
siRNA. The conditioned medium from transfected fibroblasts was used to treat human 
breast cancer cells. The primary human breast fibroblasts proved resistant to CAV1 
knockdown, and a relatively small reduction in CAV1 protein levels was achieved. 
However, this small reduction in fibroblastic CAV1 protein levels resulted in the 
secretion of factors in the culture medium that increased vimentin expression, and 
decreased E-cadherin expression, in human breast cancer cells. 
 
In both the non-contact and contact co-culture systems, high levels of variability in 
CAV1 expression levels between experimental replicates, and between different 
batches of fibroblasts were observed. The variability between experimental replicates 
was reduced by the elimination of foetal bovine serum, a commonly used cell culture 
additive, from the co-culture system. However, the variability in CAV1 levels 
between experimental replicates, and between fibroblast batches, found in this study, 
in addition to the resistance to CAV1 knockdown by siRNA, points to complex 
regulatory mechanisms underlying CAV1 expression. This, together with the 
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conflicting reports in the field about the complex tumour-promoting and tumour-
suppressing roles of CAV1 in the breast cancer microenvironment, underline the 
importance of further investigation of the regulatory mechanisms behind CAV1 
expression in the breast cancer microenvironment. Understanding the regulation of 
CAV1 expression in fibroblasts may provide novel therapeutic targets for the 
treatments of a subset of breast cancer patients. 
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Breast cancer 
Breast cancer is by far the most predominant form of cancer in women, and only 
comes second to lung cancer as the most prevalent cause of cancer deaths globally 
(Ferlay et al., 2015). Data from the World Health Organisation GLOBOCAN project 
shows that, worldwide, 1.67 million cases of breast cancer were diagnosed, and 
522,000 deaths were due to breast cancer, in 2012 (Ferlay et al., 2015).  
 
Classification 
Breast cancer should not be considered a single disease, but rather a collection of 
subtypes, with distinct histopathologies, genetic characteristics, and treatment 
requirements (Goldhirsch et al., 2011; Vargo-Gogola and Rosen, 2007). Different 
subtypes can be classified via a number of methods. Over the recent years, a number 
of multigene arrays, for example, have proposed several very distinct subtypes in the 
literature (Goldhirsch et al., 2011). However, gene expression array information is not 
always obtainable in a clinical setting.  
 
In 2011, a panel of experts, the St Gallen Consensus, has reached general consensus 
on the classification of 4 subtypes of breast cancer, on the basis of oestrogen receptor 
(ER) and progesterone receptor (PR) expression, human epidermal growth factor 
receptor 2 (HER2) expression levels, and Ki-67 labelling index, a marker for cell 
proliferation (Goldhirsch et al., 2011). The subsequent St Gallen conferences, in 2013 
and 2015, have further refined the criteria to identify breast cancer subgroups and 
have provided current insights into the most appropriate treatments for different 
subtypes of breast cancer (Coates et al., 2015; Goldhirsch et al., 2013). The clinical 
distinction between ER-, PR- and HER2-positive breast cancers has been expanded 
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on with the classifications luminal A-like, luminal B-like, HER2-enriched, and basal-
like. These classifications are based on extensive gene profiling of breast cancers, and 
while there is not a perfect overlap with the clinical subtypes, most luminal tumours 
are ER- and PR-positive, HER2-enriched tumours show HER2 overexpression, and 
most basal-like tumours are triple negative (Perou et al., 2000; Tyanova et al., 2016).  
 
Carcinogenesis 
The normal breast is composed of milk glands, surrounded by stroma composed 
mainly of adipose tissue and a framework of fibres called Cooper’s ligaments 
(Ramsay et al., 2005). Milk glands consist of a network of ducts and lobules for the 
production, storage, and secretion of milk during lactation. Breast cancer is neoplastic 
growth, originating most commonly in the epithelia of the milk gland. The milk duct 
and lobule are the most common sites for this initial lesion to occur, ductal carcinoma 
and lobular carcinoma being the most frequent forms of breast cancer diagnosed. 
However, on rare occasions breast tumours originate from the myoepithelial 
compartment (Gudjonsson et al., 2005). 
 
Cancer cells are associated with gene mutations and epigenetic changes that alter the 
intracellular signalling mechanisms of healthy cells, and interrupt homeostasis (Jones 
and Baylin, 2002). In normal tissues, cell numbers are homeostatically controlled by a 
range of cell signals and growth factors. An important feature of cancer cells is their 
ability to escape these homeostatic mechanisms, and sustain chronic proliferation. 
 
 Cancer cells characteristically show sustained proliferation and limited apoptosis, 
leading to tumour growth (Hanahan and Weinberg, 2011). Mechanisms utilized by 
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cancer cells to generate proliferative signalling are the production of their own growth 
factor ligands, the stimulation of cells in tumour-associated stroma to provide growth 
factors, and the elevation of receptor proteins levels (Hanahan and Weinberg, 2011). 
 
The continued and uncontrolled proliferation of cancer cells that have escaped 
homeostatic regulation can lead to the formation of tumours. Tumours, however, are 
more than masses of proliferating cancer cells; they are complex organs, consisting of 
multiple cell types. Like organs, tumours create their own supply of oxygen and 
nutrients by initiating the formation of vasculature, through a process called 
angiogenesis. Populations of cancer cells within the tumour can acquire high motility 
and migrate into the vasculature, spreading to local and distant sites, in a process 
referred to as metastasis (Nguyen and Massague, 2007).  
 
Metastasis 
Although survival rates for breast cancer are slowly improving, the prognosis of 
breast cancer worsens dramatically once the carcinoma becomes invasive (Ferlay et 
al., 2015; Massagué et al., 2017). Common sites of breast cancer metastasis are bone, 
lung, liver, and brain (Nguyen et al., 2009). Although tissues have many mechanisms 
in place that are highly unfavourable to invasion by foreign cell types, some tumours, 
due to their heterogeneity and genetic instability, will generate cell types that are able 
to overcome these challenges (Nguyen and Massague, 2007; Sethi and Kang, 2011). 
In addition, primary tumours secrete factors, such as cytokines, and extracellular 
vesicles, that will affect distant sites before metastasis, creating niches that are 
favourable to secondary tumour growth (Peinado et al., 2017). 
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Epithelial-to-mesenchymal transition  
Epithelial cells are well anchored in the surrounding tissue by the formation of 
intercellular junctions and extracellular matrix (ECM) attachment. The loss of 
epithelial cell characteristics and progression to a more mesenchymal phenotype, in a 
process referred to as epithelial-to-mesenchymal transition (EMT), is a normal part of 
embryogenesis and tissue regeneration (Kalluri and Weinberg, 2009). EMT is a 
reversible process and cells can move back and forth between EMT and 
mesenchymal-epithelial transition (MET) states (Kalluri and Weinberg, 2009). 
 
EMT has been proposed to be associated with the development of metastasis (Peinado 
et al., 2007). Downregulation of E-cadherin, a hallmark of EMT, has been linked to 
invasiveness in a number of studies (Heimann et al., 2000; Oka et al., 1993). 
However, several studies have shown evidence of epithelial morphology in invasive 
or metastatic cancer lesions, as reviewed by Christiansen and Rajasekaran (2006). 
More recent studies have found a close association between cancer stem cells and 
EMT (Liu et al., 2014b; Mani et al., 2008).  
 
Cancer stem cells 
Recently, the importance of a subset of cancer cells, referred to as cancer stem cells, 
has become apparent (Hanahan and Weinberg, 2011). Cancer stem cells are cancer 
cells that can form new tumours, which is the reason they are also referred to as 
tumour initiating cancer cells (Mani et al., 2008). Only a small portion of cells within 
the tumour possess the ability to establish themselves at distant sites and form new 
tumours. Upon in vitro induction of EMT, breast epithelial cells have been found to 
display both characteristics of EMT-like cells, and of breast cancer stem cells (Mani 
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et al., 2008). Additionally, this overlap between EMT and cancer stem cell 
characteristics was found in a cell population isolated from clinical samples of human 
invasive breast carcinoma (Liu et al., 2014b). In addition to this EMT-like cancer 
stem cell population, an epithelial-like cancer stem cell population was found, and the 
authors have proposed that breast cancer stem cells are likely to reversibly transition 
between EMT and MET states (Liu et al., 2014b). As metastasis worsens cancer 
prognosis significantly, a focus on specifically targeting cancer stem cells may 
improve cancer treatment. 
 
Cancer and inflammation 
In recent years, scientists have become increasingly aware of the importance of the 
role of signals from outside the tumour on the progression of cancer. For many years, 
cancer research focussed predominantly on the cancer cell, but for the past two 
decades, more and more attention has been given to the tumour as part of a larger 
system.  
 
Inflammatory mediators in the tumour microenvironment are important players in 
setting the context for cancer cells (Bissell and Hines, 2011; Shalapour and Karin, 
2015). Cancer and inflammation are interconnected, the expression of different 
oncogenes drives inflammation, and inflammation can promote cancer (Mantovani 
and Sica, 2010; Shalapour and Karin, 2015). The increased occurrence of cancer at 
the site of inflammation is well described (Arias et al., 2012; Bromberg and Wang, 
2009). Commonly cited examples to illustrate the link between inflammation and 
cancer include the increased risk of bowel cancer in chronic inflammatory bowel 
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disease patients (Koliaraki et al., 2017), and gastric cancer in patients with 
Helicobacter pylori infection (Lee et al., 2016). 
 
Inflammation is a normal part of wound healing. Interestingly, there are many 
similarities between the composition of tumour stroma and healing wound tissue 
(Bissell and Radisky, 2001; Dvorak, 1986). Both tumour stroma and healing wound 
tissue promote angiogenesis, changes in the ECM, and increased cell motility 
(Kessenbrock et al., 2010). Similar to wound healing, tumour stroma is characterised 
by the induction of myofibroblasts, the upregulation of matrix metalloproteinases 
(MMPs), and the presence of invading immune cells and chemotactic factors, such as 
PDGF and TGF-β (Bissell and Radisky, 2001; Kalluri, 2016).  
 
Inflammation can disrupt the normal interaction between fibroblasts and epithelial 
cells. In the case of prolonged interruption, this can lead to the proliferation of cells. 
Abnormal signalling can cause epithelial cells with an innate tumorigenic potential to 
start to display a carcinogenic phenotype, as well as cause genetic instability, which 
can give rise to a tumorigenic potential (Bissell and Radisky, 2001). An inflammatory 
microenvironment leads to a constant presence of reactive nitrogen and oxygen 
species, cytokines, and chemokines (Hussain and Harris, 2007).  This, in turn, leads to 
the activation of pro-carcinogenic transcription factors, like NF-κB and STAT3 
(Moore et al., 2010). It is no wonder that tumours are often referred to as wounds that 
never heal (Bissell and Hines, 2011; Dvorak, 1986). 
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Tumour microenvironment 
Normal breast tissue is highly organized. Glandular tissue is separated from the 
surrounding connective tissue, or stroma, by the basement membrane. A major cell 
type within the breast stroma is the fibroblast. Fibroblasts maintain the structure of the 
stroma by synthesizing ECM components, like polysaccharides, fibronectin, and 
collagen. Fibroblasts can become activated, for example in wound healing, and 
secrete higher than normal amounts of ECM components. The activated fibroblast is 
also referred to as myofibroblast, characterised by the upregulation of α-smooth 
muscle actin (αSMA) (Orimo et al., 2005). The newly formed matrix, generated by 
myofibroblasts, then serves as a base for tissue regeneration. Other important factors 
in tissue remodelling are MMPs, proteinases that can degrade ECM proteins, such as 
collagen, fibronectin, and laminin. 
 
The strong association between cancer and inflammation suggest that the stroma 
surrounding the tumour is a critical partner in tumour progression. In the initial stages 
of cancer, the primary tumour is generally contained within the epithelia, separated 
from other parts of the tissue by the basement membrane. During cancer progression, 
the stroma around a tumour undergoes changes that resemble the reorganisation of 
tissue that takes place during inflammation (Bissell and Radisky, 2001). This 
changing stroma, also referred to as reactive stroma, contains an increased number of 
fibroblasts, many displaying an activated, or myofibroblast, phenotype, and is 
characterised by large deposits of fibronectin and collagen, and the presence of 
proteases, such as MMPs, and invading immune cells (Coussens and Werb, 2002; 
Kalluri, 2016).  
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Signalling between the tumour and the microenvironment evolves progressively with 
the development toward a more invasive cancer, with the signalling from the tumour 
supporting an altered microenvironment, and signalling from an altered 
microenvironment supporting tumour progression and, possibly, metastasis (Bissell 
and Hines, 2011). 
 
Cancer-associated fibroblasts 
The subset of fibroblasts that is involved in most cancers is termed cancer-associated 
fibroblasts (CAFs). The CAFs found in tumour stroma are a heterogeneous 
population; with a large proportion of CAFs displaying a myofibroblastic phenotype 
(i.e., express αSMA), intermixed with other CAFs that do not express αSMA (Erez et 
al., 2010; Sugimoto et al., 2006). 
 
CAFs play a role in all stages of cancer, including invasion and metastasis (Kalluri, 
2016). Like their non-cancer-associated counterparts, CAFs greatly influence the 
structure of the ECM (Kalluri, 2016). Normal breast tissue shows collagen fibres 
wrapped around the epithelium of mammary glands in a circular fashion, suggesting a 
containing and anchoring function (Provenzano et al., 2008). Thickened collagen 
fibres that lay perpendicular to the tumour, however, are commonly found in 
desmoplastic stroma, and are associated with an increase in ‘stiffness’ of the matrix 
(Malik et al., 2015). The remodelled ECM, displaying increased ‘stiffness’, has been 
used to detect cancer (Butcher et al., 2009), and collagen alignment has been 
proposed as a diagnostic marker for breast cancer (Conklin et al., 2011). Functionally, 
the rearrangement of collagen fibres, to align perpendicular to the tumour, may 
	 21	
enhance cancer cell invasion of the surrounding stroma by providing cancer cells with 
an ECM track (Goetz et al., 2011; Provenzano et al., 2006).  
 
Matrix metalloproteinases 
Other factors in the stroma that play an important role in the remodelling of the ECM 
are MMPs. Both wounding and the presence of tumour cells can trigger increased 
levels of MMPs in the ECM. Expressed by both cancer cells and stromal cells, MMPs 
exert their pro-carcinogenic function by remodelling the ECM to make it more 
favourable to cancer cell invasion (Egeblad and Werb, 2002; Malik et al., 2015; 
Sternlicht and Werb, 2001). Of the family of MMPs, MMP2 and MMP9 are most 
frequently implicated for their role in breast cancer (Merdad et al., 2014; Pellikainen 
et al., 2004; Wiercinska et al., 2011). 
 
The ECM is not merely a structural framework that supports cells and arranges 
tissues, but also provides vital information to cells about their environment. 
Remodelling of the ECM, such as by MMPs, therefore, does not merely result in a 
structural framework that physically favours cancer cell invasion, but also changes 
cell behaviour through a change in the informational content relayed to nearby cells 
(Sternlicht and Werb, 2001).  
 
Tumour-associated macrophages 
Besides the presence of CAFs, the tumour-associated stroma is characterized by 
increased numbers of macrophages. Monocytes continuously patrol the blood and 
lymph system, invading tissues and differentiating into macrophages in response to 
inflammation signals. Macrophages are phagocytic immune cells that play an 
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important role in tissue homeostasis, by clearing apoptotic cells and producing growth 
factors. When stimulated by an antigen, they elicit an immune response through the 
production of inflammatory cytokines (Geissmann et al., 2010). Macrophages can 
express both pro- and anti-tumour activity (Mantovani and Sica, 2010). A subset of 
tumour-associated macrophages (TAMs), referred to as ‘alternatively’ activated (M2) 
macrophages, promotes EMT and metastasis, and is correlated to poor prognosis 
(Chen et al., 2011; Su et al., 2014). 
 
Caveolin-1 and cancer 
Caveolin-1 (CAV1) is the 22-24 kDa structural protein of caveolae, 60-80 nm 
diameter invaginations of the cell membrane. Caveolea where first described in 1953 
(Palade), and named for their resemblance to little caves (cavae) in electron 
microscopy. A more recent study has, however, shown the shape of caveolae to be 
affected by aldehyde-fixation, and suggests the invagination to range from almost flat, 
to most commonly cup-shaped, to rarely omega-shaped, in vivo (Schlormann et al., 
2010). When the expression of CAV1 is lost, e.g., in CAV1 null mice, no caveolae are 
formed (Razani et al., 2001a). See Figure 1 for a transmission electron image of 
caveolae in a primary human breast fibroblast. 
 
Caveolae are abundant in fibroblasts, adipocytes, smooth and striated muscle cells, 
and endothelial cells (Couet et al., 1997). Unlike clathrin-coated pits, caveolae are not 
present on the cell membrane of every cell type with the same abundance, and the 
distribution of caveolae across the cell membrane is uneven, with more caveolae at 
the rear of migrating cells (Martinez-Outschoorn et al., 2015). The number of 
caveolae present on the cell membrane is variable, and influenced by environmental 
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cues. Loss of integrin-mediated attachment to the ECM, for example, results in the 
internalisation of caveolae (del Pozo et al., 2005).  
 
Caveolae are invaginated lipid rafts. Lipid rafts are microdomains of the plasma 
membrane that are more ordered and tightly packed than surrounding membrane 
regions, and are rich in cholesterol, sphingolipids, and membrane proteins (Kirkham 
and Parton, 2005). Caveolae have been shown to be involved in endocytosis, 
cholesterol homeostasis, cellular signalling, and mechanosensing (Bastiani and 
Parton, 2010), and the functions of caveolae are still studied with much interest.  
 
 
Figure 1: Transmission electron microscopy image of Fre85 primary human breast 
fibroblast. The arrows show caveolae at the cell membrane. 
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The caveolin gene family consists of CAV1, CAV2 and CAV3. CAV1 contains 
alternative initiation codons, resulting in the isoforms CAV1α and CAV1β (Scherer et 
al., 1995). CAV1 and CAV2 are co-expressed in several cell types, whereas CAV3 is 
muscle specific. The CAV1 gene is localised to locus D7S522 of human chromosome 
7q31.1, a known tumour suppressor locus (Engelman et al., 1998b). The transcription 
of CAV1 is regulated by multiple transcription factors, including E2F/DP1, Sp1, 
FoxO3a, EGR-1, p53, PPARγ, and promoter shore CpG methylation (Bist et al., 
2000; Dasari et al., 2006; Dasgupta et al., 2015; Rao et al., 2013). CAV1 transcription 
is upregulated in the presence of free cholesterol (Fielding et al., 1999). 
 
Upon translation, CAV1 is targeted to the endoplasmic reticulum by a signal 
recognition particle (Monier et al., 1995). From the ER, CAV1 is transported to the 
Golgi (Ostermeyer et al., 2001). Many cell types show accumulation of CAV1 in the 
Golgi. These pools of CAV1 differ structurally from the protein inserted in the cell 
membrane. Exiting from the Golgi, CAV1 is assembled into an exocytic structure, 
containing high levels of cholesterol and sphingolipids, to be inserted into the 
membrane and form caveolae (Parton and Simons, 2007). The budding of these 
exocytic caveolar-carriers has been shown to be dependent on cholesterol (Bastiani 
and Parton, 2010). 
 
At the plasma membrane, hetero-oligomeric complexes of a group of proteins called 
cavins associate with the newly formed caveolar structures (Hayer et al., 2010). The 
cavin protein family consists of four members; cavin-1 is required for the formation 
of caveolae (Hill et al., 2008), cavin-2 plays a role in cavin-1 localisation to the 
plasma membrane (Breen et al., 2012), cavin-3 localises to caveolae, but is not 
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required for caveolar formation (Liu et al., 2014a), and cavin-4 is a muscle-specific 
component of the caveolar complex (Bastiani et al., 2009). Cavin-1 is ubiquitously 
expressed, and its absence in knock-out animals leads to a complete loss of caveolae 
formation in all tissues (Hill et al., 2008). 
 
CAV1 is phosphorylated by the tyrosine kinase Src at its tyrosine 14 (Y14) residue. 
As CAV1β is composed of residues 32-178, only CAV1α (1-178) can be 
phosphorylated by Src (Li et al., 1996). Other tyrosine kinases capable of 
phosphorylating CAV1 on Y14 are Fyn and c-Abl (Goetz et al., 2008). Serine 
phosphorylation at serine 80 (S80) causes CAV1 to be excreted as a soluble protein 
(Schlegel et al., 2001). Palmitoylation is required for CAV1 oligomerization, but not 
for localisation to caveolae (Dietzen et al., 1995; Goetz et al., 2008).  
 
Caveolae signalling hypothesis 
CAV1 has been implicated as a regulator of several different signalling pathways. It 
has been suggested that CAV1 in caveolae directly binds to a number of different 
signalling molecules, as CAV1 has been shown to immunoprecipitate with several of 
these signalling molecules (Martinez-Outschoorn et al., 2015; Sargiacomo et al., 
1995). However, functional experiments have not confirmed this for many of the 
signalling molecules in question, as reviewed by Parton and Simons (2007).  
 
The CAV1 scaffolding domain, amino acid sequence 80-101 on the N-terminal side, 
has been implicated as the binding site for several signalling molecules (Smart et al., 
1999). Moreover, CAV1-binding motifs have been identified in the active catalytic 
domain of several signalling molecules (Smart et al., 1999).  However, the CAV1 
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scaffolding domain also has membrane-binding activity, possibly causing it to insert 
into the caveolar membrane, and may not even be accessible to those molecules it has 
been proposed to interact with (Collins et al., 2012; Parton and del Pozo, 2013). This 
is supported by the observation that antibodies against the CAV1 scaffolding domain 
do not stain the cell membrane, but do stain the Golgi network (Pol et al., 2005), 
indicating the CAV1 scaffolding domain is hidden once CAV1 takes part in the 
formation of caveolae. This lead Parton and Simons (2007) to speculate that it may be 
the non-caveolar pools of CAV1 that have a functional effect on some of the 
implicated signalling pathways. See Figure 2 for a schematic representation of CAV1 
in caveolae.  
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Figure 2: CAV1 inserted in the cell membrane. CAV1 has a hairpin-like structure spanning 
the cell membrane. CAV1 contains an oligomerization domain and a scaffolding domain. 
Caveolar membrane regions contain increased concentrations of sphingolipids and 
cholesterol. 
 
In addition to the controversy around the functional role of the CAV1 scaffolding 
domain, there is doubt around the functional availability of the CAV1 binding domain 
that has been identified in many putative CAV1-binding proteins. Structural analysis 
of several putative CAV1-interacting proteins showed that the CAV1 binding domain 
is tightly packed within the hydrophobic core of the protein (Collins et al., 2012). 
 
Taken together, the model of caveolae as signalling nodes, where signalling 
molecules are bound, by their CAV1 binding domain to the CAV1 scaffolding 
domain, needs to be reassessed. Alternatively, the widespread effect of the loss of 
CAV1 may indirectly result in aberrant signalling (Parton and del Pozo, 2013). 
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Examples of this include the roles of CAV1 in endocytosis of surface receptors, in 
exocytosis and ubiquitylation pathways, as well as the changes in membrane 
structure, particularly in lipid rafts, that occur when CAV1 levels are altered (Parton 
and del Pozo, 2013).  A recent study by Ariotti et al. (2014) illustrated the relationship 
between caveolae, the composition of the plasma membrane, and Ras signalling. 
Interestingly, the loss of CAV1, the loss of cavin1, and the loss of caveolae, all affect 
plasma membrane organisation and Ras signalling, suggesting a caveolae-dependent, 
rather than a CAV1 dependent effect (Ariotti et al., 2014). 
 
The role of CAV1 in signalling pathways 
A functional interaction has been shown in vitro between CAV1 and a number of 
signalling pathways. Functional effects of CAV1 have been described for the 
MEK1/ERK1/2, PI3K/Akt, nitric oxide synthase, JAK/STAT and WNT/β-catenin 
pathways, as reviewed by Shatz and Liscovitch (2008). It is important to note, 
however, that these signalling pathways are not impaired in cells that naturally lack 
caveolae, nor in CAV1 knock-out cells (Parton and Simons, 2007). 
 
MAPK 
The Raf/mitogen-activated and extracellular signal-regulated kinase kinase 
(MEK)/extracellular signal-regulated kinase (ERK) signalling pathway is commonly 
dysregulated in breast cancer (Saini et al., 2013). As part of the mitogen activated 
protein kinase (MAPK) signalling cascade, activation of the signalling molecules 
MEK and ERK results in the activation of transcription factors that regulate the 
transcription of molecules involved in proliferation, apoptosis, and 
migration/invasion, including growth factors, cytokines, and cyclins.   
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CAV1 is able to inhibit the MEK1/ERK1/2 pathway through direct interaction with 
MEK1 and ERK1/2 (Engelman et al., 1998a). On the other hand, CAV1 has been 
shown to play a role in the activation of this same pathway, by coupling the integrin 
alpha subunit to the tyrosine kinase Fyn, and setting into motion a sequence of events 
that links integrins to the MAPK/ERK pathway (Wary et al., 1998). More recently, 
CAV1 knockdown in Ewing sarcoma cells was shown to decrease MEK1/2 and 
ERK1/2 phosphorylation. Its co-localisation with CAV1 and ability to modulate 
ERK2 activity, suggest that the scaffold protein Ras GTPase-activating-like protein 
(IQGAP1) may provide a link between CAV1 and MEK/ERK (Lagares-Tena et al., 
2016). 
 
PI3K/Akt 
Another signalling pathway that is highly implicated in cancer is the phosphoinositide 
3-kinase (PI3K) and protein kinase B (PKB, also known as Akt) signalling pathway. 
Akt is an important signalling molecule involved in many pathways regulating 
cellular processes, such as apoptosis, protein synthesis, cell motility, and proliferation. 
 
 Similar to its role in the MEK1/Erk1/2 pathway, CAV1 can both inhibit and stimulate 
the PI3K/Akt pathway. In a study using a human prostate cancer cell line, protein 
phosphatases PP1 and PP2A were inhibited by vector-induced CAV1 expression, 
leading to increased levels of activated Akt (Li et al., 2003). In a study using an 
inflammatory breast cancer cell line, downregulation of CAV1 was found to 
inactivate Akt (Joglekar et al., 2015). A study using prostate cancer cells found that 
treatment with the bioactive flavonoid baicalein resulted in reduced proliferation and 
migration, in addition to decreased CAV1 expression and reduced Akt 
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phosphorylation (Guo et al., 2015). Conversely, a study in a cardiomyocyte-derived 
cell line suggests that CAV1 dependent targeting of PP2A to caveolae can lead to 
inhibition of Akt (Zuluaga et al., 2007).  
 
eNOS 
The nitric oxide synthases (NOSs) are a family of enzymes that catalyse the 
production of nitric oxide (NO). NOS overproduction, and the resulting increase in 
reactive oxygen species (ROS), may lead to higher mutation rates, increased cell 
proliferation, and tumour progression (Brown and Bicknell, 2001). Co-expression of 
endothelial nitric oxide synthase (eNOS) with CAV1 in COS-7 cells inhibits the basal 
release of NO, demonstrating a functional effect of CAV1 on the NOS pathway 
(Garcı́a-Cardeña et al., 1997). A mouse study that selectively overexpressed CAV1 in 
endothelial cells lining the tumour blood vessels in vivo, showed decreased NO 
production, decreased tumour microvessel density, and decreased tumour blood flow 
(Brouet et al., 2005). 
 
TGF- β 
Transforming growth factor β (TGF-β)-activated Smad signalling plays a role in a 
wide range of biological functions, including proliferation, differentiation, ECM 
production, and cell death. In fibroblasts, TGF-β induces increased αSMA expression 
and myofibroblast differentiation (Evans et al., 2003; Midgley et al., 2013). Cancer 
cell-derived MMP9 has been shown to activate TGF-β in fibroblasts, and drive 
myofibroblast differentiation (Dayer and Stamenkovic, 2015). CAV1 has been shown 
to inhibit TGF- β/SMAD signalling in NIH-3T3 fibroblasts (Razani et al., 2001b). 
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Activated TGF-β receptors are endocytosed through two distinct pathways: the 
clathrin-coated vesicle pathway, and the caveolar pathway (Di Guglielmo et al., 
2003). Endocytosis of activated TGF-β receptors through clathrin-coated pits leads to 
Smad activation, and transcription of TGF-β-responsive genes, whereas endocytosis 
through caveolae leads to receptor ubiquitylation and degradation (Di Guglielmo et 
al., 2003; Meyer et al., 2013). 
 
JAK/STAT 
The Janus kinase (JAK) and Signal Transducer and Activator of Transcription 
(STAT) signalling pathway is a highly conserved signalling pathway that relays 
signals, usually cytokines, from outside the cell to the nucleus, to activate gene 
transcription. This pathway is the main alternative to the second messenger system.  
 
JAK and Src activation of STAT3 has been shown to contribute to breast cancer cell 
growth and survival in vitro (Garcia et al., 2001). Levels of activated STAT3 are 
increased in CAV1 -/- pulmonary fibroblasts, compared to wild type fibroblasts, after 
PDGF-BB and TGF-β treatments (Ryter et al., 2014). Signals from outside the cell 
that are implicated in activating STAT3 through JAKs in breast cancer cells, include 
EGF (Garcia et al., 2001), and IL-6 (Bromberg and Wang, 2009). In conjunction with 
these findings, EGF has been reported to downregulate the expression of CAV1 in 
human cancer cell lines (Lu et al., 2003). EGF is a strong chemotactic factor and is 
expressed by many tumour types (Goswami et al., 2005). EGF is also produced by 
cells in the tumour microenvironment, such as T cells and macrophages. Interestingly, 
both CAFs (Studebaker et al., 2008), and CAV1-null-mammary fibroblasts (Sotgia et 
al., 2009), have been shown to secrete increased levels of IL-6.  
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Functional analysis of the interaction of STAT3 with the CAV1 promoter, combined 
with evidence of the effect of CAV1 expression on the invasiveness of brain 
metastatic cell lines, suggests that STAT3 influences brain metastasis by binding the 
CAV1 promoter directly, and negatively regulating CAV1 transcription (Chiu et al., 
2011). Conversely, overexpression of CAV1 inhibits STAT3 (Chiu et al., 2011).  
 
This combined evidence suggests that CAV1 expression in breast cancer may be 
regulated through the JAK/STAT3 pathway by growth factors and other cytokines. 
Both the study of CAV1 knockout fibroblasts, and the co-culture of cancer cells and 
fibroblasts, have found an increase in the secretion of numerous growth factors and 
other cytokines (Martinez-Outschoorn et al., 2011; Sotgia et al., 2009). Therefore, 
signalling through the JAK/STAT pathway could both underlie the CAV1 
downregulation, and be a consequence of CAV1 downregulation. However, the 
downregulation of CAV1 through STAT3 has so far only been shown in epithelial 
cells, and not in CAFs. 
 
CAV1 and mitochondrial function 
The observation that subsets of cancer cells produce lactate, even in the presence of 
oxygen, has been well described, and is widely known as the Warburg effect (Vander 
Heiden et al., 2009). However, this does not mean that cancer cells are less dependent 
on oxidative phosphorylation. Mutations in the TCA cycle occasionally occur in some 
cancers, but are interestingly correlated to increased patient survival (Yan et al., 
2009). A study by Bosch et al. (2011) has suggested that a lack of CAV1 leads to 
increased mitochondrial cholesterol, which in turn leads to mitochondrial dysfunction 
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and aerobic glycolysis. Mitochondrial dysfunction causes the accumulation of ROS in 
the cell, ultimately leading to cell death.  
 
In recent years, it has been hypothesized that cancer cells initiate aerobic glycolysis in 
stromal cells leading to oxidative stress in the tumour stroma, which in turn causes 
autophagy of stromal cells, and the release of metabolites, such as lactate, ketones, 
and fatty acids, to be used by cancer cells for oxidative phosphorylation (Martinez-
Outschoorn et al., 2016).  
 
Loss of CAV1 in stromal fibroblasts may result in aerobic glycolysis via 
mitochondrial dysfunction, causing autophagy and the potential transfer of 
metabolites to cancer cells (Sotgia et al., 2011). These energy-rich metabolites are 
transported across the cell membrane via the monocarboxylate transporters (MCT) -1 
and -4. MCT4 has been proposed as a biomarker for identifying high-risk breast 
cancer patients, and the expression of stromal MTC4 is inversely related to the 
expression of stromal CAV1 (Martins et al., 2013; Witkiewicz et al., 2012).  
 
CAV1 and integrin-mediated endocytosis 
Endocytosis through clathrin-coated pits is well characterised, however clathrin-
independent endocytosis, such as through caveolar budding, is less well described. 
Endocytosis, through the budding and internalisation of caveolae, is clathrin-
independent and dynamin dependent. Both caveolae and non-caveolar CAV1 can be 
targeted to early endosomes upon endocytosis, and then recycled back to the plasma 
membrane (Parton and del Pozo, 2013). Alternatively, monoubiquitylation of CAV1 
will result in targeting to multivesicular bodies (endosomes containing luminal 
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vesicles, also referred to as late endosomes) for degradation (Parton and del Pozo, 
2013). The endocytosis of caveolae may play a role in modulating signalling 
pathways by uncoupling signalling intermediates at the lipid raft, in a process 
regulated by integrins (Salanueva et al., 2007). 
 
Integrins provide the physical connection of the cell with the ECM, and modulate 
signalling pathways of membrane receptor kinases. Integrins interact with multiple 
growth regulatory pathways, inhibiting growth when anchorage is lost.  In cancer, on 
the other hand, these growth regulatory pathways become constitutively activated, 
and adhesion through integrins is no longer required for growth (Guadamillas et al., 
2011). Therefore, anchorage-independent growth is strongly related to tumorigenicity 
and metastasis.  
 
A study by del Pozo et al. (2005), carried out in WT and CAV1 -/- cell lines of human 
and murine origin, suggests that caveolar endocytosis plays a role in anchorage-
independent growth through the internalisation of lipid rafts upon cell detachment 
from the ECM. The internalisation of lipid rafts inhibits growth regulatory pathways, 
such as Rac, Erk and Akt signalling pathways (del Pozo et al., 2005). Integrin-
dependent endocytosis of lipid rafts is dependent on the phosphorylation of CAV1 at 
Y14. In the absence of CAV1, internalisation of lipid rafts does not take place, and 
growth regulatory pathways remain activated (del Pozo et al., 2005). Src kinases and 
PKC are known to phosphorylate CAV1 at Y14 and, therefore, are likely to play an 
important part in the regulation of anchorage-independent growth by CAV1. 
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CAV1 and exosomes 
Exosomes are secreted vesicles that can contain cytoplasmic components and genetic 
material (Simons and Raposo, 2009). Exosomes are released from multivesicular 
bodies once fusion with the cell membrane has taken place (Théry et al., 2009). Both 
cancer cells and stromal cells secrete exosomes that promote cancer progression 
(Luga et al., 2012; Peinado et al., 2012). Exosomes play a role in cancer through the 
transfer of signalling molecules and RNAs, and the release of exosomes is 
dramatically increased in cancer (Logozzi et al., 2009). The secretion of exosomes by 
stromal cells has been shown to drive metastasis, and chemotherapy and radiation 
resistance, of breast cancer cells (Boelens et al., 2014; Luga et al., 2012).  
 
A study by Svensson et al. (2013) found that exosomes enter the cell by clathrin-
independent endocytosis, and that exosome uptake is negatively regulated by CAV1. 
Exosomes isolated from plasma from SCID mice engrafted with melanoma tumours 
strongly expressed CAV1, while CAV1 was undetectable in exosomes from control 
animals, and increased amounts of CAV1-positive exosomes were found in the 
plasma from melanoma patients (Logozzi et al., 2009). It is not yet clear how stromal 
CAV1 levels might affect exosome signalling in the tumour microenvironment. 
 
CAV1 expression by breast cancer cells 
The role of CAV1 in breast cancer is a complex one. CAV1 has been described as an 
oncogene, as well as a tumour suppressor, in breast cancer cells. Studies have shown 
CAV1 to be over-expressed by a subtype of breast cancer that is associated with poor 
prognosis (Pinilla et al., 2006). CAV1 expression was strongly associated with a 
basal-like phenotype in the immunohistochemical evaluation of 556 BrCa1/BrCa2 –
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associated carcinomas (Pinilla et al., 2006), and of 245 invasive breast cancers 
(Savage et al., 2007).  
 
Other studies, however, have found CAV1 expression by cancer cells to be associated 
with a less aggressive phenotype. Analysis of CAV1 mRNA and protein expression of 
4 normal mammary epithelial, and 6 breast cancer, cell lines, showed that CAV1 
expression was lower or not detectable in the breast cancer cell lines (Lee et al., 
1998). In addition, the overexpression of CAV1 in human breast cancer cells that 
showed no detectable CAV1 expression before, led to substantial growth inhibition 
(Lee et al., 1998). 
 
Loss of CAV1 in a breast cancer mouse model, using CAV1 -/- mice interbred with 
metastatic mammary tumour-forming MMTV-PyMT mice, resulted in accelerated 
tumorigenesis and metastasis (Williams et al., 2004). PyMT-CAV1 -/- mice lack 
CAV1 expression in both the epithelial and stromal compartment. To determine the 
effect of CAV1 expression in stromal fibroblast versus epithelial cells on tumour 
burden, nude mice were injected with PyMT-transformed CAV1 wild type, and 
CAV1 -/- MEFs, and with mammary adenocarcinoma cells transfected with a CAV1 
construct. It was found that the presence of CAV1 in fibroblasts, as well as the 
presence of CAV1 in cancer cells, reduced the tumour burden (Williams et al., 2004). 
 
A review by Shatz and Liscovitch (2008) on CAV1 levels in several cell lines and 
patient cancers concluded that CAV1 appears to be acting as a tumour suppressor in 
early stages of cancer, but is upregulated in metastatic and multi-drug resistant cell 
lines and patient tumour samples. More recently, CAV1 has been found to be 
	 37	
upregulated in breast cancer cell lines after chemotherapy, and to be enriched in 
breast cancer stem cells (Wang et al., 2014). 
 
Evidence for a protective role of CAV1 in the microenvironment 
The clinical relevance of CAV1 expression in the breast tumour microenvironment 
has been shown by several unrelated studies examining separate patient cohorts. 
CAV1 expression in patient breast tissue biopsies, as determined by 
immunohistochemical analysis, was compared to disease outcome. Loss of CAV1 
expression in the tumour stroma has been found to be strongly associated with 
advanced tumour stage, lymph node metastasis, and reduced progression-free survival 
(El-Gendi et al., 2012; Sloan et al., 2009; Witkiewicz et al., 2009b). Qian et al. (2011) 
confirmed a strong correlation between reduced disease-free survival and a loss of 
CAV1 expression in the tumour stroma, but combined with a high level of CAV1 
expression in the tumour. 
 
A similar study, looking specifically at CAV1 expression in CAFs in tissue biopsies 
from breast cancer patients, also showed a strong link between the loss of CAV1 
expression and the reduction in overall survival and disease-free survival (Simpkins et 
al., 2012), pointing to a key role for fibroblasts. Analysis of CAV1 levels in 
fibroblasts isolated from human breast cancer lesions has shown that CAV1 was 
downregulated in 8 out of 11 samples (Mercier et al., 2008). A study on ER+ DCIS 
patients showed that 7 out of 8 patients that underwent recurrence to invasive breast 
cancer had reduced or absent levels of stromal Cav1, whereas 35 out of 36 ER+ DCIS 
patients with high levels of stromal Cav1 did not show recurrence to invasive breast 
cancer during the time of the study (Witkiewicz et al., 2009a). This combined 
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evidence points to the potential use of CAV1 as an independent predictor of disease 
outcome in breast cancer patients.  Furthermore, the association between CAV1 
expression in the stroma and cancer progression has led to the question of what 
mechanisms might be behind this. 
 
To investigate the effects of cancer cells on CAV1 expression in fibroblasts, human 
fibroblasts were cultured with a human breast cancer cell line (MCF7). This resulted 
in downregulation of CAV1 expression in the fibroblasts, mimicking what occurs in 
the stroma of high-risk breast cancer patients (Martinez-Outschoorn et al., 2010b). 
Interestingly, treatment with an inhibitor of the lysosomal pathway rescued CAV1 
expression, suggesting that downregulation of CAV1 in co-cultures was mediated by 
autophagic/lysosomal degradation. Co-culture of fibroblasts with cancer cells was 
reported to result in the upregulation of myofibroblast markers, such as α-SMA, 
calponin, and vimentin, in the fibroblasts, suggesting a phenotype switch. It is 
important to note however, that no quantitative analysis of these reported changes in 
protein expression after co-culture, including the downregulation of CAV1, was 
provided. 
 
Similar to the effect of co-culture with cancer cells, fibroblasts treated with CAV1 
siRNA upregulated myofibroblast markers (Martinez-Outschoorn et al., 2010b). This 
suggests that the shift to a myofibroblast phenotype after co-culture with cancer cells 
is due to the loss of CAV1 expression, and that the loss of CAV1 expression is not 
merely a marker for the myofibroblast phenotype, but is a driver of it. 
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Like CAFs, CAV1-deficient fibroblasts have been shown to be pro-tumorigenic and 
angiogenic in vivo. Co-injection of CAV-1-deficient fibroblasts with a human breast 
cancer cell line (MDA-MB-231) into nude mice resulted in larger tumours, as 
measured by weight and volume, and an increase in angiogenesis, as measured by 
vessel area and vessel number (Bonuccelli et al., 2010). Additionally, a study of 
CAV1 -/- mice has reported abnormal growth and differentiation of stromal cells 
(Yang et al., 2008). The authors noted that in many organs abnormalities in epithelial 
cell growth and differentiation were also present, while epithelial CAV1 expression 
was normally low or non-detectable. It was therefore hypothesised that the loss of 
CAV1 leads to disruption of normal stromal-epithelial interactions (Yang et al., 
2008). 
 
Furthermore, CAV1 deficient fibroblasts have been shown to increase invasiveness of 
cancer cells and induce EMT in vitro (Simpkins et al., 2012; Sotgia et al., 2009). 
Treatment of cancer cells with conditioned media from monocultures of CAV1 -/- 
murine mammary fibroblasts, or CAV1 siRNA-transfected immortalised human 
breast fibroblasts, resulted in less cohesion, and induced the expression of αSMA and 
downregulation of E-cadherin, markers of EMT (Simpkins et al., 2012; Sotgia et al., 
2009). 
 
Immortalized human skin fibroblasts co-cultured with MCF7 cells have been further 
reported to have increased ROS levels, combined with decreased CAV1 levels, 
compared to monocultures (Martinez-Outschoorn et al., 2010a). In this study, CAV1 
expression in fibroblasts was rescued by treatment with a ROS scavenger, and 
similarly with the anti-oxidant metformin, whereas treatment with the pro-oxidant 
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buthionine sulfoximine (BSO) downregulated CAV1 expression, and induced DNA 
damage (Martinez-Outschoorn et al., 2010a). Furthermore, treatment with CAV1 
siRNA induced DNA damage, mitochondrial dysfunction, and a glycolytic switch in 
fibroblasts. 
 
Proteomic and transcriptional analysis of CAV-1-deficient fibroblasts has been 
reported to show an upregulation of the expression of glycolytic enzymes (Bonuccelli 
et al., 2010). CAV1 is an inhibitor of NOS (Garcı́a-Cardeña et al., 1997). NO 
overproduction can lead to DNA damage, mitochondrial dysfunction, and an increase 
in ROS levels. Together, this points toward the induction of oxidative stress in 
fibroblasts by the presence of cancer cells, with CAV1 acting as an important marker 
and potential regulator. Again, only immunofluorescence was used to detect changes 
in protein expression levels after co-culture with cancer cells, as in the experimental 
findings described above. Even though there is strong evidence of oxidative stress in 
fibroblasts that have lost CAV1 expression (Bonuccelli et al., 2010; Martinez-
Outschoorn et al., 2010a; Pavlides et al., 2010), and the role of CAV1 as a NOS 
inhibitor (Garcı́a-Cardeña et al., 1997), more research is required to determine what 
triggers the cycle of CAV1 downregulation and oxidative stress in fibroblasts. 
 
Evidence for a pro-carcinogenic role of CAV1 in the microenvironment 
In an apparent contradiction to the finding that a downregulation of CAV1 in the 
tumour stroma is strongly correlated to reduced survival, research by Goetz et al. 
(2011) suggests that the presence of CAV1-expressing fibroblasts in the stroma leads 
to a more invasive cancer cell. An analysis of 132 breast tumours and 35 normal 
breast tissues showed an increased expression of CAV1 in CAFs, and further analysis 
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indicated that CAV1 expression in CAFs is associated with an increased mortality 
risk for patients (Goetz et al., 2011). This is a finding that seems to directly contradict 
the inverse relationship between CAV1 and patient survival found by other studies 
(El-Gendi et al., 2012; Qian et al., 2011; Simpkins et al., 2012; Sloan et al., 2009; 
Witkiewicz et al., 2009b). It is important to note that most of these studies, with the 
exception of Simpkins et al. (2012), did not link CAV1 expression to a positive CAF 
marker, and, with the exception of El-Gendi et al. (2012) did not correlate stromal 
CAV1 with metastasis. 
 
To elucidate the effects of endogenous CAV1 on fibroblasts, wild type and CAV1 -/- 
mouse embryonic fibroblasts (MEFs) were grown in a cell-free 3D matrix generated 
by 6-8 day confluent cultures of fibroblasts. In addition, MEFs were grown in 
matrices generated by wild type and CAV1 -/- MEFs, to elucidate the effect of an 
ECM generated by CAV1 -/- fibroblasts on wild type and CAV1 -/- fibroblasts. Goetz 
et al. described the effect of endogenous CAV1, and a CAV1 -/- MEFs-generated 
microenvironment on cell shape, cell contractility, and matrix organization. Their 
results show that both CAV1 -/- MEFs, and MEFs seeded in matrices produced by 
CAV1 -/- MEFs, display decreased cell elongation and lower cell contractility.  
 
A decrease in cell contractility is consistent with the role of CAV1 in Rho mediated 
contractility (Grande-Garcia et al., 2007). CAV1 promotes actomyosin contraction 
through the sequestration of the endogenous Rho inhibitor p190RHOGAP outside 
lipid rafts (Goetz et al., 2011). In the absence of CAV1, p190RHOGAP associates 
with the lipid raft and inhibits Rho-mediated actomyosin contraction. Actomyosin 
contraction results in ECM-remodelling by integrins (Goetz et al., 2011; Parton and 
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del Pozo, 2013). 
 
Compared to CAV1 -/- MEFs, WT MEFs further generated a more parallel 
orientation of fibronectin fibres in the matrix. The reorganisation of the tumour 
stroma by CAFs is a normal process during the progression of cancer (Kalluri and 
Zeisberg, 2006). Matrices generated by CAFs have been reported to be rich in 
fibronectin and collagen (Amatangelo et al., 2005), and collagen fibre deposition 
perpendicular to the tumour has been linked to tumour cell invasiveness (Provenzano 
et al., 2008). Highly aligned and thickened collagen fibres result in increased matrix 
‘stiffness’, which is a feature of a desmoplastic stroma (Malik et al., 2015). 
 
Consistent with their hypothesis that CAV1 is required for a highly ordered and pro-
carcinogenic matrix, Goetz et al. (2011) found that wild type MEFs promoted tumour 
cell invasion and metastasis. Tumours generated in CAV1 -/- mammary glands 
displayed less stromal fibre alignment, compared to those generated in wild type 
mammary glands, and the transplantation of ‘wild type’ tumours into nude mice 
resulted in more metastases (Goetz et al., 2011). 
 
It is important to note that MEFs are an embryonic cell type, and potentially elicit a 
different response, compared to adult mammary fibroblasts. However, in accordance 
with a pro-tumorigenic role of CAV1, others have found that the injection of 
melanoma cells into CAV1 -/- mice led to reduced tumour growth and diminished 
angiogenesis, compared to WT mice (Chang et al., 2009). Additionally, in line with 
the findings by Sloan et al. in the breast cancer stroma, high CAV1-expression in the 
stroma of malignant pleural mesothelioma is associated with worse patient outcome 
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(Righi et al., 2014). 
 
CAV1 clearly is of significance in breast cancer, and several studies point to a 
potential use of CAV1 expression levels in the tumour stroma as a predictor for 
clinical outcome, and as such may be useful in determining treatment strategies (El-
Gendi et al., 2012; Qian et al., 2011; Simpkins et al., 2012; Sloan et al., 2009; 
Witkiewicz et al., 2009b). Furthermore, evidence from studies on CAV1 KO/KD 
systems in vitro (Goetz et al., 2011; Martinez-Outschoorn et al., 2010a; Martinez-
Outschoorn et al., 2010c; Simpkins et al., 2012; Sotgia et al., 2009), and in vivo 
(Bonuccelli et al., 2010; Goetz et al., 2011), suggests that CAV1 is not merely a 
marker of a progressive tumour stroma, but plays an active role in the mechanism(s) 
that favour tumour cell invasiveness and metastasis.  
 
The exact nature of these mechanisms is still largely unclear. There is mounting 
evidence of the association of CAV1 with oxidative stress, hypoxia, and autophagy in 
fibroblasts (Sotgia et al., 2011). It has been hypothesized that cancer cells utilize the 
increased autophagy/mitophagy in the tumour stroma through a form of metabolic 
coupling, whereby the stroma cells undergo aerobic glycolysis, and secrete high 
energy metabolites, directly feeding adjacent cancer cells (Sotgia et al., 2011).  
 
The role of CAV1 in the remodelling of the ECM (Goetz et al., 2011), and the effect 
of changes in the ECM on tumour cell invasiveness (Provenzano et al., 2008), is 
another mechanism that can potentially explain how a change in CAV1 levels in the 
stroma affects tumour progression and metastasis. Additionally, the observation that a 
range of cytokines are differentially secreted between fibroblasts isolated from CAV1 
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-/- mice, and WT fibroblasts (Sotgia et al., 2009) opens up a multitude of additional 
regulatory mechanisms that may play a role in the interplay between cancer cells and 
their microenvironment. 
 
The functions of CAV1 in the cell appear to be diverse. Caveolae have been shown to 
be involved in endocytosis, cholesterol homeostasis, cellular signalling and 
mechanosensing (Bastiani and Parton, 2010) and a role in cancer may be associated 
with each of these functions. Moreover, CAV1 outside of caveolae may have different 
functions to CAV1 associated with caveolae. Therefore, the role of CAV1 in cancer is 
a complex one, potentially involving multiple mechanisms related to different roles of 
CAV1 in the cell. The aim of the research described in this thesis was to investigate 
the effect of interactions between fibroblasts, breast cancer cells, and (differentiated) 
monocytes on fibroblastic CAV1 levels using a co-culture system, as well as to 
investigate the effect of loss of fibroblastic CAV1 on breast cancer cell EMT in vitro. 
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Chapter 2: Materials and methods 
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Isolation of primary murine fibroblasts 
Primary murine fibroblasts were harvested from the mammary fat pads of female 
BALB/c mice, aged 5-15 weeks. Procedures were performed in accordance with 
Deakin University animal ethics approval number AEX03-2013. For each batch of 
fibroblasts, a single mouse was euthanized with isoflurane (MilliporeSigma, 
Darmstadt, Germany), and the 2 inguinal fat pads were separated from the peritoneal 
wall and skin.  The mammary fat pads were minced in 1 mL phosphate-buffered 
saline (PBS) (Amresco, Solon, OH, USA) with 2% (v/v) foetal bovine serum (FBS) 
(Bovogen Biologicals, East Keilor, VIC, Australia), and penicillin (100 units/mL) 
(Thermo Fisher Scientific, Waltham, MA, USA) and streptomycin (100 units/mL) 
(Thermo Fisher Scientific, Waltham, MA, USA). The tissue was digested with 5 mL 
Dulbecco's Modified Eagle Medium/F-12 (DMEM/F12, Thermo Fisher Scientific, 
Waltham, MA, USA) with collagenase I (3 mg/mL) (MilliporeSigma, Darmstadt, 
Germany) and dispase (4 mg/mL) (Thermo Fisher Scientific, Waltham, MA, USA), at 
37 oC for 1 hour, with agitation. The digested tissue was centrifuged for 5 minutes at 
300xg. The pellet was resuspended in DMEM/F12 with penicillin (100 units/mL) and 
streptomycin (100 units/mL). The cell suspension was centrifuged twice for the 
duration required for the centrifuge to reach 400xg, and the pellet was resuspended in 
10 mL DMEM/F12 with penicillin (100 units/mL) and streptomycin (100 units/mL) 
each time; fibroblast fractions were isolated by collecting the supernatant after each 
centrifugation. Fibroblast fractions were combined, and centrifuged at 300xg for 5 
minutes. The pellet was resuspended in 15 mL DMEM/F12 with 10% (v/v) FBS, 
penicillin (100 units/mL), streptomycin (100 units/mL), insulin (0.2 units/mL) (Eli 
Lilly Australia), and basic fibroblast growth factor (FGF2) (1 ng/mL) (Thermo Fisher 
Scientific, Waltham, MA, USA), and transferred to a culture flask. Murine fibroblasts 
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were cultured at 37oC with 5% CO2 and 5% O2 for at least one week prior to use in 
experiments.   
 
Cell culture 
67RN, 168FARN, 66CL4 and 4T1.2 murine cancer cells were a kind gift from Dr 
Robin Anderson, and were cultured in α-MEM (Thermo Fisher Scientific, Waltham, 
MA, USA) with 5% foetal bovine serum (FBS) (Bovogen Biologicals, East Keilor, 
VIC, Australia). hTERT-BJ immortalized human skin fibroblasts were a kind gift 
from Dr Robin Anderson, and were cultured in DMEM/199 (4:1) (Thermo Fisher 
Scientific, Waltham, MA, USA) with 10% FBS.  PMC42-LA human breast cancer 
cells were cultured in Roswell Park Memorial Institute (RPMI) medium (Thermo 
Fisher Scientific, Waltham, MA, USA) with 10% FBS. MCF7 and MDA-MB-231 
human breast cancer cells were cultured in DMEM (Thermo Fisher Scientific, 
Waltham, MA, USA) with 10% FBS. Fre85 primary human breast fibroblasts were a 
kind gift from Dr Lily Huschtscha, and were cultured in DMEM with 10% FBS. 
THP-1 human leukemic monocytes were a kind gift from Dr Robin Anderson, and 
cultured in RPMI with 10% FBS. All cells were cultured at 37oC with 5% CO2, in a 
humidified incubator. For subculturing, cell lines were detached by incubation with 
0.05% trypsin/EDTA (Thermo Fisher Scientific, Waltham, MA, USA). 
 
Macrophage differentiation 
THP-1 cells, at a cell concentration of 0.5-1x106 cells/mL, were treated with 100 nM 
phorbol 12-myristate 13-acetate (MilliporeSigma, Darmstadt, Germany) (200 µM 
stock in dimethyl sulfoxide (DMSO, MilliporeSigma, Darmstadt, Germany)) in RPMI 
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(Thermo Fisher Scientific, Waltham, MA, USA) for 18-24 hours. Carrier-treated 
THP-1 cells were used as a control in experiments. 
 
Co-cultures 
For non-contact co-culture, 6x105 fibroblasts were seeded on a 24 mm diameter, 0.4 
µm pore, polyester Transwell permeable support (Corning Life Sciences, Corning, 
NY, USA), while 3x105 breast cancer cells and/or monocytes were seeded on the 
bottom of the 9 mm2 well of a 6-well plate, with 4 mL of culture medium with 10% 
(v/v) foetal bovine serum (FBS) (Bovogen Biologicals, East Keilor, VIC, Australia). 
See Figure 1. The cells were incubated for 3 days at 37oC, with 5% CO2.  
 
 
Figure 1: A schematic overview of non-contact co-culture of fibroblasts with cancer cells 
and (differentiated) monocytes. Transwell permeable supports were inserted into the 9 mm2 
well of a 6-well plate. (A) For the monoculture control fibroblasts were seeded on the 
Transwell permeable support. (B) For the non-contact co-culture fibroblasts were seeded on 
the Transwell permeable support and cancer cells and (differentiated) monocytes were seeded 
in the bottom of the well. 
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For mixed-non-contact co-cultures, 6x105 fibroblasts were seeded on a 24 mm 
diameter, 0.4 µm pore, polyester Transwell permeable support, while 6x105 
fibroblasts were seeded in the bottom of the 9 mm2 well of a 6-well plate, with 3x105 
breast cancer cells and/or monocytes. Four mL of culture medium with 10% (v/v) 
FBS was added to the well. The cells were incubated for 3 days at 37oC, with 5% 
CO2.  
 
For non-contact co-culture with minimum separation between fibroblasts and cancer 
cells/monocytes, 6x105 breast cancer cells were seeded on an inverted, 24 mm 
diameter, 0.4 µm pore, polyester Transwell permeable support, sitting in a petri dish 
containing culture medium. After overnight incubation at 37oC, with 5% CO2, the 
Transwell permeable support was placed into the well of a 6-well plate, and 6x105 
fibroblast were seeded on the Transwell permeable support, on the side opposite to 
the breast cancer cells. Cells were incubated for 3 days at 37oC, with 5% CO2. 
 
For contact co-cultures, fibroblasts and cancer cells/monocytes were seeded together 
at 2:1 or 6:1 fibroblast to cancer cell and/or monocyte ratios. The total number of cells 
seeded was 6x105 cells per 9 mm2 well of a 6-well plate. The cells were incubated at 
37oC, with 5% CO2, for 5 days. 
 
For experiments in serum replacement medium, the cells were washed twice with 
phosphate-buffered saline (PBS) (Amresco, Solon, OH, USA), 18-24 hours after the 
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cells were seeded, and 4 mL of medium containing Serum Replacement 1 
(MilliporeSigma, Darmstadt, Germany) was added. 
 
Serum starvation 
Fre85 cells were grown under normal conditions, in DMEM/F12 (Thermo Fisher 
Scientific, Waltham, MA, USA) with 10% foetal bovine serum (FBS) (Bovogen 
Biologicals, East Keilor, VIC, Australia). Cells were harvested with 0.05% trypsin-
EDTA (Thermo Fisher Scientific, Waltham, MA, USA), and seeded at 6x105 cells per 
9 cm2 well in DMEM/F12 with 10% FBS. After 18-24 hours, cultures were washed 
twice with phosphate-buffered saline (PBS) (Amresco, Solon, OH, USA), and 
cultured in DMEM/F12 with 0.2% FBS for 24 hours. 
 
Heat-inactivation of serum 
Fetal bovine serum (FBS) (Bovogen Biologicals, East Keilor, VIC, Australia) was 
incubated at 56oC, for 30 minutes, with gentle mixing every 5 minutes. Aliquots of 
heat-inactivated serum were stored at -20oC until use. 
 
Western analysis 
Cells in experimental and control wells were washed twice with phosphate-buffered 
saline (PBS) (Amresco, Solon, OH, USA), and lysed in a buffer containing 10 mM 
Tris, pH 7.5 (Biochemicals, Gymea, NSW, Australia) and 1% (w/v) sodium dodecyl 
sulfate (SDS) (Amresco, Solon, OH, USA), using 150 µL per 9 cm2 well. After the 
addition of complete mini protease inhibitor cocktail (Roche, Mannheim, Germany), 
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as per manufacturer instructions, the lysates were passed through a 20G needle five 
times, and sonicated for 30 seconds on a Microson XL ultrasonic cell disruptor 
(Misonix, Farmingdale, NY, USA), at 12.5% of maximum output power. Protein 
concentrations were determined by the Pierce bicinchoninic acid (BCA) assay 
(Thermo Fisher Scientific, Waltham, MA, USA), as per manufacturer instructions. 
 
Proteins were heat-denatured at 95oC, for 5 minutes, in sample loading buffer 
containing 17 mM Tris, pH 6.8; 0.4% (w/v) SDS, 3% (v/v) glycerol (Ajax Finechem, 
Taren Point, NSW, Australia), 0.17 mg/mL bromophenol blue (MilliporeSigma, 
Darmstadt, Germany), and 0.1M β-mercaptoethanol (MilliporeSigma, Darmstadt, 
Germany). Proteins were separated on a 12% SDS-polyacrylamide gel, and 
transferred to a 0.45-µm pore-size nitrocellulose membrane (Bio-Rad, Hercules, CA, 
USA). Membranes were blocked with 5% (w/v) skim milk powder in Tris-buffered 
saline (50 mM Tris, pH 7.6; 150 mM NaCl (MilliporeSigma, Darmstadt, Germany)) 
(TBS), for 1 hour at room temperature. The membranes were incubated with the 
appropriate primary antibody, diluted in TBS, overnight, at 4oC. Following four 10-
minute washes with TBS, the membranes were incubated with the appropriate HRP-
conjugated secondary antibody, diluted in TBS, for 1 hour at room temperature. 
Following four 10-minute washes with TBS, the membranes were incubated with 
HRP chemiluminescent substrate (MilliporeSigma, Darmstadt, Germany), and imaged 
on a ChemiDoc MP imaging system (Bio-Rad, Hercules, CA, USA).  
 
For re-probing, membranes were stripped with ReBlot Plus Strong (MilliporeSigma, 
Darmstadt, Germany), for 5 minutes, at room temperature. Following blocking with 
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5% (w/v) skim milk powder in TBS, for 15 minutes, at room temperature, the 
membranes were incubated with the appropriate primary antibody, diluted in TBS, for 
1 hour, at room temperature. Following four 10-minute washes in TBS, the 
membranes were incubated with the appropriate HRP-conjugated secondary antibody, 
diluted in TBS, for 30 minutes, at room temperature. 
 
Antibodies 
See Table 1 for antibodies used in Western analysis, immunofluorescence and flow 
cytometry. 
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Table 1: Antibodies used in Western analysis, immunofluorescence and flow cytometry. 
The manufacturer details, and dilutions used for experiments, are shown. 
Antibody Manufacturer Catalog
ue 
number 
Dilution in 
Western 
analysis 
Dilution in 
immuno-
fluorescence 
Dilution in 
flow 
cytometry 
Rb-α-
caveolin-1 
Becton Dickinson and 
Company, Franklin 
Lakes, NJ, USA 
610060 1:10,000 1:1,000  
Ms-α-CD24-
PE 
Becton Dickinson and 
Company, Franklin 
Lakes, NJ, USA 
555428   1:10 
Ms-α-CD44-
FITC 
Becton Dickinson and 
Company, Franklin 
Lakes, NJ, USA 
555478   1:10 
Ms-α-β-actin MilliporeSigma, 
Darmstadt, Germany 
A5441 1:5,000   
Ms-α-
vimentin 
Thermo Fisher 
Scientific, Waltham, 
MA, USA  
180052 1:2,000   
Ms-α-E-
cadherin 
Thermo Fisher 
Scientific, Waltham, 
MA, USA 
180223 1:200   
Ms-α-
cytokeratin 8 
Abcam, Cambridge, 
UK 
ab85823  1:500  
Gt-α-Rb-
HRP 
MilliporeSigma, 
Darmstadt, Germany 
AP307P 1:4,000   
Gt-α-Ms-
HRP 
MilliporeSigma, 
Darmstadt, Germany 
AP501P 1:4,000   
Dk-α-Rb-
Alexa Fluor 
488 
Thermo Fisher 
Scientific, Waltham, 
MA, USA  
A-
21206 
 1:2,000  
Dk-α-Ms-
Alexa Fluor 
594 
Thermo Fisher 
Scientific, Waltham, 
MA, USA  
A-
21203 
 1:2,000  
Rb-α-smooth 
muscle actin 
Abcam, Cambridge, 
UK  
ab5694 1:500   
Rb-α-
calnexin 
Santa Cruz 
Biotechnology, Dallas, 
TX, USA 
Sc-
11397 
1:500   
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Quantitative polymerase chain reaction 
Total RNA was extracted from cell pellets using the RNeasy mini kit (Qiagen, Hilden, 
Germany), following the manufacturer’s instructions. Synthesis of cDNA was 
performed using the High Capacity cDNA Reverse Transcription Kit (Thermo Fisher 
Scientific, Waltham, MA, USA). Real-time PCR (qPCR) was performed with Power 
SYBR Green master mix (Thermo Fisher Scientific, Waltham, MA, USA), 1 µM 
forward and reverse primers, and 20 ng cDNA. The sequences of the primers that 
were used for qPCR are described in Table 2. The program used was 10 minutes at 
95oC, then 40 cycles of 15 seconds at 95oC and 1 minute at 60oC. A melting curve 
was included in each run (65-95oC, 0.5oC/cycle, 5 seconds). The qPCR was 
performed on a C1000 Touch thermal cycler (Bio-Rad, Hercules, CA, USA), and data 
was analysed using CFX manager software (Bio-Rad, Hercules, CA, USA).  
 
Table 2: Forward and reverse primers used in qPCR. The primer sequences for the genes 
targeted in qPCR are shown. 
Target Forward primer Reverse primer 
Mouse CAV1 5’ 
GACCCCAAGCATCTCAACGA 
3’ 
5’ 
GTTCTGCAATCACATCTTCAAAG 
3’ 
Human CAV1 5’ 
ACCTCAACGATGACGTGGTCA 
3’ 
5’ 
ACAGTGAAGGTGGTGAAGCTGG 
3’ 
β-actin 5’ 
CACCATTGGCAATGAGCGGTT 
3’ 
5’ AGGTCTTTGCGGATGTCCAGG 
3’ 
GAPDH 5’ 
GCGAGATCCCTCCAAAATCAA 
3’ 
5’ ATGGTTCACACCCATGACGA 
3’ 
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Confocal microscopy 
Fibroblasts (hTERT-BJ or Fre85), breast cancer cells (MCF7 or MDA-MB-231) 
and/or monocytes/macrophages (undifferentiated or differentiated THP-1) were 
grown on 12 mm diameter coverslips in 2 cm2 wells (1x105 cells per well), or 
Transwell permeable supports (Corning Life Sciences, Corning, NY, USA), in 9 cm2 
wells (6x105 cell per well), for 3 to 5 days, and washed twice with phosphate-buffered 
saline (PBS) (Amresco, Solon, OH, USA). Cells were fixed in 4% (w/v) 
paraformaldehyde (MilliporeSigma, Darmstadt, Germany) in PBS, for 10 minutes, at 
room temperature. After fixing, coverslips and permeable supports were washed twice 
with PBS, and stored in 0.05% (w/v) sodium azide (MilliporeSigma, Darmstadt, 
Germany) in PBS, at 4oC, until staining. 
 
Cells were permeabilized with 0.1% (v/v) Triton X-100 (MilliporeSigma, Darmstadt, 
Germany) in PBS, for 5 minutes, and blocked in 1% (w/v) bovine serum albumin 
(BSA) (MilliporeSigma, Darmstadt, Germany) in PBS, for 10 minutes, both at room 
temperature. Then the cells were incubated with the primary antibody diluted in 1% 
(w/v) BSA in PBS, overnight, at 4oC (see Table 1 for antibodies and dilutions). Cells 
were subsequently incubated with the appropriate Alexa Fluor-conjugated secondary 
antibody, for 2 hours, and with 1 µM TOPRO-3 nuclear stain (Thermo Fisher 
Scientific, Waltham, MA, USA), for 20 minutes, both at room temperature.  
 
The cells were imaged on a Leica TCS SP2 AOBS laser scanning confocal 
microscope. Using ImageJ, an outline was drawn around the fibroblasts. The 
perimeter around the cell, the area, and the mean fluorescence were calculated, for the 
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selected cells and adjacent areas of background. The corrected total cell fluorescence 
(CTCF) was calculated. CTCF= integrated density – (area of selected cell × mean 
fluorescence of background readings), as described by McCloy et al. (2014).  
 
Transfections 
Fre85 cells were harvested with 0.05% (w/v) trypsin-EDTA (Thermo Fisher 
Scientific, Waltham, MA, USA), and kept in a 37oC water bath until they were ready 
to be transfected.  
 
RNAiMAX: 
Transfection constructs were prepared in 500 µl Opti-MEM (Thermo Fisher 
Scientific, Waltham, MA, USA), by adding 30 pmol (lamin and non-targeting) or 75 
pmol (CAV1) siRNA, and 5 µl Lipofectamine RNAiMAX (Thermo Fisher Scientific, 
Waltham, MA, USA), and incubated for 10 minutes, at room temperature (see Table 3 
for siRNAs used). A total number of 2.5x105 cells were seeded in 9 cm2 wells, with 
500 µl transfection construct, and 2.5 mL RPMI (Thermo Fisher Scientific, Waltham, 
MA, USA).  
 
siPORT: 
siPORT transfection reagent (5 µl) (Thermo Fisher Scientific, Waltham, MA, USA) 
was diluted in Opti-MEM (100 µl). siRNA was diluted, by adding 30 pmol (lamin and 
non-targeting) or 75 pmol (CAV1) siRNA, to 100 µl Opti-MEM. Diluted transfection 
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reagent was combined with diluted siRNA, and incubated for 10 minutes, at room 
temperature (see Table 3 for siRNAs used). A total number of 2.0x105 cells were 
seeded in 9 cm2 wells, with 200 µl transfection construct, and 2.5 mL RPMI. 
 
After 4-6 hours the cells were washed twice with phosphate-buffered saline (PBS) 
(Amresco, Solon, OH, USA), and the medium was changed to 4 mL DMEM (Thermo 
Fisher Scientific, Waltham, MA, USA) with Serum Replacement 1 (MilliporeSigma, 
Darmstadt, Germany). 
 
Table 3: siRNAs used in transfection. The manufacturer information for the siRNAs 
used in experiments is shown. 
Target Catalogue number Manufacturer 
CAV1 sc-29241 Santa Cruz Biotechnology, 
Dallas, TX, USA 
CAV1 L-003467-00-0005 GE Dharmacon, Lafayette, 
CO, USA 
Lamin K-002800-C4-01 GE Dharmacon, Lafayette, 
CO, USA 
Non-targeting; Silencer 
Negative Control siRNA #1 
AM4611 Thermo Fisher Scientific, 
Waltham, MA, USA 
Non-targeting; siGENOME 
Non-targeting  
K-002800-C4-01 GE Dharmacon, Lafayette, 
CO, USA 
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PMC42-LA treatments with conditioned medium  
PMC42-LA cells (6x105) were seeded in 9 cm2 wells, with RPMI (Thermo Fisher 
Scientific, Waltham, MA, USA) with 10% (v/v) foetal bovine serum (FBS) (Bovogen 
Biologicals, East Keilor, VIC, Australia). After 18-24 hours, the medium was 
changed to 0.2-µm filter-sterilised conditioned medium, from 24-hour transfections of 
Fre85 with CAV1 siRNA. Cells were incubated for 7 days, at 37oC, with 5% CO2. 
 
Flow cytometry 
After 3- and 7-day treatments with conditioned medium, PMC42-LA cells were 
harvested with 0.05% (w/v) trypsin-EDTA (Thermo Fisher Scientific, Waltham, MA, 
USA). The resulting detached cells were washed with phosphate-buffered saline 
(PBS) (Amresco, Solon, OH, USA), and 1x106 cells were resuspended in 100 µl 0.5% 
(w/v) bovine serum albumin (BSA) (MilliporeSigma, Darmstadt, Germany) in PBS, 
containing fluorochrome-conjugated antibodies (see Table 1). Cell suspensions were 
incubated on ice, in the dark, for 30 minutes. The cells were then washed twice with 
0.5% (w/v) BSA in PBS, and resuspended in 500 µl 0.5% (w/v) BSA and 1 µg/ml 
propidium iodide (MilliporeSigma, Darmstadt, Germany) in PBS. Cells were 
analysed on a BD FACSCanto II (Becton Dickinson and Company, Franklin Lakes, 
NJ, USA). 
 
Fluorescence-activated cell sorting 
Fibroblasts (1x106 cells/mL) were labelled with 2 µM 5(6)-carboxyfluorescein 
diacetate N-succinimidyl ester (CFDA-SE) (MilliporeSigma, Darmstadt, Germany) in 
phosphate-buffered saline (PBS) (Amresco, Solon, OH, USA), for 10 minutes, at 
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37oC. The cells were then washed twice, with DMEM/F12 (Thermo Fisher Scientific, 
Waltham, MA, USA) with 10% foetal bovine serum (FBS) (Bovogen Biologicals, 
East Keilor, VIC, Australia), allowing 10 minutes between washes to let CFDA-SE to 
diffuse out of the cells. The labelled fibroblasts were seeded together with breast 
cancer cells and/or monocytes at a 2:1 fibroblast to cancer cell/monocyte ratio. A total 
number of 4x106 of cells was seeded in a 75 cm2 flask, in DMEM/F12 with 10% FBS. 
Cells were incubated at 37oC, with 5% CO2, for 3 days. After 18-24 hours, the 
medium was changed to DMEM/F12 with Serum Replacement 1 (MilliporeSigma, 
Darmstadt, Germany). 
 
Cells were collected for cell sorting with 0.05% trypsin-EDTA (Thermo Fisher 
Scientific, Waltham, MA, USA), and washed twice with PBS. Cells were resuspended 
in PBS with 0.5% BSA, and sorted with a BD FACSAria II (Becton Dickinson and 
Company, Franklin Lakes, NJ, USA).  
 
Cytokine assay 
Conditioned medium (4 mL from 6x105 Fre85 cells grown in DMEM with Serum 
Replacement 1 (MilliporeSigma, Darmstadt, Germany) in 9 cm2 wells) was collected 
from co-cultures, and monoculture controls, and centrifuged twice at 10,000xg. 
Undiluted conditioned medium, or conditioned medium diluted 1:5 with DMEM 
culture medium (Thermo Fisher Scientific, Waltham, MA, USA), was assayed on a 
Milliplex MAP human cytokine/chemokine magnetic bead panel (MilliporeSigma, 
Darmstadt, Germany), as per manufacturer instructions. Samples were assayed in 
duplicate. Quality controls, standards (range 3.2-10,000 pg/mL), and matrix solution 
	 60	
(control culture medium), were added to each plate in duplicate. The minimum 
detectable concentration plus 2 standard deviations was 4.6 pg/mL (EGF), 11.8 
pg/mL (FGF-2), 15.0 pg/mL (GM-CSF), 1.1 pg/mL (IFN-γ), 1.6 pg/mL (IL-10), 1.9 
pg/mL (IL-13), 17.1 pg/mL (IL-1RA), 1.0 pg/mL (IL-1β), 1.3 pg/mL (IL-6), 0.7 
pg/mL (IL-8), 3.4 pg/mL (MCP-1), 6.2 pg/mL (MIP-1α), 1.1 pg/mL (TNFα), 47.9 
pg/mL (VEGF), 0.7 pg/mL (PDGF-AA), 2.7 pg/mL (PDGF-AB/BB) and 1.9 pg/mL 
(RANTES). The assay was read on a Bio-Plex 200 (Bio-Rad, Hercules, CA, USA). 
 
Statistical analysis 
Statistical analyses were done by Student’s t-test. Statistical significance was defined 
as p<0.05 
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Chapter 3: Caveolin-1 expression in fibroblasts in non-
contact co-culture with breast cancer cells and monocytes  
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Introduction 
The microenvironment, or stroma, of a tumour plays an important role in the 
progression of cancer. Stromal cells in the vicinity of the tumour provide it with 
growth factors, remodel the extracellular matrix (ECM), and promote genetic 
instability in cancer cells (Bissell and Radisky, 2001). An important cell type in the 
microenvironment of breast tumours that has been well studied for its part in cancer 
progression and metastasis is the cancer-associated fibroblast (CAF). CAFs stimulate 
epithelial-to-mesenchymal transition (EMT) in nearby cancer cells through the 
secretion of TGF-β, promote angiogenesis through the release of VEGF, and remodel 
the ECM by the secretion of collagen, fibrin, growth factors, and matrix 
metalloproteinases (MMPs) (Kalluri, 2016; Madar et al., 2013).  
 
The origin of CAFs is not clear. Studies have shown that breast fibroblasts can 
increase the expression of CAF markers after being cultured together with breast 
cancer cells (Martinez-Outschoorn et al., 2010b). Others have shown that autocrine 
signalling mediated by TGF-β and stromal cell-derived factor 1 (SDF-1) is involved 
with the transformation of resident fibroblasts into activated CAFs (Kojima et al., 
2010). However, other sources of CAFs have also been described. Some CAFs are 
derived from endothelial cells through endothelial-to-mesenchymal transition (Van 
Meeteren and Ten Dijke, 2012; Zeisberg et al., 2007) while others are derived from 
cancer cells through EMT (Drake and Macleod, 2014). 
 
CAFs are difficult to define, and comprise a heterogeneous population of fibroblasts 
in the tumour micro-environment (Madar et al., 2013).  There is no known marker 
that is specific for the whole CAF population (Sugimoto et al., 2006), but commonly 
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used CAF markers are α-smooth muscle actin (αSMA), vimentin, and fibroblast-
activation protein (Kalluri and Zeisberg, 2006; Shiga et al., 2015). 
 
The stroma surrounding a carcinoma displays similarities to the stroma involved in 
wound healing, including increased numbers of fibroblasts, angiogenesis, and 
collagen and fibrin deposits, and is also referred to as reactive stroma (Kalluri and 
Zeisberg, 2006). Fibroblasts involved in wound healing are referred to as 
myofibroblasts, and secrete higher amounts of ECM components and proliferate faster 
(Kalluri and Zeisberg, 2006). A distinguishing feature of myofibroblasts is the 
expression of αSMA, and αSMA expression is a commonly used identifier of CAFs 
(Kalluri and Zeisberg, 2006). However, even though CAFs can display similarities to 
myofibroblasts, and myofibroblasts are often found in the tumour stroma (Kalluri and 
Zeisberg, 2006), not all CAFs express myofibroblast markers (Sugimoto et al., 2006). 
 
CAFs from different subtypes of breast cancer express different levels of CAF 
markers. For example, expression of CAF markers is higher in fibroblasts from 
HER2-type breast cancer stroma, compared to other breast cancer subtypes, such as 
ER-positive and triple negative (Park et al., 2015). Additionally, the expression of 
CAF markers differs according to stromal histological phenotype; desmoplastic 
stroma, which is characterised by fibrosis, shows higher platelet-derived growth 
factor receptor (PDGFR) α and PDGFRβ expression, whereas inflammatory stroma 
shows higher fibroblast activation protein α (FAPα) expression (Park et al., 2015). 
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Macrophages in the tumour microenvironment 
The association of inflammation with cancer has been known for a long time, but has 
become clearer in recent years. A number of studies show a predisposition to tumour 
development for certain chronic inflammatory conditions (Danese and Mantovani, 
2010; Polk and Peek, 2010). An inflammatory microenvironment is increasingly 
accepted as a generic component of tumours (Hanahan and Weinberg, 2011). 
Tumour-associated macrophages (TAMs) are a major component of the infiltrating 
immune cells of tumours (Mantovani and Sica, 2010).  
 
Despite the proinflammatory properties of macrophages, TAMs are protumorigenic 
and suppress T-cell responses (Noy and Pollard, 2014). In addition, TAMs play a role 
in matrix remodelling, promote invasiveness and intravasation at the tumour site 
through the production of MMPs, reactive oxygen species (ROS), and other factors 
(Condeelis and Pollard, 2006). This apparent contradiction of both tumoricidal and 
tumorigenic properties of macrophages was resolved with the identification of two 
distinct populations of macrophages: ‘classically’ activated (M1) macrophages and 
‘alternatively’ activated (M2) macrophages (Mantovani et al., 2004). M1 
macrophages are proinflammatory and tumoricidal, whereas M2 macrophages are 
protumorigenic (Comito et al., 2014). TAMs have been shown to have an M2 
phenotype, caused by a lack of M1 stimuli and the presence of M2 stimuli in the 
tumour microenvironment (Sica et al., 2006; Tang, 2013). 
 
CAFs express a proinflammatory gene signature (Erez et al., 2010). A study by 
Comito et al. (2014) has shown that CAFs attract monocytes and induce their 
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differentiation into macrophages, in vitro. This highlights the important interplay 
between CAFs and TAMs in tumorigenesis. 
 
Caveolin-1 and CAFs 
Several studies have reported a reduced caveolin-1 (CAV1) expression in CAFs. For 
example, Mercier et al. (2008) measured lower CAV1 levels in fibroblasts isolated 
from breast tumour biopsies, compared to fibroblasts isolated from adjacent 
unaffected tissue, for 8 out of 11 invasive ductal carcinoma patients. A study that 
evaluated the CAV1 levels in αSMA-positive cells in patient biopsies showed that a 
loss of CAV1 levels predicts reduced disease-free survival (Simpkins et al., 2012). In 
addition to low CAV1 expression being a characteristic of CAFs, fibroblasts that 
express lower levels of CAV1, have been shown to display a CAF-like phenotype. 
Gene expression profiling of primary mammary fibroblasts isolated from CAV1 -/- 
mice, compared to wild type mice, showed a significant overlap between the 
transcriptome of CAV1 -/- fibroblasts and CAFs (Sotgia et al., 2009). In addition, the 
transfection of primary breast fibroblasts with CAV1 siRNA has been shown to 
induce fibroblastic αSMA and vimentin expression (Martinez-Outschoorn et al., 
2010b), and promote breast cancer cell invasion (Simpkins et al., 2012). 
 
It is currently not known what the mechanism is behind the loss of CAV1 expression 
in the tumour microenvironment. It is possible that breast cancer cells induce normal 
fibroblasts to downregulate CAV1 expression. Alternatively, breast cancer cells may 
be responsible for inducing low-CAV1 expressing CAFs through EMT or endothelial-
to-mesenchymal transition. However, it is also possible that cancer cells indirectly, 
rather than directly, induce the downregulation of CAV1 in CAFs. As CAFs and 
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cancer cells have been shown to attract macrophages to the tumour 
microenvironment, it is possible that macrophages play a role in the downregulation 
of CAV1 in CAFs. 
 
Aims 
The main aim of this study was to determine whether a paracrine interaction between 
tumour cells and fibroblasts influences the expression of CAV1 in fibroblasts, in 
vitro. 
 
The specific aims were: 
 
• To determine whether an effect of breast cancer cells on fibroblastic CAV1 levels was 
tissue-specific. 
 
• To investigate whether an effect of breast cancer cells on fibroblastic CAV1 levels 
was dependent on the invasiveness of the cancer cells. 
 
• To establish whether oxygen levels during co-culture had an effect on fibroblastic 
CAV1 levels. 
 
• To investigate a potential role of differentiated monocytes in influencing fibroblastic 
CAV1 levels. 
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• To determine whether paracrine signalling by contact co-cultures of fibroblasts, 
cancer cells and differentiated monocytes had an effect on CAV1 levels in physically 
separated fibroblasts. 
 
Results  
Mouse non-contact co-culture system 
A mouse non-contact co-culture system was developed by culturing primary murine 
fibroblasts together with, but physically separated from, murine mammary cancer 
cells. The mouse non-contact co-culture system showed large variability in CAV1 
levels between experiments. CAV1 mRNA levels after non-contact co-culture of 
primary murine fibroblasts with different murine mammary cancer cell lines varied 
between experiments from almost completely non-detectable to slightly higher than 
control levels. Analysis of the data from 3 separate experiments, using 3 different 
mice shows that the variability in CAV1 mRNA and protein levels in fibroblasts after 
co-culture was larger between individual mice than between different cancer cell 
lines. 
 
 Murine fat pad fibroblasts were co-cultured for 48 hours, in a non-contact fashion, 
with murine cancer lines with different invasive capacities. After non-contact co-
culture of murine fibroblasts with 67NR cancer cells, fibroblastic CAV1 mRNA 
levels were 0.94 ± 0.33 fold the monoculture control (Fig. 1A). After non-contact co-
culture of murine fibroblasts with 168FARN cancer cells, fibroblastic CAV1 mRNA 
levels were 0.79 ± 0.25 fold the monoculture control (Fig. 1A). After non-contact co-
culture of murine fibroblasts with 66cl4 cancer cells, fibroblastic CAV1 mRNA levels 
were 0.82 ± 0.39 fold the monoculture control (Fig. 1A). After non-contact co-culture 
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of murine fibroblasts with 4T1.2 cancer cells, fibroblastic CAV1 mRNA levels were 
0.83 ± 0.22 fold the monoculture control (Fig. 1A).  
 
Western blot analysis to measure CAV1 protein showed a similarly large variability 
between experiments (Fig. 1B). After non-contact co-culture of murine fibroblasts 
with 67NR cancer cells, fibroblastic CAV1 protein levels were 1.10 ± 0.41 fold the 
monoculture control (Fig. 1B). After non-contact co-culture of murine fibroblasts 
with 168FARN cancer cells, fibroblastic CAV1 protein levels were 1.26 ± 0.37 fold 
the monoculture control (Fig. 1B). After non-contact co-culture of murine fibroblasts 
with 66cl4 cancer cells, fibroblastic CAV1 protein levels were 1.05 ± 0.35 fold the 
monoculture control (Fig. 1B). Fibroblastic CAV1 protein levels were decreased after 
non-contact co-culture of murine fat pad fibroblasts with 4T1.2 (0.32 ± 0.04 fold, 
p<0.05), the most invasive cancer cell line (Fig. 1B). Co-culture of embryonic mouse 
fibroblast cell line NIH/3T3 with murine cancer cell lines 67NR, 168FARN, 66cl4, 
and 4T1.2 did not change CAV1 mRNA or protein levels in fibroblasts (data not 
shown). Figure 1C shows a representative Western image, and Figure 1D shows a 
schematic representation of the non-contact co-culture system. 
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Figure 1: Non-contact co-culture of murine primary mammary fibroblasts (NMF) with 
a non-invasive (67NR), a mildly invasive (168FARN), an invasive (66cl4) and a highly 
invasive (4T1.2) murine breast cancer cell line at 20% oxygen. Results for the co-cultures 
are relative to the fibroblast monoculture control. Error bars represent the standard error of 
the mean. * p<0.05 against control (A) CAV1 mRNA levels, relative to β-actin levels, were 
detected using qRT-PCR. No significant changes in fibroblastic CAV1 mRNA levels were 
detected after 48 hours of co-culture. Results are representative of 3 independent experiments. 
(B) Western analysis of CAV1 protein levels, relative to total protein levels, as detected by 
Ponceau staining. Fibroblastic CAV1 protein levels were significantly reduced after 48 hours 
of co-culture with 4T1.2 cancer cells. Results are representative of 3 independent 
experiments. (C) Representative Western analysis image. β-actin is shown as a loading 
control. (D) Schematic representation of the non-contact co-culture system. On the left, the 
monoculture control is shown, on the right, the non-contact co-culture is shown. 
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Tissue oxygen levels are lower than ambient oxygen levels. The increased oxygen 
levels that cells are exposed to in ambient oxygen cell culture incubators have been 
shown to affect the physiological responses of cells. To determine whether oxygen 
levels had an effect on fibroblastic CAV1 levels in the co-culture system, experiments 
were carried out at 5% and 20% oxygen levels. When physiological oxygen levels 
(5% O2) were used for incubation, instead of the ambient oxygen levels regularly 
used in cell culture, the decrease of fibroblastic CAV1 protein levels seen in Figure 1 
did not occur (Fig. 2). CAV1 mRNA levels after non-contact co-culture of primary 
murine fibroblasts with different murine cancer cell lines for 48 hours showed large 
variability between experiments (Fig. 2A). Differences in fibroblastic CAV1 mRNA 
after non-contact co-culture of murine fat pad fibroblasts with 67NR (1.11 ± 0.19), 
168FARN (1.15 ± 0.31), 66cl4 (1.14 ± 0.37), and with 4T1.2 (0.92 ± 0.06) murine 
cancer cells were not significant compared to the monoculture control (Fig. 2A). 
Fibroblastic CAV1 protein levels after non-contact co-culture of murine fat pad 
fibroblasts with 67NR (0.97 ± 0.10), 168FARN (1.06 ± 0.12), 66cl4 (1.09 ± 0.03), 
and with 4T1.2 (1.00 ± 0.16) murine cancer cells were not significantly different from 
the monoculture control (Fig. 2B). Figure 2C shows a representative Western image. 
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Figure 2: Non-contact co-culture of murine primary mammary fibroblasts (NMF) with 
a non-invasive (67NR), a mildly invasive (168FARN), an invasive (66cl4) and a highly 
invasive (4T1.2) murine breast cancer cell line at 5% oxygen. Results for the co-cultures 
are relative to the fibroblast monoculture control. Error bars represent the standard error of 
the mean. (A) CAV1 mRNA levels, relative to β-actin levels, were detected using qRT-PCR. 
No significant changes in fibroblastic CAV1 mRNA levels were detected after 48 hours of 
co-culture. Results are representative of 3 independent experiments. (B) Western analysis of 
CAV1 protein levels, relative to total protein levels, as detected by Ponceau staining. No 
significant changes in fibroblastic CAV1 protein levels were detected after 48 hours of co-
culture. Results are representative of 3 independent experiments.  (C) Representative Western 
analysis image. β-actin is shown as a loading control. 
 
As large variability in CAV1 levels was observed between experiments, baseline 
CAV1 protein levels were assessed in mammary fibroblasts from 4 different BALB/c 
mice. The mouse with the highest CAV1 levels generated a 7.4 times stronger CAV1 
band in Western analysis, compared to the mouse with the lowest CAV1 levels (Fig. 
3). The other two mice generated bands that were 2.6 and 3.8 times stronger than the 
mouse with the lowest CAV1 levels (Fig. 3).  
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Figure 3: Monocultures of primary breast fibroblasts from different mice. Western 
analysis of CAV1 protein levels, relative to total protein levels, as detected by Ponceau 
staining. Up to 7 fold differences in CAV1 protein levels were detected in 4 different mice. 
Results are representative of a single measurement. 
 
Human non-contact co-culture system 
The effects of different human fibroblast cell lines on human breast cancer cell lines 
were assessed in a non-contact co-culture system. Non-contact co-culture, for 3 days, 
of immortalised skin fibroblasts hTERT-BJ with different breast cancer cell lines, 
MCF7, and MDA-MB-231, did not result in significant changes in fibroblastic CAV1 
mRNA levels (Fig. 4). Fibroblastic CAV1 mRNA levels were 0.97 ± 0.11 fold the 
monoculture control after non-contact co-culture with MCF7 breast cancer cells, and 
1.12 ± 0.09 fold with MDA-MB-231 breast cancer cells (Fig. 4A). 
 
 Fibroblastic CAV1 protein levels after non-contact co-culture of hTERT-BJ with 
breast cancer cell line MCF7 were 1.38 ± 0.22 fold the monoculture control (Fig. 
4B,C). Conversely, hTERT-BJ CAV1 protein levels were significantly increased 
(1.69 ± 0.27, p<0.05) after non-contact co-culture with MDA-MB-231 (Fig. 4B). 
Figure 4C shows a representative Western analysis image. 
 
	 73	
 In addition to the invasive breast cancer cell lines MCF7 and MDA-MB-231, 
hTERT-BJ was co-cultured with the non-invasive breast cancer cell line PMC42-LA 
and no significant changes in fibroblastic CAV1 mRNA and protein levels were 
detected (data not shown). 
 
 
Figure 4: Non-contact co-culture of human immortalized skin fibroblasts (hTERT-BJ) 
with a mildly invasive (MCF7) and a highly invasive (MDA-MB-231) human breast 
cancer cell line. Results for the co-cultures are relative to the fibroblast monoculture control. 
Error bars represent the standard error of the mean. * p<0.05 against control (A) CAV1 
mRNA levels, relative to β-actin levels, were detected using qRT-PCR. No significant 
changes in fibroblastic CAV1 mRNA levels were detected after 3 days of co-culture. Results 
are representative of 7 independent experiments. (B) Western analysis of CAV1 protein 
levels, relative to total protein levels, as detected by Ponceau staining. Fibroblastic CAV1 
protein levels were significantly increased after 3 days of co-culture with MDA-MB-231. 
Results are representative of 6 independent experiments. (C) Representative Western analysis 
image. β-actin is shown as a loading control. BJ=hTERT-BJ, MCF=MCF7, MDA=MDA-
MB-231 
 
Primary fibroblast cell line Fre85 showed no significant changes in CAV1 mRNA 
after 3 days of non-contact co-culture with breast cancer cell lines MCF7 and MDA-
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MB-231, when compared to a monoculture of Fre85 fibroblasts (Fig. 5A). 
Fibroblastic CAV1 mRNA levels after non-contact co-culture of Fre85 fibroblasts 
with mildly invasive breast cancer line MCF7 were 0.91 ± 0.16 fold the monoculture 
control, and with highly invasive breast cancer line MDA-MB-231 were 0.84 ± 0.09 
fold the monoculture control (Fig. 5A).  
 
Fibroblastic CAV1 protein levels after non-contact co-culture with MCF7 were 1.27 ± 
0.34 fold the monoculture control (Fig. 5B). Fibroblastic CAV1 protein levels after 
non-contact co-culture with MDA-MB-231 were 1.29 ± 0.46 fold the monoculture 
control (Fig. 5B). These changes were not statistically significant. Figure 5C shows a 
representative Western analysis image. 
 
In addition to the invasive breast cancer cell lines MCF7 and MDA-MB-231, Fre85 
was co-cultured with the non-invasive breast cancer cell line PMC42-LA and no 
significant changes in fibroblastic CAV1 mRNA and protein levels were detected 
(data not shown). 
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Figure 5: Non-contact co-culture of human primary breast fibroblasts (Fre85) with a 
non-invasive (PMC42-LA), a mildly invasive (MCF7) and a highly invasive (MDA-MB-
231) human breast cancer cell line. Results for the co-cultures are relative to the fibroblast 
monoculture control. Error bars represent the standard error of the mean. (A) CAV1 mRNA 
levels, relative to β-actin levels, were detected using qRT-PCR. No significant changes in 
fibroblastic CAV1 mRNA levels were detected after 3 days of co-culture. Results are 
representative of 4 independent experiments. (B) Western analysis of CAV1 protein levels, 
relative to total protein levels, as detected by Ponceau staining. No significant changes in 
fibroblastic CAV1 protein levels were detected after 3 days of co-culture. Results are 
representative of 4 independent experiments. (C) Representative Western analysis image. β-
actin is shown as a loading control. Fre=Fre85, MCF=MCF7, MDA=MDA-MB-231 
 
Non-contact co-culture with (differentiated) monocytes 
THP-1 human monocytes were differentiated with 12-O-Tetradecanoylphorbol-13-
acetate (TPA), and introduced into the non-contact co-culture system of fibroblasts 
with MCF7 and MDA-MB-231. The THPT cells were washed twice before inclusion 
in the co-culture system, to remove any traces of TPA. Additionally, fibroblasts were 
treated with 1 nM and 100 nM TPA and no significant effect on CAV1 levels was 
found (data not shown).  
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Non-contact co-culture with carrier-treated THP-1 cells (THPD) increased CAV1 
mRNA 1.44 ± 0.10 fold (p<0.05) in hTERT-BJ immortalized human skin fibroblasts, 
compared to the monoculture control (Fig. 6A). Co-culture with TPA-treated THP-1 
cells (THPT) did not result in changes in CAV1 mRNA relative to monoculture 
control (0.93 ± 0.12 fold, Fig. 6A). Fibroblastic CAV1 mRNA levels after co-culture 
with MCF7 and THPD, and MDA-MB-231 and THPD, were 1.18 ± 0.25 and 1.08 ± 
0.15 fold the monoculture control, respectively, while fibroblastic CAV1 mRNA 
levels after co-culture with MCF7 and THPT, and MDA-MB-231 and THPT, were 
0.86 ± 0.19 and 0.82 ± 0.12 fold the monoculture control, respectively (Fig. 6A).  
 
Fibroblastic CAV1 protein levels after 3 days of non-contact co-culture of hTERT-BJ 
with MCF7 or MDA-MB-231 breast cancer cells, in the presence of TPA- or carrier-
treated THP-1 cells, were not significantly different compared to the fibroblast 
monoculture control. Non-contact co-culture of hTERT-BJ with THPD led to 
fibroblastic CAV1 protein levels that were 2.14 ± 0.45 fold the monoculture control, 
and with THPT fibroblastic Cav1 levels were 1.87 ± 0.32 fold the monoculture 
control (Fig. 6B). In the presence of both MCF7 and THPD, fibroblastic CAV1 
protein levels were 2.69 ± 1.03 fold the monoculture control, and fibroblastic CAV1 
protein levels after co-culture with MCF7 and THPT were 2.04 ± 0.33 fold the 
monoculture control (Fig. 6B). Fibroblastic CAV1 protein levels after non-contact co-
culture with MDA-MB-231 and THPD were 1.80 ± 0.81, and with MDA-MB-231 
and THPT were 2.13 ± 0.91 fold the monoculture control. Figure 6C shows a 
representative Western image, and Figure 6D shows a schematic representation of the 
non-contact co-culture system. 
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Figure 6: Non-contact co-culture of human immortalised skin fibroblasts (hTERT-BJ) 
with a mildly invasive (MCF7) or a highly invasive (MDA-MB-231) human breast 
cancer cell line and an undifferentiated (THPD) or differentiated (THPT) monocytic cell 
line. Results for the co-cultures are relative to the fibroblast monoculture control. Error bars 
represent the standard error of the mean. * p<0.05 against control (A) CAV1 mRNA levels, 
relative to β-actin levels, were detected using qRT-PCR. Fibroblastic CAV1 mRNA levels 
were significantly increased after 3 days of co-culture with undifferentiated THP-1 cells 
(THPD). Results are representative of 4 independent experiments. (B) Western analysis of 
CAV1 protein levels, relative to total protein levels, as detected by Ponceau staining. No 
significant changes in fibroblastic CAV1 protein levels were detected after 3 days of co-
culture. Results are representative of 3 independent experiments. (C) Representative Western 
analysis image. β-actin is shown as a loading control. (D) Schematic representation of the 
non-contact co-culture system. On the left, the monoculture control is shown, on the right, the 
non-contact co-culture is shown. BJ=hTERT-BJ, MCF=MCF7, MDA=MDA-MB-231, 
THPD=carrier-treated THP-1, THPT=TPA-treated THP-1  
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In Fre85 fibroblasts co-cultured with THPT cells, CAV1 mRNA levels were 0.65 ± 
0.14 fold the monoculture control, and in fibroblasts co-cultured with THPD cells, 
levels were 0.91 ± 0.05 fold the monoculture control (Fig. 7A). These changes were 
not significant. Fibroblastic CAV1 mRNA levels after non-contact co-culture with 
MCF7 and THPD were 0.74 ±0.12, and with MCF7 and THPT 0.56 ± 0.18, fold the 
monoculture control. When Fre85 was co-cultured with both MDA-MB-231 and 
THPT (0.44 ± 0.14), or MDA-MB-231 and THPD (0.59 ± 0.09), fibroblast CAV1 
mRNA levels were lower than when co-cultured with MDA-MB-231 cancer cells 
alone, and significantly lower than the monoculture control (Fig. 5A, 7A). This same 
trend was seen for co-cultures of Fre85, MCF7 and THP-1 (Fig. 5A, 7A), but the 
decrease of fibroblastic mRNA in this triple-culture was not significant.  
 
Fibroblastic CAV1 protein levels, similar to mRNA levels, but in contrast to hTERT-
BJ CAV1 protein levels, showed a trend of decrease after 3 days of non-contact co-
culture with breast cancer cells and TPA-treated THP-1 cells (Fig. 7B). Fibroblastic 
CAV1 protein levels after non-contact co-culture with THPD were 0.90 ± 0.16 fold 
the monoculture control, and after culture with THPT CAV1 levels were 0.62 ± 0.24 
fold the monoculture control (Fig. 7B). CAV1 protein levels in Fre85 after co-culture 
with MCF7 or MDA-MB-231 cancer cells, and THPD (triple culture), were 1.16 ± 
0.61 and 1.24 ± 0.62 fold the monoculture control, respectively, and with MCF7 or 
MDA-MB-231, and THPT were 0.85 ± 0.24 and 0.94 ± 0.32, respectively (Fig. 7B). 
These changes were not significant. Figure 7C shows a representative Western image. 
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Figure 7: Non-contact co-culture of human primary breast fibroblasts (Fre85) with a 
mildly invasive (MCF7) or a highly invasive (MDA-MB-231) human breast cancer cell 
line and an undifferentiated (THPD) or differentiated (THPT) monocytic cell line. 
Results for the co-cultures are relative to the fibroblast monoculture control. Error bars 
represent the standard error of the mean. * p<0.05 against control (A) CAV1 mRNA levels, 
relative to β-actin levels, were detected using qRT-PCR. Fibroblastic CAV1 mRNA levels 
were significantly decreased after 3 days of co-culture with MDA-MB-231 and THPD, and 
after co-culture with MDA-MB-231 and THPT. Results are representative of 4 independent 
experiments. (B) Western analysis of CAV1 protein levels, relative to total protein levels, as 
detected by Ponceau staining. No significant changes in fibroblastic CAV1 protein levels 
were detected after 3 days of co-culture. Results are representative of 4 independent 
experiments. (C) Representative Western analysis image. β-actin is shown as a loading 
control. Fre=Fre85, MCF=MCF7, MDA=MDA-MB-231, THPD=carrier-treated THP-1, 
THPT=TPA-treated THP-1 
 
Non-contact co-cultures showed high variability in CAV1 levels between 
experiments. Alternative reference genes were assessed for use in qRT-PCR for the 
determination of mRNA levels in fibroblasts in the co-culture system. Average 
expression levels were determined for reference genes after different co-culture 
conditions and the variability in expression levels was calculated as the standard 
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deviation from the average Ct. GAPDH had half the standard deviation as a 
percentage of the average Ct (% of AVE), compared to β-actin (1.51% versus 2.96%, 
Table 1), and was selected for continued use as a reference gene. 
 
Table 1: Average Ct of housekeeping genes measured by qPCR in Fre85 human 
primary breast fibroblasts after non-contact co-culture. The average (AVE) and standard 
deviation (STDEV) were calculated from the Ct for different co-cultures. The standard 
deviation of the Ct was calculated as a percentage of the average Ct (%AVE). The average of 
3 experiments is shown. The data show that GAPDH is more stable across the different co-
culture conditions.  
Housekeeping 
gene 
AVE Ct Average STDEV  Average STDEV 
as %AVE  
β-actin 15.4 0.43 2.96 
GAPDH 14.3 0.21 1.51 
 
Confocal microscopy using fluorescently tagged antibodies was used to confirm 
changes in CAV1 protein levels seen with Western analysis. Interestingly, confocal 
microscopy showed lower CAV1 protein levels in Fre85 fibroblasts after 3 days of 
non-contact co-culture with breast cancer cells and THPT or THPD (triple culture), 
compared to co-culture with cancer cells alone (Fig. 8), which is consistent with the 
lower mRNA levels seen in Figure 7, however, the fibroblastic CAV1 levels after co-
culture with cancer cells appeared higher compared to the monoculture control. 
CAV1 staining in Fre85 fibroblasts in the monoculture control (A), or after non-
contact co-culture with MCF7 (B), MDA-MB-231 (C), THPD (D), THPT (E), MCF7 
and THPD (F), MCF7 and THPT (G), MDA-MB-231 and THPD (H), and MDA-MB-
231 and THPT (I), can be seen in Figure 8. Quantification of the CAV1 fluorescent 
signal is shown in Figure 8J. 
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Figure 8: Immunofluorescence microscopy of non-contact co-culture of human primary 
breast fibroblasts (Fre85) with a mildly invasive (MCF7) or a highly invasive (MDA-
MB-231) human breast cancer cell line and an undifferentiated (THPD) or 
differentiated (THPT) monocytic cell line. After 3 days of co-culture, cells were fixed and 
immuno-labelled with antibodies against CAV1 (green). Nuclei were stained with ethidium 
bromide (red). Results for the co-cultures are relative to the fibroblast monoculture control. 
Error bars represent the standard error of the mean. (A) Mono-culture of human primary 
breast fibroblasts (Fre85). (B) Human primary breast fibroblasts (Fre85) were co-cultured 
with a mildly invasive human breast cancer cell line (MCF7). (C) Human primary breast 
fibroblasts (Fre85) were co-cultured with a highly invasive human breast cancer cell line 
(MDA-MB-231).  (D) Human primary breast fibroblasts (Fre85) were co-cultured with 
carrier-treated THP-1 cells (THPD). (E) Human primary breast fibroblasts (Fre85) were co-
cultured with TPA-treated THP-1 cells (THPT). Fre=Fre85, MCF=MCF7, MDA=MDA-MB-
231, THPD=carrier-treated THP-1, THPT=TPA-treated THP-1 
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Figure 8 continued: Immunofluorescence microscopy of non-contact co-culture of 
human primary breast fibroblasts (Fre85) with a mildly invasive (MCF7) or a highly 
invasive (MDA-MB-231) human breast cancer cell line and an undifferentiated (THPD) 
or differentiated (THPT) monocytic cell line. After 3 days of co-culture, cells were fixed 
and immuno-labelled with antibodies against CAV1 (green). Nuclei were stained with 
ethidium bromide (red). Results for the co-cultures are relative to the fibroblast monoculture 
control. Error bars represent the standard error of the mean. (F) Human primary breast 
fibroblasts (Fre85) were co-cultured with a mildly invasive human breast cancer cell line 
(MCF7) and carrier-treated THP-1 cells (THPD). (G) Human primary breast fibroblasts 
(Fre85) were co-cultured with a mildly invasive human breast cancer cell line (MCF7) and 
TPA-treated THP-1 cells (THPT). (H) Human primary breast fibroblasts (Fre85) were co-
cultured with a highly invasive human breast cancer cell line (MDA-MB-231) and carrier-
treated THP-1 cells (THPD). (I) Human primary breast fibroblasts (Fre85) were co-cultured 
with a highly invasive human breast cancer cell line (MDA-MB-231) and TPA-treated THP-1 
cells (THPT). (J) Mean total CAV1 fluorescence of fibroblasts in co-culture, based on 1 
experiment, 2 separate images, 6 separate cells. Fre=Fre85, MCF=MCF7, MDA=MDA-MB-
231, THPD=carrier-treated THP-1, THPT=TPA-treated THP-1 
 
To examine whether physical contact between fibroblasts and cancer cells and 
differentiated monocytes would affect nearby fibroblasts in the same system, human 
	 83	
primary breast fibroblasts (Fre85) were cultured for 3 days in the presence of, but 
physically separated from, a contact co-culture of Fre85, MDA-MB-231 breast cancer 
cells, and THPT cells. Non-contact co-culture of Fre85 with MDA-MB-231 resulted 
in decreased fibroblastic CAV1 mRNA levels (0.61 ± 0.05 fold monoculture control, 
p<0.05) (Fig. 9A), but this reduction in mRNA levels did not translate into lower 
fibroblastic CAV1 protein levels (0.99 ± 0.04 fold the monoculture control, Fig. 9B). 
The reduction of fibroblastic CAV1 mRNA and protein levels was enhanced in the 
presence of THPT cells (mRNA levels were 0.21 ± 0.07 fold the monoculture control 
(p<0.01), and protein levels were 0.52 ± 0.12 fold the monoculture control, Fig. 
9A,B), compared to non-contact co-culture of Fre85 with MDA-MB-231 alone. The 
reduction of fibroblastic CAV1 mRNA and protein levels was also slightly enhanced 
in the presence of, but physically separate from, a contact co-culture of fibroblasts and 
breast cancer cells compared to non-contact co-culture with breast cancer cells alone, 
however this change was not statistically significant (Fig. 9A,B). Figure 9C shows a 
representative Western image, and Figure 9D shows a schematic representation of the 
non-contact co-culture system. 
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Figure 9: Non-contact co-culture of human primary breast fibroblasts (Fre85) with 
contact co-cultures of Fre85 with a mildly invasive (MCF7) or a highly invasive (MDA-
MB-231) human breast cancer cell line and an undifferentiated (THPD) or 
differentiated (THPT) monocytic cell line. Results for the co-cultures are relative to the 
fibroblast monoculture control. Error bars represent the standard error of the mean. * p<0.05 
** p<0.01 (A) CAV1 mRNA levels, relative to GAPDH levels, were detected using qRT-
PCR. Fibroblastic CAV1 mRNA levels were significantly decreased after 3 days of non-
contact co-culture with all of the cell populations tested. Results are representative of 3 
independent experiments. (B) Western analysis of CAV1 protein levels, relative to total 
protein levels, as detected by Ponceau staining. Fibroblastic CAV1 protein levels were 
significantly decreased after 3 days of non-contact co-culture with a mixed population of 
Fre85 and THPT. Fibroblastic CAV1 protein levels were also significantly lower after non-
contact co-culture with a mixed population of MDA-MB-231 and THPT, compared to non-
contact co-culture with MDA-MB-231 alone. Results are representative of 3 independent 
experiments. (C) Representative Western analysis image. β-actin is shown as a loading 
control. Fre=Fre85, MDA=MDA-MB-231, THPT=TPA-treated THP-1 
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Figure 9 continued: Non-contact co-culture of human primary breast fibroblasts (Fre85) 
with contact co-cultures of Fre85 with a mildly invasive (MCF7) or a highly invasive 
(MDA-MB-231) human breast cancer cell line and an undifferentiated (THPD) or 
differentiated (THPT) monocytic cell line. (D) Schematic representation of the non-contact 
co-culture system. On the left, the monoculture control is shown, on the right, the non-contact 
co-culture is shown.  
 
Fibroblastic αSMA expression 
A commonly used marker for the identification of activated fibroblasts, or 
myofibroblasts, is the expression of αSMA. Levels of αSMA in fibroblasts were 
assessed after 3 days of non-contact co-culture with cancer cells and differentiated 
monocytes, or with a mixed culture of cancer cells and differentiated monocytes. 
Although these culture conditions led to significant changes in fibroblastic CAV1 
protein levels, significant changes in fibroblastic αSMA protein levels were not 
observed. Fibroblastic αSMA levels after non-contact co-culture of primary human 
breast fibroblasts Fre85 with MDA-MB-231 breast cancer cells were 1.05 ± 0.14 fold 
the monoculture control (Fig. 10A,B). When these fibroblasts were cultured in the 
presence of, but physically separated from, a co-culture of Fre85 fibroblasts and 
MDA-MB-231 cancer cells, fibroblastic αSMA protein levels were 1.30 ± 0.24 fold 
the monoculture control (Fig. 10A,B). Fibroblastic αSMA protein levels after non-
contact co-culture of Fre85 fibroblasts with THPT cells were 0.81 ± 0.04 fold the 
monoculture control, which was just outside of statistical significance (Fig. 10A,B, 
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p=0.05). Fibroblastic αSMA protein levels after non-contact co-culture with a mixed 
Fre85 and THPT population were 1.09 ± 0.23 fold the monoculture control (Fig. 
10A,B). Fibroblastic αSMA protein levels after non-contact co-culture with a mixed 
population of MDA-MB-231 and THPT were 1.01 ± 0.14 fold the monoculture 
control, and with a mixed population of Fre85, MDA-MB-231, and THPT, levels 
were 0.93 ± 0.15 fold the monoculture control (Fig. 10A,B). 
 
 
Figure 10: αSMA levels in non-contact co-cultures of human primary breast fibroblasts 
(Fre85) with mixed cultures of human primary breast fibroblasts, a highly invasive 
breast cancer cell line (MDA-MB-231) and a differentiated monocytic cell line (THPT). 
Results for the co-cultures are relative to the fibroblast monoculture control. Error bars 
represent the standard error of the mean. (A) Western analysis of α-smooth muscle actin 
(αSMA) protein levels, relative to total protein levels, as detected by Ponceau staining. No 
significant changes in fibroblastic αSMA protein levels were detected after 3 days of co-
culture. Results are representative of 3 independent experiments. (B) Representative Western 
analysis image. β-actin is shown as a loading control. Fre=Fre85, MDA=MDA-MB-231, 
THPT=TPA-treated THP-1  
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Discussion 
A correlation between low CAV1 levels in the tumour stroma and cancer progression 
has reported in several studies (Bonuccelli et al., 2010; Simpkins et al., 2012; Sloan et 
al., 2009; Witkiewicz et al., 2009b), however the mechanism through which CAV1 is 
downregulated in CAFs is unclear. The results presented in this chapter show that 
non-contact co-culture with some cancer cells and immune cells affects fibroblastic 
CAV1 levels, suggesting the involvement of a secreted factor. Additionally, the 
results presented in this chapter point to a potential role for paracrine signalling 
between fibroblasts and immune cells in the reduction of CAV1 in fibroblasts. 
 
The data presented in this chapter show that fibroblasts respond differently to co-
culture with different cancer cell lines, with the more invasive cancer cell lines 
generally eliciting a stronger change in fibroblastic CAV1 levels. After co-culture 
with MDA-MB-231 breast cancer cells, hTERT-BJ CAV1 protein levels were 
significantly increased to 1.69 (± 0.27, p<0.05) fold that of control levels, whereas co-
culture with the more epithelial-like MCF7 cells led to fibroblastic CAV1 protein 
levels of 1.38 (± 0.22) fold control levels. Furthermore, co-culture of murine 
mammary fibroblasts with the invasive murine cancer cell line 4T1.2 resulted in a 
significant reduction of fibroblastic CAV1 protein levels to 0.32 (± 0.04, p<0.05) fold 
control levels, whereas co-culture with less invasive cancer lines led to fibroblastic 
CAV1 protein levels between 1.05 and 1.26 fold the control. This is consistent with in 
vivo data that show that low stromal CAV1 levels are associated with advanced 
tumour stage and metastasis (Witkiewicz et al., 2009b). 
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The mouse system 
The use of mice allows for extensive in vivo analysis of the role of CAV1 in the 
tumour stroma. This chapter evaluated the usefulness of an in vitro murine co-culture 
model. Results from co-culture of murine primary fibroblasts with murine cancer cells 
showed large variability between mice. As all murine fibroblasts used were isolated 
from BALB/c mice, genetic variability would be limited compared to the variability 
expected between breast cancer patients. Despite the large variability between mice, 
the results presented in this chapter show a strong and statistically significant (0.32 ± 
0.04, p<0.05) reduction of fibroblastic CAV1 protein levels after non-contact co-
culture with highly invasive murine cancer cell line 4T1.2. CAV1 mRNA levels 
measured at the same time-point did not show any changes compared to the control. 
This suggests either that mRNA levels may have returned to normal levels after an 
initial reduction, or that the reduction in CAV1 protein levels is not regulated by 
changes in transcription. A study by Martinez-Outschoorn et al. (2010b) similarly 
found that a reduction of CAV1 protein levels after co-culture of immortalised 
hTERT-BJ skin fibroblasts with MCF7 breast cancer cells was not accompanied by a 
reduction of CAV1 mRNA levels. The authors further reported that pre-treatment 
with lysosome-specific inhibitors rescued CAV1 levels that were otherwise found to 
be reduced after co-culture with MCF7 cancer cells. This suggests that CAV1 
reduction after contact co-culture is mediated by autophagic/lysosomal degradation, 
rather than changes in transcription (Martinez-Outschoorn et al., 2010b).  
 
The human system 
The use of cell lines reduces genetic variability even further, compared to using 
individual mice from the same strain. This can be advantageous when a stable system 
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is required to investigate mechanisms of cell signalling. Fibroblasts and breast cancer 
cells from a number of different origins were co-cultured and evaluated for their 
usefulness in a co-culture system. Immortalised skin fibroblasts hTERT-BJ responded 
differently to non-contact co-culture with breast cancer cells and monocytes, 
compared to primary breast fibroblasts. Where Fre85 primary breast fibroblasts 
showed no change in CAV1 mRNA and protein levels after non-contact co-culture 
with MDA-MB-231 breast cancer cells, hTERT-BJ cells showed an increase in CAV1 
protein levels after non-contact co-culture with MDA-MB-231. Similarly, small 
differences were observed when CAV1 levels of a primary human breast fibroblasts 
line (Fre85) co-cultured with cancer cells were compared to that of a primary human 
skin fibroblast line (800211) (data not shown). There may, therefore, be a difference 
in the response of fibroblasts originating from different tissues. Furthermore, 
immortalised fibroblasts may behave differently compared to primary fibroblasts. In 
studies on both immortalised retinal pigment epithelial (hTERT-RPE) cells (Alge et 
al., 2006) and immortalised skin fibroblasts (hTERT-BJ) (Lindvall et al., 2003), 
results showed significant differences in expression patterns between the 
immortalised cells and their primary counterparts.  
 
Non-contact co-culture of human fibroblasts and breast cancer cells has been reported 
as having no effect on fibroblastic CAV1 levels (Martinez-Outschoorn et al., 2010b). 
Martinez-Outschoorn et al. reported that no changes in fibroblast CAV1 levels occur 
after non-contact co-culture of hTERT-BJ with MCF7. This is in line with the results 
presented in this chapter, which show no significant changes in hTER-BJ CAV1 
levels after non-contact co-culture with MCF7. However, the results presented in this 
chapter show that non-contact co-culture with human breast cancer cell line MDA-
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MB-231 did increase CAV1 protein levels in immortalised human skin fibroblasts 
(hTERT-BJ). This increase of CAV1 levels suggests that soluble factors secreted in 
the media mediate communication between cancer cells and fibroblasts, resulting in 
the regulation of CAV1 levels.  
 
The role of differentiated monocytes 
Macrophages are a well described component of the tumour microenvironment 
(Mantovani and Sica, 2010). Macrophages have numerous ways of communicating 
with, and altering the expression profiles of, cells in the local microenvironment. 
Alveolar macrophages have, for example, been shown to alter IL-8 expression levels 
in pulmonary fibroblasts in co-culture (Rolfe et al., 1991).  
 
The results presented in this chapter indicate that CAV1 levels of primary human 
breast fibroblasts Fre85 were decreased after non-contact co-culture with cancer cells 
and differentiated monocytes. There was a trend towards lower fibroblastic CAV1 
levels after co-culture with THPT alone, however there was no statistically significant 
effect. CAFs express a proinflammatory gene-signature in breast, skin, and pancreatic 
cancers, and promote macrophage recruitment (Erez et al., 2010). Thus recruitment of 
macrophages to the tumour microenvironment during cancer progression may account 
for the decrease in fibroblastic CAV1 levels, rather than interactions between 
fibroblasts and cancer cells alone.  
 
The macrophages included in the co-culture system were THP-1 cells differentiated 
with TPA. Treatment with TPA differentiates THP-1 monocytes into a macrophage-
like phenotype (Auwerx, 1991). TPA is a phorbol diester that activates protein   
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kinase C. TPA-treated THP-1 cells resemble native monocyte-derived macrophages 
with respect to morphology, antigen and receptor expression, oncogene expression, 
and the production of secretory products (Auwerx, 1991).  
 
A potential mechanism, through which macrophages could reduce CAV1, is the 
production of ROS. Macrophages produce ROS at the tumour site (Comito et al., 
2014). A study by Ishimoto et al. (2014) measured abundant ROS production by M1- 
and M2-polarised THP-1 macrophages, in vitro. ROS have been reported to drive 
CAV1 downregulation in CAFs. In a study by Martinez-Outschoorn et al. (2010a), 
using CM-H2DCFDA ROS staining for confocal microscopy, hTERT-BJ skin 
fibroblasts in contact co-culture with MCF7 breast cancer cells displayed signs of 
oxidative stress. CAV1 protein expression was restored in hTERT-BJ fibroblasts co-
cultured with MCF7 breast cancer cells after treatment with ROS scavenger N-
Acetyl-Cysteine (NAC) (Martinez-Outschoorn et al., 2010a).  
 
The fibroblastic CAV1 protein downregulation in contact co-cultures of hTERT-BJ 
fibroblasts with MCF7 cancer cells, reported by Martinez-Outschoorn et al. (2010b), 
did not result in changes in CAV1 mRNA. In the co-cultures of Fre85 fibroblasts with 
cancer cells and differentiated monocytes described in this chapter, on the other hand, 
the decrease in CAV1 mRNA translated into a decrease in CAV1 protein levels. This 
consistency between CAV1 mRNA and CAV1 protein levels suggests that the 
decrease seen here, could be based on a different regulatory mechanism to the 
downregulation by autophagic/lysosomal degradation of CAV1 in the absence of 
mRNA changes, reported by Martinez-Outschoorn et al. (2010b).  
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The role of oxygen and distance 
Physiological oxygen levels differ from the oxygen levels commonly used in cell 
culture. Oxygen levels in tissues vary, and are generally lower than those in cell 
culture conditions. The pO2 in brain tissue is approximately 30-50 mmHg, and the 
pO2 in superficial skin tissue is approximately 8 mmHg (Carreau et al., 2011). 
Oxygen levels in cell culture media cultured with 5% CO2 in air are approximately 
18-20% or 140 mmHg (Newby et al., 2005). Cells cultured at 20% oxygen levels may 
show oxidative stress, DNA damage, and decreased genetic stability (Estrada et al., 
2012). Cells require oxygen for the generation of energy in the form of ATP, however 
excess oxygen leads to the generation of ROS. High levels of ROS cause DNA 
damage and genetic instability (Cooke et al., 2003). When oxygen levels in co-culture 
conditions in the mouse system were reduced to physiological levels of 5%, the 
previously observed reduction of CAV1 protein levels was absent. This suggests that 
the model may require a degree of oxidative stress for changes in CAV1 levels to be 
detected. This oxygen effect was, however, not seen in the human cell culture system 
(data not shown).  
 
Increased ROS in cancer cells is a well-described phenomenon. In addition to 
increased oxygen levels, the expression of oncogenes, dysfunctional mitochondria, 
and the loss of p53, are other potential causes of increased ROS levels that have been 
reported in cancer cells (Trachootham et al., 2009). As mentioned above, co-culture 
with human breast cancer cells has been shown to increase oxidative stress in human 
skin fibroblasts (Martinez-Outschoorn et al., 2010a). Co-cultures showed increased 
ROS and decreased CAV1 levels in fibroblasts and increased aneuploidy in breast 
cancer cells, whereas both cell types showed increased DNA damage (Martinez-
Outschoorn et al., 2010a). Furthermore, CAV1 knockdown has been shown to lead to 
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oxidative stress and oxidative stress has in turn been shown to lead to CAV1 
downregulation in fibroblasts (Martinez-Outschoorn et al., 2010a), indicating a 
positive feedback mechanism involving CAV1 and oxidative stress. 
 
Distance is a factor in the effectiveness of secreted signalling molecules inducing a 
response in nearby cells. To examine this effect, the co-culture system, in which the 
fibroblasts were separated from the breast cancer cells by a distance of approximately 
1-2 mm, was adapted to decrease the distance between fibroblasts and breast cancer 
cells, by culturing these cell types on either side of the membrane of a transwell filter 
insert, with a thickness of 10 µm. The results suggested that CAV1 levels are not 
altered when the distance between fibroblasts and breast cancer cells is decreased 
(data not shown). This suggests that any signalling that is occurring in the non-contact 
co-culture system is sustained over a larger distance. 
 
Direct physical contact between fibroblasts and breast cancer cells or macrophages 
could potentially induce the secretion of signalling molecules, which in turn could 
alter CAV1 expression in nearby, but physically separated, fibroblasts. To test this, a 
cell culture system was set up, in which a mixed population of fibroblasts and breast 
cancer cells was cultured together with, but physically separated from, a monoculture 
of fibroblasts. The results presented in this chapter suggest that contact co-culture of 
fibroblasts and breast cancer cells may lower CAV1 protein levels in a nearby 
monoculture of fibroblasts, however the effect was small and outside of statistical 
significance. No difference was seen between non-contact co-culture of fibroblasts 
with differentiated monocytes in the presence and absence of direct contact with 
fibroblasts.   
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In contrast, co-culture of hTERT-fibroblasts stably expressing eNOS with control 
hTERT fibroblasts resulted in CAV1 downregulation in both types of fibroblasts, 
suggesting a ‘field effect’ driven by oxidative stress (Martinez-Outschoorn et al., 
2010a). In this study co-cultures of hTERT-BJ with MCF7 showed evidence of 
increased fibroblastic ROS and NO production and it was proposed that CAFs 
activate neighbouring fibroblasts through the production of ROS and nitric oxide 
(NO) species (Martinez-Outschoorn et al., 2010a).  
 
CAF marker expression 
Loss of fibroblastic CAV1 levels has been proposed to drive fibroblast activation and 
induce a myofibroblast phenotype, characterised by increased αSMA expression 
(Martinez-Outschoorn et al., 2010b). A study by Martinez-Outschoorn et al. (2010b) 
reported increased fibroblastic αSMA expression after contact co-culture of 
immortalised skin fibroblasts with breast cancer cells, as well as in CAV1 siRNA 
transfected fibroblasts. In contrast, a study by Kunz-Schughart et al. (2001) showed 
that breast cancer cells were not capable of inducing αSMA expression in normal skin 
fibroblasts after co-culture.  
 
The results presented in this chapter do not show a correlation between low 
fibroblastic CAV1 levels and high αSMA expression. Neither non-contact co-culture 
with cancer cells, nor non-contact co-culture with differentiated monocytes, resulted 
in altered fibroblastic αSMA levels. Interestingly, the highest fibroblastic αSMA 
levels were measured after non-contact co-culture with a mixed population of breast 
cancer cells and fibroblasts, although these levels were not significantly higher than 
the control. This trend may provide a further indication that close contact between 
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fibroblasts and cancer cells resulted in the activation of physically separated 
fibroblasts through a paracrine effect. It is important to note, however, that not all 
CAFs express αSMA and CAFs that do not express αSMA may also play a role in 
cancer progression (Sugimoto et al., 2006). 
 
Variability in CAV1 levels between experiments 
The effect on fibroblastic CAV1 levels that is seen after non-contact co-cultures of 
fibroblasts with breast cancer cells and differentiated monocytes is subject to large 
variability between replicates. This variability may be in part due to instability of the 
reference gene β-actin. Indeed, the level of β-actin mRNA across co-culture 
conditions was found to be more variable compared to GAPDH mRNA levels.  
 
Figures 7 and 9 both show fibroblastic CAV1 levels after co-culture of Fre85 
fibroblasts with MDA-MB-231 breast cancer cells and differentiated monocytes. The 
fibroblastic CAV1 mRNA levels from co-cultures shown in Figure 7 were measured 
against the β-actin reference gene. As part of the cytoskeleton, β-actin mediates 
internal cell motility.  Caveolae are closely associated with actin fibres and CAV1 is 
thought to physically link to actin fibres through filamin A (Muriel et al., 2011). Both 
caveolae lateral migration and internalisation are facilitated by the actin cytoskeleton, 
and its associated proteins (Parton and del Pozo, 2013). It is therefore possible that 
changes in CAV1 levels have an effect on β-actin levels in the cell and vice versa.  
 
In addition to a different reference gene used to assess CAV1 mRNA levels, the Fre85 
fibroblasts used in the experiment shown in Figure 7 were from different batches of 
frozen stocks. In the experiment shown in Figure 9, the same batch of fibroblasts was 
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used for the replicate co-cultures, and a strongly significant reduction of fibroblastic 
CAV1 mRNA levels, relative to the more stable reference gene GAPDH, was seen in 
the presence of breast cancer cells and differentiated monocytes. The experiment 
shown in Figure 7 included a batch of fibroblasts that showed higher fibroblastic 
CAV1 protein levels, but not mRNA levels, after co-culture with cancer cells and 
differentiated monocytes (single experiment, data not shown). Interestingly, after 16 
days and 2 passages in culture, that same batch of cells showed lower fibroblastic 
CAV1 protein levels after co-culture with cancer cells and differentiated monocytes 
(single experiment, data not shown). This variability in response to co-culture 
contributed to the variability in the data seen in Figure 7. The apparent switch in the 
response of Fre85 fibroblasts to co-culture, was further observed in one other batch of 
Fre85 fibroblasts (single experiment, data not shown), and suggests that changes in 
the phenotype of the cells, occurring over the culture period, for example epigenetic 
changes, may play a role in the regulation of fibroblastic CAV1 levels. 
 
Conclusion 
The results shed light on the potential role of a soluble factor/factors in the reduction 
of CAV1 in CAFs, relative to normal fibroblasts. Although the study suggests that 
breast cancer cells have a minimal influence on CAV1 levels in human fibroblasts in 
a non-contact fashion in this in vitro setting, the study shows for the first time that the 
involvement of differentiated monocytes does significantly reduce fibroblastic CAV1 
levels in a non-contact co-culture. This points to the possibility that the reduced levels 
of CAV1 levels observed in the tumour stroma from a population of cancer patients 
with significantly worse outcomes, as found by multiple independent studies (El-
Gendi et al., 2012; Qian et al., 2011; Simpkins et al., 2012; Sloan et al., 2009; 
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Witkiewicz et al., 2009b), may be caused by the recruitment of macrophages to the 
tumour site.  
 
The cell lines included in this research were embryonic mouse fibroblasts, mouse 
primary mammary fibroblasts, human primary skin fibroblasts, human immortalized 
skin fibroblasts, and human primary breast fibroblasts (chapters 3-6). Unfortunately, 
access to further relevant cell lines and human tumour tissue was not available. 
Further research is needed to determine the effect of monocytes/macrophages on 
fibroblastic CAV1 levels in different cell lines, and to evaluate the findings from the 
in vitro system presented in this chapter in vivo. 
 
A significant finding of the experiments was that CAV1 levels in fibroblasts appear 
unstable, with relatively large variability between experiments and between batches of 
fibroblasts. Others have found that CAV1 levels in CAFs can either be lower (8 out of 
11 invasive ductal carcinoma (IDC) patients), the same (1 out of 11 IDC patients), or 
higher (2 out of 11 IDC patients), than in nearby unaffected fibroblasts (Mercier et al., 
2008). In hTERT-BJ and MCF7 contact co-cultures described by Martinez-
Outschoorn et al. (2010b), after 7 days of co-culture with MCF7 breast cancer cells, 
some sections of the co-culture were found to contain fibroblasts that showed higher 
levels of CAV1 protein. Furthermore, in the co-culture system reported in this 
chapter, the increase in CAV1 protein in hTERT-BJ fibroblasts after non-contact co-
culture with MDA-MB-231 breast cancer cells was not accompanied by a concurrent 
increase in CAV1 mRNA levels, whereas the reduction of CAV1 levels in Fre85 
fibroblasts after non-contact co-culture with MDA-MB-231 breast cancer cells and 
TPA-treated THP-1 cells was evident at both the mRNA and protein level. Together, 
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this suggests the involvement of additional regulatory mechanisms of CAV1 
expression in fibroblasts. Further research is required to determine the mechanism(s) 
of CAV1 regulation in Fre85 fibroblasts. 
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Chapter 4: Caveolin-1 expression in fibroblasts in contact 
co-culture with cancer cells  
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Introduction 
The previous chapter found that non-contact co-culture between Fre85 fibroblasts, 
and MCF7 or MDA-MB-231 breast cancer cells, did not lead to significant changes in 
fibroblastic caveolin-1 (CAV1) levels; however, the inclusion of differentiated 
monocytes did result in a significant decrease in CAV1 levels in Fre85 fibroblasts. 
The current chapter will investigate the effect of contact co-culture on fibroblastic 
CAV1 levels. 
 
In breast cancer, most tumours develop as a lesion in the ductal or lobular epithelium. 
In this situation, the tissue architecture is largely intact, and the cancer cells are 
contained in the epithelial compartment by the basement membrane (Bissell and 
Hines, 2011). Interaction between the cancer cells and stromal cells occurs through 
the extracellular matrix (ECM), rather than through direct cell contact (Joyce and 
Pollard, 2009).  
 
As the cancer progresses, and once the basement membrane is compromised, the 
cancer cells make contact with the stromal ECM. The interaction of the cancer cells 
with the stromal ECM results in the upregulation of MMPs and invasion and 
metastasis promoting signalling (Bissell and Hines, 2011). At this stage, the 
neoplastic growth may break out of the epithelial compartment, and physical contact 
between cancer cells and fibroblasts can occur.  
 
In non-contact co-cultures, the signalling between the physically separated cell 
populations is limited to paracrine (e.g., cytokines or exosomes), and autocrine, 
interactions. In addition, the distance between the cell populations in the co-culture 
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system potentially limits paracrine signalling. In contact co-culture systems, 
juxtacrine interactions (e.g., membrane proteins-ligands or gap junctions) are 
possible, in addition to paracrine and autocrine signalling. 
 
In a study by Martinez-Outschoorn et al. (2010b), hTERT-BJ immortalised human 
skin fibroblasts were grown together with MCF7 human breast cancer cells in a 
contact co-culture system. When cancer cells were seeded at low numbers in relation 
to fibroblast numbers (i.e., a 5:1 fibroblast to cancer cell ratio), MCF7 showed better 
proliferation, compared to being seeded in the absence of fibroblasts. The fibroblasts 
showed an altered shape and orientation in co-culture with MCF7 cancer cells, 
compared to monoculture, as well.  
 
In this study, a reduction in CAV1 protein expression by fibroblasts was seen after 5 
days of co-culture with MCF7 breast cancer cells by confocal microscopy (Martinez-
Outschoorn et al., 2010b). This downregulation of CAV1 was reported to be mediated 
through lysosomal degradation, as treatment with lysosomal inhibitor chloroquine, but 
not with proteasomal inhibitor MG-132, rescued CAV1 expression (Martinez-
Outschoorn et al., 2010b). Interestingly, after 7 days of co-culture with MCF7 breast 
cancer cells, some sections of the co-culture were found to contain fibroblasts that 
showed an upregulation of CAV1 protein (Martinez-Outschoorn et al., 2010b). 
 
The current chapter investigates whether the results reported by Martinez-Outschoorn 
et al. (2010b) can be replicated with primary human breast fibroblasts Fre85, and 
using qPCR and Western analysis to determine CAV1 levels. In addition, the role of 
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THP-1 monocytes in fibroblast and cancer co-cultures, and their effect on fibroblastic 
CAV1 levels is examined. 
 
Aims 
The main aim of this study was to determine whether contact co-culture of tumour 
cells and fibroblasts influences the expression of CAV1 in fibroblasts. 
 
The specific aims were: 
 
• To determine whether an effect of breast cancer cells on fibroblastic CAV1 levels was 
tissue-specific; i.e., whether breast fibroblasts respond differently compared to skin 
fibroblasts. 
 
• To determine whether an effect of breast cancer cells on fibroblastic CAV1 levels was 
dependent on the invasiveness of the cancer cells. 
 
• To investigate a potential role of (differentiated) monocytes in influencing fibroblastic 
CAV1 levels. 
 
Results 
Co-cultures of immortalised human skin fibroblasts and breast cancer cells 
The data presented in the previous chapter showed no significant changes in hTERT-
BJ CAV1 levels after non-contact co-culture with breast cancer cells. To investigate 
whether there is an effect on fibroblastic CAV1 levels in contact co-cultures, CAV1 
levels in hTERT-BJ were analysed in contact co-cultures with MCF7 using confocal 
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microscopy on immunofluorescently labelled cells. No significant changes in 
fibroblastic CAV1 levels were observed after 5 days of contact co-culture with MCF7 
(Fig 1A-C). Quantification of the immunofluorescent signal showed CAV1 levels in 
hTERT-BJ in co-culture to be 1.16 ± 0.14 fold the levels in hTERT-BJ monocultures 
for co-cultures with a 2 to 1 fibroblast to cancer cell ratio (Fig. 1D analysis based on 1 
experiment, 2 separate images, 6 individual cells). For a 6 to 1 fibroblast to cancer 
cell ratio, the CAV1 fluorescent signal was 2.05 ± 0.14 fold the levels in hTERT-BJ 
monocultures (Fig. 1D analysis based on 1 experiment, 2 separate images, 6 
individual cells). 
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Figure 1: Immunofluorescence microscopy of contact co-culture of immortalised human 
skin fibroblasts (hTERT-BJ) with a mildly invasive (MCF7) breast cancer cell line. After 
5 days of contact co-culture, cells were fixed and immuno-labelled with antibodies against 
CAV1 (green) and cytokeratin 8 (red). Nuclei were stained with Draq5 (blue). (A) Mono-
culture of immortalised human skin fibroblasts (hTERT-BJ). (B) Immortalised human skin 
fibroblasts (hTERT-BJ) were co-cultured with a mildly invasive human breast cancer cell line 
(MCF7) at a 6:1 fibroblast to cancer cell ratio. (C) Immortalised human skin fibroblasts 
(hTERT-BJ) were co-cultured with a mildly invasive human breast cancer cell line (MCF7) at 
a 2:1 fibroblast to cancer cell ratio. (D) Mean total CAV1 fluorescence of fibroblasts in co-
culture, based on 1 experiment, 2 separate images, 6 separate cells. Results for the co-cultures 
are relative to the fibroblast monoculture control. Error bars represent the standard error of 
the mean. BJ=hTERT-BJ, MCF=MCF7 
 
In addition to confocal microscopy on immunofluorescently labelled co-cultures, 
CAV1 levels in fibroblasts were also measured using Western analysis and qPCR. 
Triplicate contact co-culture experiments showed lower CAV1 mRNA and protein 
levels in co-cultures of hTERT-BJ immortalised human skin fibroblasts and MCF7 
human breast cancer cells (Fig. 2). CAV1 levels were measured in the mixed cell 
population of fibroblasts and cancer cells, after 48 hours of co-culture. Figure 2A 
shows lower CAV1 mRNA levels after co-culture of hTERT-BJ with MCF7 (0.37 ± 
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0.08 fold), compared to monocultures of hTERT-BJ. Likewise, CAV1 protein levels 
are reduced (0.39 ± 0.18 fold) in hTERT-BJ and MCF7 co-cultures, compared to the 
monoculture control (Fig. 2B,C). As can be seen from the MCF7 monoculture control 
in Figure 2, MCF7 human breast cancer cells did not express detectable levels of 
CAV1 mRNA or protein (Fig. 2), thus causing a dilution of CAV1 to occur in mixed 
populations of fibroblasts and MCF7 cells. The reduction in CAV1 mRNA and 
protein seen in the co-cultures is, therefore, at least in part due to the presence of 
MCF7 cells that are CAV1 negative.  
 
 
Figure 2: Contact co-culture of immortalised human skin fibroblasts (hTERT-BJ) with 
a mildly invasive (MCF7) breast cancer cell line. Results for the co-cultures are relative to 
the fibroblast monoculture control. Error bars represent the standard error of the mean.  
* p<0.05 (A) CAV1 mRNA levels, relative to β-actin levels, were detected using qRT-PCR. 
CAV1 mRNA levels were significantly decreased after 48 hours of co-culture with MCF7. 
CAV1 mRNA levels in MCF7 monocultures were significantly lower than in hTER-BJ 
monocultures. Results are representative of 3 independent experiments. (B) Western analysis 
of CAV1 protein levels, relative to total protein levels, as detected by Ponceau staining. 
CAV1 protein levels in MCF7 monocultures were significantly lower than in hTER-BJ 
monocultures. Results are representative of 3 independent experiments. (C) Representative 
Western analysis image. β-actin is shown as a loading control. BJ=hTERT-BJ, MCF=MCF7 
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In addition to the mildly invasive MCF7 breast cancer cells, that were reported by 
others to cause a reduction in hTERT-BJ CAV1 levels after contact co-culture, the 
effect of the presence of highly invasive MDA-MB-231 breast cancer cells in contact 
co-culture was analysed in this study. Triplicate 48-hour contact co-culture 
experiments of HTERT-BJ with MDA-MB-231 resulted in fibroblastic CAV1 mRNA 
levels that were 1.57 ± 0.26 fold the monoculture control (Fig. 3A) and fibroblastic 
CAV1 protein levels that were 1.14 ± 0.39 fold the monoculture control (Fig. 3B). 
Baseline CAV1 protein levels differed significantly between experiments, resulting in 
large error bars that may have obscured changes (Fig. 3B). Figure 3C shows a 
representative Western image.  
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Figure 3: Contact co-culture of immortalised human skin fibroblasts (hTERT-BJ) with 
a highly invasive (MDA-MB-231) breast cancer cell line. Results for the co-cultures are 
relative to the fibroblast monoculture control. Error bars represent the standard error of the 
mean. (A) CAV1 mRNA levels, relative to β-actin levels, were detected using qRT-PCR. No 
significant changes in CAV1 mRNA levels were detected after 48 hours of co-culture. Results 
are representative of 3 independent experiments. (B) Western analysis of CAV1 protein 
levels, relative to total protein levels, as detected by Ponceau staining. No significant changes 
in CAV1 protein levels were detected after 48 hours of co-culture. Results are representative 
of 3 independent experiments. (C) Representative Western analysis image. β-actin is shown 
as a loading control. BJ=hTERT-BJ, MDA=MDA-MB-231 
 
CAV1 levels in hTERT-BJ fibroblasts after contact co-culture with MDA-MB-231 
were not analysed using confocal microscopy of immunofluorescently labelled cells, 
as these two cell types display great resemblance, both in cell shape and size, and in 
the cellular markers they express (e.g., CK8, αSMA, and fibroblast surface antigen 
(SFA), data not shown), thus being difficult to distinguish using this technique (see 
Figure 4 for the appearance of MCF7 (A) and MDA-MB-231 (B) in 
immunofluorescence microscopy). 
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Figure 4: Immunofluorescence microscopy of human breast cancer cells. Cells were fixed 
and immuno-labelled with antibodies against CAV1 (green) and cytokeratin 8 (red). Nuclei 
were stained with Draq5 (blue). (A) Mildly invasive human breast cancer cell line MCF7. (B) 
Highly invasive human breast cancer cell line MDA-MB-231.  
 
Co-cultures of primary human breast fibroblasts with breast cancer cells 
In the previous chapter human primary breast fibroblasts (Fre85) were shown to 
respond differently, compared to immortalised hTERT-BJ fibroblasts, to non-contact 
co-culture with breast cancer cells. In the case of contact co-culture of Fre85 
fibroblasts with MCF7 or MDA-MB-231 breast cancer cells, confocal microscopy of 
fluorescently labelled cultures showed no significant changes in fibroblastic CAV1 
levels (Fig. 5A-C), which was similar to the response seen in hTERT-BJ fibroblasts, 
as described above and shown in Figure 1.  
 
Contact co-culture of Fre85 with MCF7 for 5 days, at a 6:1 fibroblast to cancer cell 
ratio, resulted in a fibroblastic fluorescent signal from CAV1 that was 1.65 ± 0.17 
fold the signal from the monoculture control (Fig. 5D). Duplicate contact co-culture 
experiments of Fre85 with MCF7, at a 2:1 fibroblast to cancer cell ratio, resulted in a 
fibroblastic fluorescent signal from CAV1 that was 1.14 ± 0.14 fold the signal from 
the monoculture control (Fig. 5D, analysis based on 2 experiments, 4 separate images, 
12 individual cells). 
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Figure 5: Immunofluorescence microscopy of contact co-cultures of immortalised 
human skin fibroblasts (hTERT-BJ) with a mildly invasive (MCF7) breast cancer cell 
line. After 5 days of co-culture cells were fixed and immuno-labelled with antibodies against 
CAV1 (green) and cytokeratin 8 (red). Nuclei were stained with Draq5 (blue). (A) Mono-
culture of primary human breast fibroblasts (Fre85). (B) Primary human breast fibroblasts 
(Fre85) were co-cultured with a mildly invasive human breast cancer cell line (MCF7) at a 6 
fibroblasts to 1 cancer cell ratio. (C) Primary human breast fibroblasts (Fre85) were co-
cultured with a mildly invasive human breast cancer cell line (MCF7) at a 2 fibroblasts to 1 
cancer cell ratio. (D) Mean total CAV1l fluorescence of fibroblasts in co-culture, based on 2 
experiments, 4 separate images, 12 separate cells. Results for the co-cultures are relative to 
the fibroblast monoculture control. Error bars represent the standard error of the mean. 
Fre=Fre85, MCF=MCF7 
 
As MCF7 cells were shown to have undetectable CAV1 levels, leading to dilution of 
overall levels in the co-culture, 48-hour triplicate co-cultures of Fre85 fibroblasts with 
MDA-MB-231 cells were analysed using qPCR and Western analysis. In contact co-
cultures of Fre85 with MDA-MB-231, the CAV1 mRNA levels were 1.21 ± 0.25 fold 
the CAV1 mRNA levels in Fre85 monocultures (Fig. 6A). CAV1 protein levels in co-
cultures of Fre85 fibroblasts with MDA-MB-231 cancer cells were 1.65 ± 0.55 fold 
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the CAV1 protein levels in monoculture controls (Fig. 6B). There was a high degree 
of variability in CAV1 levels measured between experiments and none of the changes 
were statistically significant.  
 
Figure 6: Contact co-culture of primary human breast fibroblasts (Fre85) with a highly 
invasive (MDA-MB-231) breast cancer cell line. Results for the co-cultures are relative to 
the fibroblast monoculture control. Error bars represent the standard error of the mean. (A) 
CAV1 mRNA levels, relative to β-actin levels, were detected using qRT-PCR. No significant 
changes in CAV1 mRNA levels were detected after 48 hours of co-culture. Results are 
representative of 2 independent experiments. (B) Western analysis of CAV1 protein levels, 
relative to total protein levels, as detected by Ponceau staining. No significant changes in 
CAV1 protein levels were detected after 48 hours of co-culture. Results are representative of 
3 independent experiments. (C) Representative Western analysis image. β-actin is shown as a 
loading control. Fre=Fre85, MDA=MDA-MB-231 
 
Co-cultures of primary human breast fibroblasts with monocytes 
As there was significant variability in CAV1 mRNA and protein levels after 3-day co-
cultures of fibroblasts with cancer cells, CAV1 levels were assessed over the course 
of 10 days, to determine whether a time point could be found at which CAV1 levels 
were more consistent between experiments. Triplicate contact co-cultures of Fre85 
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with MDA231, as well as triplicate monocultures of MDA-MB-231, showed large 
variability in CAV1 protein levels over the course of 10 days (Fig. 7A).  
 
Previous experiments showed a reduction of fibroblastic CAV1 levels after the 
inclusion of THP-1 cells in non-contact co-cultures of Fre85 and MDA-MB-231. To 
investigate whether THP-1 monocytes influence the expression of CAV1 in 
fibroblasts upon contact co-culture in a similar way, Fre85 fibroblasts were cultured 
together with THP-1 monocytes. The inclusion of THP-1 in this contact co-culture 
model resulted in the decrease of CAV1 levels in the mixed cell populations of 
fibroblast and monocyte (Fig. 7B). 
 
In contrast to Fre85 co-cultures with cancer cells, CAV1 protein levels in triplicate 
Fre85 co-cultures with monocytes were significantly lower after 10 days. CAV1 
levels were 0.58 ± 0.22 fold the monoculture control after 3 days, 0.53 ± 0.25 fold the 
monoculture control after 5 days, 0.42 ± 0.19 fold the monoculture control after 7 
days, and 0.54 ± 0.07 fold the monoculture control (p<0.05 after 10 days (Fig. 7B). 
THP-1 is a non-adherent cell line that does not express high levels of CAV1. A small 
portion of the THP-1 cells were observed to adhere to the culture substrate and, 
therefore, contributed to overall CAV1 levels measured in the mixed populations.  
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Figure 7: Non-contact co-culture of human primary breast fibroblasts (Fre85) with a 
highly invasive (MDA-MB-231) human breast cancer cell line and an undifferentiated 
(THPD) or differentiated (THPT) monocytic cell line over 10 days. Results for the co-
cultures are relative to the fibroblast monoculture control. Error bars represent the standard 
error of the mean. * p<0.05 (A) Western analysis of CAV1 protein levels, relative to total 
protein levels, as detected by Ponceau staining. Results are representative of 3 independent 
experiments. (B) Presenting the Fre85 and THP-1 co-cultures only. Western analysis of 
CAV1 protein levels, relative to total protein levels, as detected by Ponceau staining. CAV1 
protein levels were significantly lower after 10 days of co-culture of Fre85 and THP-1 
compared to a Fre85 monoculture control. Results are representative of 3 independent 
experiments. Fre=Fre85, MDA=MDA-MB-231, THP=THP-1  
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The reduction in CAV1 levels seen in contact co-cultures of Fre85 fibroblasts with 
THP-1 monocytes using Western analysis was not corroborated with confocal 
microscopy of fluorescently labelled 5-day co-cultures. A monoculture of Fre85 (Fig. 
8A), a contact co-culture of Fre85 with THP-1 (Fig. 8B) and a triple culture of Fre85, 
MCF7 and THP-1 (Fig. 8C), were immunofluorescently labelled with antibodies to 
CAV1 and cytokeratin 8.  Analysis of the fluorescent signal from the confocal images 
showed that fibroblastic CAV1 levels in contact co-cultures of Fre85 and THP-1 were 
1.05 ± 0.11 fold levels in the monoculture control (Fig. 8D). Analysis of confocal 
images did, however, show a trend towards a reduction (0.41 ± 0.15 fold, analysis 
based on 2 experiments, 4 separate images, 12 individual cells) of fibroblastic CAV1 
levels after contact co-culture of Fre85 fibroblasts with MCF7 cancer cells and THP-1 
monocytes combined (triple culture). 
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Figure 8: Immunofluorescence microscopy of contact co-culture of primary human 
breast fibroblasts (Fre85) with a mildly invasive (MCF7) breast cancer cell line and a 
monocytic cell line (THP-1). After 5 days of culture, cells were fixed and immuno-labelled 
with antibodies against CAV1 (green) and cytokeratin 8 (red). Nuclei were stained with 
Draq5 (blue). (A) Mono-culture of primary human breast fibroblasts (Fre85). (B) Primary 
human breast fibroblasts (Fre85) were co-cultured with a monocytic cell line (THP-1) at a 2 
fibroblasts to 1 monocyte ratio. (C) Primary human breast fibroblasts (Fre85) were co-
cultured with a mildly invasive human breast cancer cell line (MCF7) and a monocytic cell 
line (THP-1) at a 2 fibroblasts to 1 cancer cell and 1 monocyte ratio. (D) Mean total CAV1 
fluorescence of fibroblasts in co-culture, based on 2 experiments, 4 separate images, 12 
separate cells. Results for the co-cultures are relative to the fibroblast monoculture control. 
Error bars represent the standard error of the mean. Fre=Fre85, MCF=MCF7, THP=THP-1 
 
To investigate whether this trend towards a reduction in fibroblastic CAV1 levels was 
specific to Fre85 fibroblasts, hTERT-BJ fibroblasts were similarly cultured in the 
presence of MCF7 cancer cells and THP-1 monocytes, and cultures were labelled for 
confocal microscopy (Fig. 9A,B). Analysis of the fluorescent signal from CAV1 
antibody labelling of cultures revealed a trend towards an increase of fibroblastic 
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CAV1 levels after contact co-culture (1.79 fold ± 0.40) (Fig. 9C, analysis based on 1 
experiment, 2 separate images, 6 individual cells). 
 
 
Figure 9: Immunofluorescence microscopy of contact co-culture of primary human 
breast fibroblasts (Fre85) with a mildly invasive (MCF7) breast cancer cell line and a 
monocytic cell line (THP-1). After 5 days of culture, cells were fixed and immuno-labelled 
with antibodies against CAV1 (green) and cytokeratin 8 (red). Nuclei were stained with 
Draq5 (blue). (A) Mono-culture of human immortalised skin fibroblasts (hTERT-BJ). (B) 
Human immortalised skin fibroblasts (hTERT-BJ) were co-cultured with a mildly invasive 
human breast cancer cell line (MCF7) and a monocytic cell line (THP-1) at a 2 fibroblasts to 
1 cancer cell and 1 monocyte ratio. (C) Mean total CAV1 fluorescence of fibroblasts in co-
culture, based on 1 experiment, 2 separate images, 6 separate cells. Results for the co-cultures 
are relative to the fibroblast monoculture control. Error bars represent the standard error of 
the mean. BJ=hTERT-BJ, MCF=MCF7, THP=THP-1 
 
Fluorescence Activated Cell Sorting 
To provide further support for data showing changes in CAV1 levels after co-culture, 
the fibroblast compartment and the cancer cell compartment were analysed separately, 
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using Fluorescence Activated Cell Sorting (FACS). In order to be able to sort cells 
using FACS, cell populations had to be made distinguishable through fluorescent 
labelling. In initial experiments, MCF7 cells labelled with tdTomato fluorescent 
protein were used in the co-cultures. FACS analysis of tdTomato-labelled MCF7 
cells, however, showed the presence of unlabelled cells (20% of viable cells), thus 
MCF7 cells could not be reliably identified in the co-cultures during FACS. 
 
To resolve the issue of contamination of the fibroblast population with unlabelled 
cancer cells, positive sorting (i.e., sorting for labelled cells), instead of negative 
sorting (i.e., sorting for unlabelled cells), was performed. Fre85 fibroblasts were 
labelled with CFDA-SE, and successfully removed from the mixed population of the 
co-culture system by FACS. The effect of the labelling procedure, and the preparation 
of cells for FACS, on cell viability was analysed and found to be insignificant (data 
not shown). 
 
Analysis after cell sorting showed large inter-experimental variability in fibroblastic 
CAV1 mRNA and protein levels, after 5 days of co-culture with human breast cancer 
cells (Fig. 10, 11 and 13), and changes were not significant. Triplicate contact co-
cultures of Fre85 primary human fibroblasts with MCF7 breast cancer cells resulted 
in a 1.02 fold ± 0.22 change in fibroblastic CAV1 mRNA levels (Fig. 10A), and a 
1.06 fold ± 0.53 change in fibroblastic CAV1 protein levels (Fig. 10B,C).   Triplicate 
contact co-cultures of Fre85 primary human fibroblasts with MDA-MB-231 breast 
cancer cells resulted in a 1.20 fold ± 0.53 increase in fibroblastic CAV1 mRNA levels 
(Fig. 11A), and a 1.04 fold ± 0.60 change in fibroblastic CAV1 protein levels (Fig. 
11B,C).   
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Figure 10: Fibroblastic CAV1 levels in contact co-cultures of primary human breast 
fibroblasts (Fre85) with a mildly invasive (MCF7) breast cancer cell line after FACS. 
CAV1 levels in fibroblasts were measured after cell sorting. Results for the co-cultures are 
relative to the fibroblast monoculture control. Error bars represent the standard error of the 
mean. (A) CAV1 mRNA levels, relative to β-actin levels, were detected using qRT-PCR. No 
significant changes in fibroblastic CAV1 mRNA levels were detected after 5 days of co-
culture. Results are representative of 3 independent experiments. (B) Western analysis of 
CAV1 protein levels, relative to total protein levels, as detected by Ponceau staining. No 
significant changes in fibroblastic CAV1 protein levels were detected after 5 days of co-
culture. Results are representative of 3 independent experiments. (C) Representative Western 
analysis image. β-actin is shown as a loading control. Fre=Fre85, MCF=MCF7 
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Figure 11: Fibroblastic CAV1 levels in contact co-cultures of primary human breast 
fibroblasts (Fre85) with a highly invasive (MDA-MB-231) breast cancer cell line after 
FACS. CAV1 levels in fibroblasts were measured after cell sorting. Results for the co-
cultures are relative to the fibroblast monoculture control. Error bars represent the standard 
error of the mean. (A) CAV1 mRNA levels, relative to β-actin levels, were detected using 
qRT-PCR. No significant changes in fibroblastic CAV1 mRNA levels were detected after 5 
days of co-culture. Results are representative of 3 independent experiments. (B) Western 
analysis of CAV1 protein levels, relative to total protein levels, as detected by Ponceau 
staining. No significant changes in fibroblastic CAV1 protein levels were detected after 5 
days of co-culture. Results are representative of 3 independent experiments. (C) 
Representative Western analysis image. β-actin is shown as a loading control. Fre=Fre85, 
MDA=MDA-MB-231 
 
In contrast, triplicate contact co-cultures with THP-1 monocytes showed a more 
consistent change in fibroblastic CAV1 levels, and resulted in fibroblastic CAV1 
mRNA levels that were 0.41 fold ± 0.20 fold the control (Fig. 12A, p=0.1), and in a 
0.36 fold ± 0.11 (p<0.05) reduction in fibroblastic CAV1 protein levels (Fig. 12B,C), 
compared the monoculture control.  
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Figure 12: Fibroblastic CAV1 levels contact co-cultures of primary human breast 
fibroblasts (Fre85) with a monocytic cell line (THP-1) after FACS. CAV1 levels in 
fibroblasts were measured after cell sorting. Results for the co-cultures are relative to the 
fibroblast monoculture control. Error bars represent the standard error of the mean. * p<0.05 
against control (A) CAV1 mRNA levels, relative to β-actin levels, were detected using qRT-
PCR. No significant changes in fibroblastic CAV1 mRNA levels were detected after 5 days 
of co-culture. Results are representative of 3 independent experiments. (B) Western analysis 
of CAV1 protein levels, relative to total protein levels, as detected by Ponceau staining. 
Fibroblastic CAV1 protein levels were significantly lower after 5 days of contact co-culture 
with THP-1. Results are representative of 3 independent experiments. (C) Representative 
Western analysis image. β-actin is shown as a loading control. Fre=Fre85, THP=THP-1 
 
Analysis of fibroblastic CAV1 protein levels of FACS sorted hTERT-BJ fibroblasts 
after 5 days of contact co-culture with MCF7 breast cancer cells did not show a 
significant change compared to levels in hTERT-BJ monocultures (1.07 fold ± 0.30) 
(Fig. 13A,B).  
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Figure 13: Fibroblastic CAV1 levels in contact co-cultures of immortalised human skin 
fibroblasts (Fre85) with a mildly invasive breast cancer cell line (MCF7) after FACS. 
CAV1 levels in fibroblasts were measured after cell sorting. Results for the co-cultures are 
relative to the fibroblast monoculture control. Error bars represent the standard error of the 
mean. (A) Western analysis of CAV1 protein levels, relative to total protein levels, as 
detected by Ponceau staining. No significant changes in fibroblastic CAV1 protein levels 
were detected after 5 days of co-culture. Results are representative of 3 independent 
experiments. (B) Representative Western analysis image. β-actin is shown as a loading 
control. BJ=hTERT-BJ, MCF=MCF7 
 
Discussion 
CAV1 downregulation in fibroblast has been proposed as a marker of cancer 
progression (Sloan et al., 2009; Witkiewicz et al., 2009b). This study examined the 
effect of contact co-culture of fibroblasts with cancer cells and monocytes on 
fibroblastic CAV1 levels. The results show that contact co-culture of primary human 
breast fibroblasts with monocytes resulted in a decrease of CAV1 protein levels in the 
fibroblasts. This decrease in fibroblastic CAV1 levels was not seen in co-cultures of 
primary human breast fibroblasts with breast cancer cells, nor was a decrease in 
CAV1 protein levels seen in immortalised skin fibroblasts after contact co-culture 
with breast cancer cells, as has been reported previously (Martinez-Outschoorn et al., 
2010a; Martinez-Outschoorn et al., 2010b; Martinez-Outschoorn et al., 2010c). 
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Contact co-culture of fibroblasts with breast cancer cells 
Other reports have described contact co-culture of hTERT-BJ with MCF7 resulting in 
a reduction of fibroblastic CAV1 protein levels, as seen in confocal microscopy of 
antibody-labelled cells (Martinez-Outschoorn et al., 2010a; Martinez-Outschoorn et 
al., 2010b). This reduction was, however, not shown by Western analysis and solely 
shown by immunofluorescence.  
 
Confocal microscopy 
This study looked at the effects of contact co-culture of fibroblasts with breast cancer 
cells on fibroblastic CAV1 mRNA and protein levels, using immunofluorescent 
confocal microscopy, qPCR and Western analysis. For confocal microscopy, co-
cultures of fibroblasts were labelled with green-fluorescent antibodies to CAV1 and 
red-fluorescent antibodies to cytokeratin 8 (CK8). Cell nuclei were labelled with a 
nuclear stain. The use of a fluorescently labelled antibody to CAV1 enabled the level 
of CAV1 protein in cells to be determined. The use of CK8 staining enabled 
epithelial-like cancer cells, expressing high levels of CK8, to be distinguished from 
fibroblasts, which express little CK8. As MDA-MB-231 breast cancer cells have lost 
many of the epithelial-like characteristics of their pre-cancerous origins, among which 
is CK8 expression, distinguishing MDA-MB-231 cells from fibroblasts was difficult.  
 
Analysis of the fluorescent signal from CAV1 antibody staining showed no effect of 
contact co-culture of hTERT-BJ fibroblasts with MCF7 breast cancer cells on 
fibroblastic CAV1 levels. Likewise, contact co-culture of primary human breast 
fibroblasts Fre85 with MCF7 breast cancer cells showed no significant change in 
fibroblastic CAV1 levels.  
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qPCR and Western analysis 
Contact co-culture of immortalised human skin fibroblasts (hTERT-BJ) with mildly 
invasive (MCF7) or highly invasive (MDA-MB-231) breast cancer cells did not 
significantly affect fibroblastic CAV1 mRNA or protein levels, as determined by 
qPCR and Western analysis of the different cell populations after FACS. Similarly, 
breast cancer cells did not significantly affect CAV1 levels in primary human breast 
fibroblasts (Fre85).  
 
Co-cultures of hTERT-BJ fibroblasts and MCF7 breast cancer cells showed lower 
levels of CAV1 mRNA and protein levels compared to those in hTERT-BJ alone. 
However, as MCF7 cells did not express CAV1 to a detectable level, lower levels of 
CAV1 in co-cultures, as determined by qPCR and Western analysis, cannot be 
positively ascribed to reduced levels of CAV1 in hTERT-BJ, but could merely be an 
effect of diluting the pool of CAV1 expressing cells (hTERT-BJ) with CAV1 non-
expressing cells (MCF7). 
 
As MDA-MB-231 breast cancer cells express similar CAV1 mRNA and protein 
levels to hTERT-BJ fibroblasts, and slightly higher levels than Fre85 fibroblasts, a 
reduction in CAV1 levels after co-culture of fibroblasts with MDA-MB-231 breast 
cancer cells would be due to a reduction in CAV1 levels, rather than to dilution. For 
this reason, CAV1 levels were measured after contact co-culture of both hTERT-BJ, 
and Fre85, with MDA-MB-231, whereas contact co-culture with MCF7 was not 
duplicated in Fre85. No significant changes in CAV1 levels were found after contact 
co-culture of hTERT-BJ or Fre85 fibroblasts with MDA-MB-231 breast cancer cells. 
However, it cannot be determined whether any changes in this system would be due 
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to changes in the fibroblast compartment, or in the cancer cell compartment. 
Furthermore, it would be possible that any changes in the fibroblast compartment 
would, in this system, be masked by changes in the cancer cell compartment.  
 
To overcome the issues caused by measuring CAV1 levels in the whole system, 
CAV1 levels were measured in the individual cell compartments. To determine the 
CAV1 levels in the fibroblast compartment of our system, fibroblasts were separated 
from cancer cells by fluorescence-activated cell sorting (FACS) the cell populations 
after co-culture. FACS was attempted with tdTomato fluorescent protein labelled 
MCF7 cells and unlabelled fibroblasts, however, a population of insufficiently 
labelled MCF7 cells was detected. To prevent contamination of the fibroblast 
population with insufficiently labelled cancer cells, fibroblasts were fluorescently 
labelled and pulled out of the mixed co-culture, using FACS. This way, any 
insufficiently labelled cells would be included in the cell population that would not be 
evaluated for CAV1 levels, and contamination of the fibroblast fraction would be 
minimised. 
 
The fluorescent protein used for labelling the fibroblasts was 5(6)-carboxyfluorescein 
diacetate N-succinimidyl ester (CFDA-SE). Concentrations of CFDA-SE above 5 µM 
caused cell death in Fre85 fibroblasts (data not shown). Confocal microscopy on 
Fre85 fibroblasts labelled with different concentrations of CFDA-SE showed a 
concentration of 2 µM CFDA-SE to have a minimal effect on cell proliferation, while 
generating sufficient fluorescence in Fre85 (data not shown). However, analysis of the 
cell populations using FACS suggested that populations of non-viable and 
insufficiently labelled cells were present. Non-viable and insufficiently labelled cells 
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were excluded from the fibroblast population and were not analysed for CAV1 levels. 
The presence of non-viable cells suggests that the CFDA-SE-labelling of fibroblasts 
increased the sensitivity of cells to cell death during the cell sorting process. 
 
Analysis of fibroblastic CAV1 mRNA and protein levels in the fibroblastic 
compartment after FACS was performed using qPCR and Western analysis. CAV1 
levels in both immortalised human skin fibroblasts (hTERT-BJ), and primary human 
breast fibroblasts (Fre85), were not changed after contact co-culture with breast 
cancer cells. These findings are in line with the observations of fluorescently labelled 
co-cultures using confocal microscopy. However, these findings do not corroborate 
results published by others, which suggest that contact co-culture of hTERT-BJ with 
MCF7 results in a reduction of fibroblastic CAV1 protein levels (Martinez-
Outschoorn et al., 2010b). 
 
Data from immunofluorescence analysis using confocal microscopy is to be 
interpreted with caution when assessing expression levels of proteins. Fluorescence 
intensity is dependent on many factors, such as bleaching by excitation, focus-plane 
position, and quenching due to the presence of nearby dye molecules, to name a few. 
Any observed changes in fluorescence intensity should be confirmed by assessing 
protein levels through other techniques. This study has been unable to find a 
significant reduction of hTERT-BJ CAV1 protein levels after co-culture with MCF7 
by Western or qPCR, nor has it been able to reproduce the results described by 
Martinez-Outschoorn et al. (2010b) by confocal microscopy. This study, in contrast, 
shows that contact co-culture with breast cancer cells does not alter fibroblastic 
CAV1 levels, irrespective of the fibroblast cell line tested (hTERT-BJ or Fre85), the 
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cancer cell line included (MCF7 or MDA-MB-231) or the technique used for CAV1 
measurement (qPCR, Western analysis or confocal microscopy).  
 
Contact co-culture of fibroblasts with differentiated monocytes 
Previous experiments using a non-contact co-culture system have shown that 
differentiated THP-1 monocytes downregulated CAV1 levels in Fre85 fibroblasts. 
THP-1 cells express CAV1 at a very low level. THP-1 cells are non-adherent and 
should, therefore, not be collected together with the fibroblasts. However, a small 
portion of THP-1 cells was seen to attach in the cell culture system and, therefore, this 
same principle of dilution with low-expressing cells could explain the downregulation 
seen in contact co-culture with THP-1. 
 
To investigate whether there was a reduction in fibroblastic CAV1 levels in contact 
co-cultures of fibroblasts with monocytes, co-cultures were sorted into individual cell 
populations using FACS. Analysis of the fibroblasts collected after FACS of co-
cultures, showed a reduction in CAV1 mRNA and protein levels, although changes in 
mRNA levels were just outside of statistical significance. This confirms that the 
changes that were seen prior to cell sorting were indeed caused by a reduction of 
CAV1 levels in fibroblasts, and not by dilution of overall CAV1 levels in the co-
culture by low CAV1 expression in THP-1 monocytes. 
 
In contrast to the reduction in fibroblastic CAV1 levels seen after contact co-culture 
with monocytes by Western analysis and qPCR, confocal microscopy of 
immunofluorescently labelled co-cultures did not show a change in fibroblastic CAV1 
levels. It is possible that a difference in antibody sensitivity in immunofluorescent 
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labelling for confocal microscopy versus Western blotting is causing a potential 
reduction in CAV1 levels to be detected with Western blotting, but not with confocal 
microscopy.  
 
Although fluorescently labelled contact co-cultures of Fre85 fibroblasts and THP-1 
monocytes did not show a reduction in fibroblastic CAV1 levels by confocal 
microscopy, triple cultures of Fre85, MCF7 and THP-1, on the other hand, did show a 
trend towards reduced fibroblastic CAV1 levels by confocal microscopy. These 
results are in line with what was found in non-contact triple cultures with the same 
cell lines (previous chapter). It is possible that the presence of both cancer cells and 
immune cells results in a signalling dynamic that leads to reduced CAV1 levels in 
fibroblasts, or enhances the fibroblastic CAV1 reduction caused by immune cells 
alone. Further investigation is required to resolve the inconsistencies between 
immunofluorescence and Western blotting, where present. 
 
Fibroblastic CAV1 protein levels were decreased in a subset of breast cancer patients, 
and lower stromal CAV1 levels have been linked to worse outcomes in breast cancer 
(El-Gendi et al., 2012; Qian et al., 2011; Simpkins et al., 2012; Sloan et al., 2009; 
Witkiewicz et al., 2009b). In this study, contact co-cultures of fibroblasts and breast 
cancer cells did not result in decreased fibroblastic CAV1 levels. Possibly, the 
decrease in fibroblastic CAV1 levels seen in certain patients is caused by the 
recruitment of monocytes to the tumour site. The recruitment of monocytes, and 
infiltration of tumours by macrophages, is a well-described part of tumour 
progression (Hanahan and Weinberg, 2011; Ueno et al., 2000).  
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Interaction between cancer cells and fibroblasts involves the production of a plethora 
of cytokines, some of which play a role in the recruitment and differentiation of 
monocytes. Both fibroblasts and cancer cells can secrete cytokines that recruit 
monocytes. Cancer-associated fibroblasts secrete stromal cell-derived factor 1 
(SDF1), which recruits monocytes in a chemo-attraction assay, as does monocyte 
chemoattractant protein 1 (MCP1/CCL2) secreted by cancer cells (Comito et al., 
2014). In addition, macrophages produce cytokines, such as macrophage 
inflammatory protein 1α (MIP-1α), a monocyte/macrophage chemoattractant and 
macrophage activator, upon contact with fibroblasts (Steinhauser et al., 1998).  
 
There are several cytokines that have been shown to affect CAV1 expression. 
Macrophages express epidermal growth factor (EGF) and expression levels are, 
interestingly, increased in the presence of colony stimulating factor 1 (CSF-1), which 
is secreted by cancer cells (Goswami et al., 2005). EGF has been shown to 
downregulate CAV1 expression in human squamous carcinoma cells (Lu et al., 2003). 
GM-CSF secreted by fibroblasts increases CAV1 expression in monocytes and 
differentiates monocytes to macrophages (Fu et al., 2012). Further research is needed 
to investigate whether cytokines secreted in fibroblast and monocyte/macrophage co-
cultures are responsible for the reduction in fibroblastic CAV1 levels that was seen. 
 
Conclusion 
The reduction of CAV1 levels in cancer-associated fibroblasts has been associated 
with decreased survival in breast cancer patients. This in vitro study did not show an 
effect of cancer cells alone on changing CAV1 levels in fibroblasts. The study 
indicates, however, that the presence of monocytes/macrophages reduces CAV1 
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levels in fibroblasts. This suggests that the recruitment and differentiation of 
monocytes may play an important role in the reduction of fibroblastic CAV1 observed 
in patients. Increased tumour growth and angiogenesis in nude mice injected with 
human breast cancer cells and CAV1 -/- fibroblasts (Bonuccelli et al., 2010), shows 
that CAV1 downregulation is not merely a marker of  a progressive tumour stroma, 
but plays an active role in cancer progression. Therefore, understanding the 
mechanisms of CAV1 downregulation in fibroblasts may provide therapeutic targets 
for the treatment of a subset of breast cancer patients. 
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Chapter 5: Cytokines secreted by co-cultures of fibroblasts, 
breast cancer cells and (differentiated) monocytes 
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Introduction 
The data presented in Chapters 3 and 4 showed that non-contact and contact co-
culture of primary human fibroblasts with human breast cancer cells and 
(differentiated) monocytes alters fibroblastic caveolin-1 (CAV1) levels. In addition, 
unexplained variability in fibroblastic CAV1 levels between experiments was seen. 
This chapter will investigate factors that could affect variability in cell culture 
experiments.  
 
A potential mechanism through which co-culture could affect CAV1 levels is the 
secretion of soluble factors. This chapter will investigate the secretion of cytokines in 
non-contact and contact co-cultures. Cytokine concentrations are ideally measured in 
serum-free cell culture medium and this chapter will investigate the effect of a serum 
replacement on fibroblastic CAV1 levels and variability. 
 
Cytokines	in	co-cultures	
As the cell populations are physically separated in non-contact co-culture systems, 
one way that the different cell populations can communicate and affect gene 
regulation, is through paracrine signalling (Holt et al., 2010). In contact co-culture, 
the signalling that may occur could be of a paracrine or juxtacrine nature. Paracrine 
signalling can occur through the secretion of soluble factors, such as growth factors, 
cytokines (e.g., interleukins, chemokines, tumour necrosis factors, and other 
cytokines), as well as Wnt and Hedgehog proteins. Examples of other signalling 
mechanisms that could play a role in non-contact and contact co-culture are exosome 
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transfer, and signalling through metabolic cues (Ata and Antonescu, 2017; Luga et al., 
2012). 
 
Growth factors and cytokines are secreted by a wide range of cells, including 
macrophages, monocytes, fibroblasts, and cancer cells. The tumour 
microenvironment, a location these cell types share, is known to contain increased 
levels of many cytokines and growth factors (Korkaya et al., 2011). Co-culture of 
stromal cells with cancer cells, in vitro, has similarly been shown to lead to increased 
levels of different cytokines and growth factors. For example, co-culture of 
mesenchymal cells with breast cancer cells resulted in the increased production of 
CXC chemokines: CXCL5, CXCL6, and CXCL1, and of interleukins IL-6 and IL-8, 
in a study by Liu et al. (2011). Co-culture of fibroblasts with macrophages led to the 
increased production of IL-6, monocyte chemotactic protein-1 (MCP-1), and 
RANTES, in a study by Holt et al. (2010). 
 
Examples of CAV1 regulation by cytokines and growth factors have been reported in 
several different cell types. Epithelial growth factor (EGF), granulocyte-macrophage 
colony stimulating factor (GM-CSF), interferon γ (IFN-γ), and MCP-1, alter CAV1 
levels in human squamous carcinoma cells, monocytes, thyrocytes, and brain 
microvascular endothelial cells, respectively (Fu et al., 2012; Lu et al., 2003; Marique 
et al., 2014; Song et al., 2007).  
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In this chapter, the concentrations of several growth factors and cytokines in the 
conditioned medium from non-contact, and contact, co-cultures that show lowered 
fibroblastic CAV1 levels, was measured using a cytokine assay. The data from this 
assay could be used to select cytokine and growth factor candidates that can be 
investigated further for their potential ability to regulate CAV1 levels in fibroblasts. 
 
The	role	of	serum	in	cell	culture	
It is important that the measurements of cytokines and growth factors are performed 
against a controlled background. The conditioned medium that is used to determine 
the concentrations of cytokines and growth factors secreted by cells in the co-culture 
system is derived from cell culture medium. The addition of growth factor containing 
supplements to cell culture medium is common practice in cell culture, with foetal 
bovine serum (FBS) being a commonly used additive. FBS contains growth and 
adhesion factors, hormones, lipids, and minerals, and, being a natural product, the 
exact composition is variable, depending on the source (Baker, 2016). 
 
Alternatives to FBS as a supplement to cell culture medium have been developed, and 
implemented by researchers when factors in FBS are expected to interfere with 
experimental measurements or reproducibility (Van der Valk et al., 2010). For 
example, when cellular processes that are influenced by serum components (e.g., 
hormones, growth factors) are investigated, the use of serum is often problematic. 
Similarly, when studies require the measurement of secreted cellular products, the 
presence of serum proteins can complicate the measurements. This chapter will 
therefore investigate the effect of a chemically defined, serum-free cell culture 
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supplement (Serum Replacement 1, Sigma) on experimental outcomes and 
reproducibility in non-contact and contact co-cultures, preceding the measurement of 
cytokines in conditioned medium from the co-culture system.  
 
Aims 
The main aims of this study were to investigate the effect of factors, such as 
homogeneity in cell cycle phase, and the presence of serum, on experimental 
outcomes and reproducibility, and to measure cytokines in conditioned medium from 
co-cultures of fibroblasts, breast cancer cells, and (differentiated) monocytes. 
 
The specific aims were: 
 
• To investigate the effect of serum starvation on fibroblastic CAV1 levels after non-
contact co-culture with highly invasive breast cancer cells (MDA-MB-231) and 
differentiated monocytes (THPT). 
 
• To investigate the effect of serum concentration on fibroblastic CAV1 levels after 
non-contact co-culture with highly invasive breast cancer cells (MDA-MB-231) and 
THPT. 
 
• To investigate the effect of Serum Replacement 1 on fibroblastic CAV1 levels after 
non-contact co-culture with highly invasive breast cancer cells (MDA-MB-231) and 
THPT. 
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• To measure the concentrations of several cytokines in conditioned medium from non-
contact and contact co-cultures with lowered fibroblastic CAV1 levels.  
 
Results 
Previous experiments, including both non-contact (chapter 3) and contact co-cultures 
(chapter 4) of fibroblasts with cancer cells and lymphocytes, showed unexplained 
variability in CAV1 protein levels between experiments. To explore whether the 
presence of FBS could account for CAV1 variability between experiments, non-
contact co-cultures of Fre85 primary human breast fibroblasts with MDA-MB-231 
human breast cancer cells, and differentiated human monocytes (THPT), were 
cultured with 10% FBS, 2% FBS, heat-inactivated FBS, and with a serum 
replacement.  
 
The effect of serum starvation on fibroblastic CAV1 protein levels in co-cultures 
An often-cited technique to standardize cell culture experiments is serum starvation. 
Serum starvation causes cells to withdraw from the cell cycle and arrest in the G0/G1 
phase. The addition of serum after starvation causes cells to start dividing again, with 
all cells entering the cell cycle simultaneously, resolving any variability that may be 
caused by cells residing in different stages of the cell cycle. The comparison of 3-day 
non-contact co-cultures containing fibroblasts that were cultured with 0.2% FBS for 
24 hours prior to co-culture (starved fibroblasts), with non-contact co-cultures 
containing fibroblasts that were not starved prior to co-culture, showed no difference 
in CAV1 protein levels, or variability, between experiments (Fig. 1). Non-contact co-
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culture of Fre85 that had not been starved prior to co-culture, with MDA-MB-213 and 
THPT, led to CAV1 protein levels of 1.21 ± 0.30 fold the control levels (Fig. 1A,B). 
Non-contact co-culture of starved Fre85 with MDA-MB-213 and THPT in the 
presence of 10% FBS led to CAV1 protein levels of 1.15 ± 0.31 fold control (Fig. 
1A,B). In addition, fibroblastic CAV1 protein levels were analysed after 24 hours of 
co-culture, and no significant changes were detected (data not shown). 
 
Figure 1: Non-contact co-culture of human primary breast fibroblasts (Fre85) with a 
highly invasive (MDA-MB-231) human breast cancer cell line and a differentiated 
monocytic cell line (THPT) after serum starvation. Co-cultures using Fre85 that were 
serum-starved (0.2% FBS for 24 hours before co-cultures were set up) were compared with 
normal co-cultures. Results for the co-cultures are relative to the fibroblast monoculture 
control. Error bars represent the standard error of the mean. (A) Western analysis of CAV1 
protein levels, relative to total protein levels, as detected by Ponceau staining. No significant 
changes in fibroblastic CAV1 protein levels were detected after 3 days of co-culture. Serum 
starvation did not result in changes in experimental outcome or variability. Results are 
representative of 4 independent experiments. (B) Representative Western analysis image. β-
actin is shown as a loading control. Fre=Fre85, MDA=MDA-MB-231, THPT=TPA-treated 
THP-1 
 
The effect of serum reduction on fibroblastic CAV1 protein levels in co-cultures 
The reduction of FBS from 10% to 2% led to a reduction in variability of CAV1 
mRNA levels between experiments for 3 out of 5 conditions, and an increase for 2 out 
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5 conditions (Fig. 2). Non-contact co-culture of Fre85 with MDA-MB-231 led to 
CAV1 mRNA levels of 1.49 ± 0.29 (relative standard error (RSE) 20%) with 10% 
FBS (Fig. 2A, Table 1), and to levels of 0.91 ± 0.02 (RSE 2%) with 2% FBS (Fig. 2B, 
Table 2). Non-contact co-culture of Fre85 with THPT led to CAV1 mRNA levels of 
1.05 ± 0.05 (RSE 5%) with 10% FBS (Fig. 2A, Table 1), and to levels of 0.88 ± 0.15 
(RSE 17%) with 2% FBS (Fig. 2B, Table 2). Non-contact co-culture of Fre85 with 
undifferentiated THP-1 cells (THPD) led to CAV1 mRNA levels of 1.35 ± 0.14 (RSE 
10%) with 10% FBS (Fig. 2A, Table 1), and to levels of 0.74 ± 0.15 (RSE 21%) with 
2% FBS (Fig. 2B, Table 2). Non-contact co-culture of Fre85 with MDA-MB-231 and 
THPD led to CAV1 mRNA levels of 0.80 ± 0.53 (RSE 66%) with 10% FBS (Fig. 2A, 
Table 1), and to levels of 1.54 ± 0.54 (RSE 35%) with 2% FBS (Fig. 2B, Table 2). 
Non-contact co-culture of Fre85 with MDA-MB-231 and THPT led to CAV1 mRNA 
levels of 1.25 ± 0.82 (RSE 66%) with 10% FBS (Fig. 2A, Table 1), and to levels of 
0.43 ± 0.09 (RSE 21%) with 2% FBS (Fig. 2B, Table 2). 
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Figure 2: Fibroblastic CAV1 mRNA levels after non-contact co-culture of human 
primary breast fibroblasts (Fre85) with a highly invasive (MDA-MB-231) human breast 
cancer cell line and an undifferentiated (THPD) or a differentiated (THPT) monocytic 
cell line at different serum levels. Cultures at normal 10% FBS were compared with cultures 
at 2% FBS. Results for the co-cultures are relative to the fibroblast monoculture control. Error 
bars represent the standard error of the mean. (A) CAV1 mRNA levels, relative to β-actin 
levels, after non-contact co-culture at 10% FBS, were detected using qRT-PCR. No 
significant changes in fibroblastic CAV1 mRNA levels were detected after 5 days of co-
culture. Results are representative of 3 independent experiments. (B) CAV1 mRNA levels, 
relative to β-actin levels, after non-contact co-culture at 2% FBS, were detected using qRT-
PCR. Fibroblastic CAV1 mRNA levels were significantly lower after 5 days of non-contact 
co-culture with MDA-MB-231 and with MDA-MB-231 and THPT. Results are representative 
of 3 independent experiments.  
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Table 1: Variability in CAV1 mRNA levels in non-contact co-cultures of human 
primary breast fibroblasts (Fre85) with a highly invasive (MDA-MB-231) human breast 
cancer cell line and an undifferentiated (THPD) or a differentiated (THPT) monocytic 
cell line, at 10% FBS. Relative standard error (RSE) is the standard error of the mean (SEM) 
calculated as a percentage of the average CAV1 mRNA levels for different 5-day non-contact 
co-cultures at 10% FBS. Fre=Fre85, MCF=MCF7, MDA=MDA-MB-231, THPD=carrier-
treated THP-1, THPT=TPA-treated THP-1 
Cultures at 10% 
FBS 
Average SEM RSE (%) 
Fre+MDA 1.49 0.29 20 
Fre+THPD 1.35 0.14 10 
Fre+THPT 1.05 0.05 5 
Fre+MDA+THPD 0.80 0.53 66 
Fre+MDA+THPT 1.25 0.82 66 
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Table 2: Variability in CAV1 mRNA levels in non-contact co-cultures of human 
primary breast fibroblasts (Fre85) with a highly invasive (MDA-MB-231) human breast 
cancer cell line and an undifferentiated (THPD) or a differentiated (THPT) monocytic 
cell line, at 2% FBS. Relative standard error (RSE) is the standard error of the mean (SEM) 
calculated as a percentage of the average CAV1 mRNA levels for different 5-days non-
contact co-cultures at 2% FBS. Fre=Fre85, MCF=MCF7, MDA=MDA-MB-231, 
THPD=carrier-treated THP-1, THPT=TPA-treated THP-1 
Cultures at 10% 
FBS 
Average SEM RSE (%) 
Fre+MDA 0.91 0.02 2 
Fre+THPD 0.74 0.15 21 
Fre+THPT 0.88 0.15 17 
Fre+MDA+THPD 1.54 0.54 35 
Fre+MDA+THPT 0.43 0.09 21 
 
The reduction of FBS from 10% to 2% led to a decrease in variability for 1 out of 5 
conditions, and an increase in variability of CAV1 protein levels for 4 out of 5 
conditions (Fig. 3). Non-contact co-culture of Fre85 with MDA-MB-231 led to CAV1 
mRNA levels of 1.27 ± 0.28 (RSE 22%) with 10% FBS (Fig. 3A, Table 3), and to 
levels of 2.91 ± 1.00 (RSE 34%) with 2% FBS (Fig. 3B, Table 4). Non-contact co-
culture of Fre85 with THPT led to CAV1 mRNA levels of 0.60 ± 0.14 (RSE 23%) 
with 10% FBS (Fig. 3A, Table 3), and to levels of 2.60 ± 0.91 (RSE 35%) with 2% 
FBS (Fig. 3B, Table 4). Non-contact co-culture of Fre85 with THPD led to CAV1 
mRNA levels of 0.80 ± 0.12 (RSE 15%) with 10% FBS (Fig. 3A, Table 3), and to 
levels of 2.61 ± 1.41 (RSE 54%) with 2% FBS (Fig. 3B, Table 4). Non-contact co-
culture of Fre85 with MDA-MB-231 and THPD led to CAV1 mRNA levels of 1.19 ± 
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0.30 (RSE 26%) with 10% FBS (Fig. 3A, Table 3), and to levels of 0.47 ± 0.30 (RSE 
64%) with 2% FBS (Fig. 3B, Table 4). Non-contact co-culture of Fre85 with MDA-
MB-231 and THPT led to CAV1 mRNA levels of 0.74 ± 0.26 (RSE 35%) with 10% 
FBS (Fig. 3A, Table 3), and to levels of 1.03 ± 0.21 (RSE 20%) with 2% FBS (Fig. 
3B, Table 4). 
 
 
Figure 3: Fibroblastic CAV1 protein levels after non-contact co-culture of human 
primary breast fibroblasts (Fre85) with a highly invasive (MDA-MB-231) human breast 
cancer cell line and an undifferentiated (THPD) or a differentiated (THPT) monocytic 
cell line at different serum levels. Cultures at normal 10% FBS were compared with cultures 
at 2% FBS. Results for the co-cultures are relative to the fibroblast monoculture control. Error 
bars represent the standard error of the mean. (A) Western analysis of CAV1 protein levels, 
relative to total protein levels, after non-contact co-culture at 10% FBS, as detected by 
Ponceau staining. No significant changes in fibroblastic CAV1 mRNA levels were detected 
after 5 days of co-culture. Results are representative of 3 independent experiments. (B) 
Western analysis of CAV1 protein levels, relative to total protein levels, after non-contact co-
culture at 2% FBS, as detected by Ponceau staining. No significant changes in fibroblastic 
CAV1 mRNA levels were detected after 5 days of co-culture.  Results are representative of 3 
independent experiments. Fre=Fre85, MCF=MCF7, MDA=MDA-MB-231, THPD=carrier-
treated THP-1, THPT=TPA-treated THP-1 
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Table 3: Variability in CAV1 protein levels in non-contact co-cultures of human 
primary breast fibroblasts (Fre85) with a highly invasive (MDA-MB-231) human breast 
cancer cell line and an undifferentiated (THPD) or a differentiated (THPT) monocytic 
cell line, at 10% FBS. Relative standard error (RSE) is the standard error of the mean (SEM) 
calculated as a percentage of the average CAV1 mRNA levels for different 5-day non-contact 
co-cultures at 10% FBS. Fre=Fre85, MCF=MCF7, MDA=MDA-MB-231, THPD=carrier-
treated THP-1, THPT=TPA-treated THP-1 
Cultures at 10% 
FBS 
Average SEM RSE (%) 
Fre+MDA 1.27 0.28 22 
Fre+THPD 0.80 0.12 15 
Fre+THPT 0.60 0.14 23 
Fre+MDA+THPD 1.19 0.30 26 
Fre+MDA+THPT 0.74 0.26 35 
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Table 4: Variability in CAV1 protein levels in non-contact co-cultures of human 
primary breast fibroblasts (Fre85) with a highly invasive (MDA-MB-231) human breast 
cancer cell line and an undifferentiated (THPD) or a differentiated (THPT) monocytic 
cell line, at 2% FBS. Relative standard error (RSE) is the standard error of the mean (SEM) 
calculated as a percentage of the average CAV1 mRNA levels for different 5-day non-contact 
co-cultures at 2% FBS. Fre=Fre85, MCF=MCF7, MDA=MDA-MB-231, THPD=carrier-
treated THP-1, THPT=TPA-treated THP-1 
Cultures at 10% 
FBS 
Average SEM RSE (%) 
Fre+MDA 2.91 1.00 34 
Fre+THPD 2.61 1.41 54 
Fre+THPT 2.60 0.91 35 
Fre+MDA+THPD 0.47 0.30 64 
Fre+MDA+THPT 1.03 0.21 20 
 
The effect of heat-inactivated serum and serum replacement on fibroblastic 
CAV1 protein levels in co-cultures 
To further explore the role of FBS in the regulation of CAV1 levels, 3-day non-
contact co-cultures were set up to compare the addition of 10% FBS with the addition 
of 10% heat-inactivated FBS, and with the addition of a serum replacement. Non-
contact co-culture of Fre85 with MDA-MB-213 and THPT in the presence of 10% 
FBS led to CAV1 protein levels of 1.21 ± 0.30 fold control. Non-contact co-culture of 
Fre85 with MDA-MB-213 and THPT in the presence of 10% heat-inactivated FBS 
led to CAV1 protein levels of 0.80 ± 0.22 fold control. Non-contact co-culture of 
Fre85 with MDA-MB-213 and THPT in the presence of serum replacement led to 
CAV1 protein levels of 0.65 ± 0.10 fold control (p<0.05, Fig. 4A,B). In addition, 
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fibroblastic CAV1 protein levels were assessed after 24 hours of co-culture, and no 
significant changes were detected (data not shown). 
 
 
Figure 4: Non-contact co-culture of human primary breast fibroblasts (Fre85) with a 
highly invasive (MDA-MB-231) human breast cancer cell line and a differentiated 
monocytic cell line (THPT) using heat-inactivated serum or a serum replacement. 
Cultures at normal 10% FBS were compared with cultures at heat-inactivated FBS and Serum 
Replacement 1. Results for the co-cultures are relative to the fibroblast monoculture control. 
Error bars represent the standard error of the mean. * p<0.05 against control (A) Western 
analysis of CAV1 protein levels, relative to total protein levels, as detected by Ponceau 
staining. Fibroblastic CAV1 protein levels were significantly lower after 3 days of co-culture 
with MDA-MB-231 and THPT using serum replacement. The use of a serum replacement 
resulted in changes in experimental outcome and variability compared to 10% FBS. Results 
are representative of 4 independent experiments. (B) Representative Western analysis image. 
β-actin is shown as a loading control. Fre=Fre85, MDA=MDA-MB-231, THPD=carrier-
treated THP-1, THPT=TPA-treated THP-1, HI=heat-inactivated, SR=Serum Replacement 1 
 
As the replacement of FBS with Serum Replacement 1 reduced the variability 
between experiments in triple cultures with fibroblasts (Fre85), cancer cells (MDA-
MB-231), and differentiated monocytes (THPT), the effect of using Serum 
Replacement was tested for the other non-contact co-cultures assayed previously in 
chapter 3. Using serum replacement improved the reproducibility of 3-day co-culture 
effects on CAV1 levels across the co-culture system, compared to previously 
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described results (chapter 3). Non-contact co-culture of Fre85 with MDA-MB-231 
resulted in fibroblastic CAV1 protein levels of 0.61 ± 0.16 fold the monoculture 
control. Non-contact co-culture of Fre85 with THPD resulted in fibroblastic CAV1 
protein levels of 0.59 ± 0.12 fold the monoculture control. Non-contact co-culture of 
Fre85 with THPT resulted in fibroblastic CAV1 protein levels of 0.43 ± 0.12 fold the 
monoculture control (p<0.05). Non-contact co-culture of Fre85 with MDA-MB-231 
and THPD resulted in fibroblastic CAV1 protein levels of 0.52 ± 0.07 fold the 
monoculture control (p<0.05). Non-contact co-culture of Fre85 with MDA-MB-231 
and THPT resulted in fibroblastic CAV1 protein levels of 0.71 ± 0.10 fold the 
monoculture control (Fig. 5A,B). 
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Figure 5: Non-contact co-culture of human primary breast fibroblasts (Fre85) with a 
highly invasive (MDA-MB-231) human breast cancer cell line and an undifferentiated 
(THPD) or differentiated (THPT) monocytic cell line using Serum Replacement 1. 
Results for the co-cultures are relative to the fibroblast monoculture control. Error bars 
represent the standard error of the mean. * p<0.05 against control (A) Western analysis of 
CAV1 protein levels, relative to total protein levels, as detected by Ponceau staining. 
Fibroblastic CAV1 protein levels were significantly lower after 3 days of co-culture with 
THPT alone or with MDA-MB-231 and THPD, or with MDA-MB-231 and THPT. Results 
are representative of 3 independent experiments (7 independent experiments for Fre+MDA-
MB-231+THPT. (B) Representative Western analysis image. β-actin is shown as a loading 
control. Fre=Fre85, MDA=MDA-MB-231, THPD=carrier-treated THP-1, THPT=TPA-
treated THP-1 
 
Similarly, the use of serum replacement in the contact co-culture system led to higher 
reproducibility of CAV1 protein levels compared to previously described results 
(chapter 4). Contact co-culture of Fre85 with MDA-MB-231 led to fibroblastic CAV1 
protein levels of 1.67 ± 0.21 fold the monoculture control. Contact co-culture of 
Fre85 with THPD led to fibroblastic CAV1 protein levels of 0.72 ± 0.11 fold the 
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monoculture control. Contact co-culture of Fre85 with THPT led to fibroblastic 
CAV1 protein levels of 0.83 ± 0.27 fold the monoculture control. Contact co-culture 
of Fre85 with MDA-MB-231 and THPD led to fibroblastic CAV1 protein levels of 
1.70 ± 0.61 fold the monoculture control. Contact co-culture of Fre85 with MDA-
MB-231 and THPT led to fibroblastic CAV1 protein levels of 2.02 ± 0.86 fold the 
monoculture control. CAV1 protein levels in the MDA-MB-231 monoculture control 
were 2.59 ± 0.44 fold the monoculture control (Fig. 6A,B).  
 
Figure 6: Contact co-culture of human primary breast fibroblasts (Fre85) with a highly 
invasive (MDA-MB-231) human breast cancer cell line and an undifferentiated (THPD) 
or differentiated (THPT) monocytic cell line using Serum Replacement 1. Results for the 
co-cultures are relative to the fibroblast monoculture control. Error bars represent the standard 
error of the mean. (A) Western analysis of CAV1 protein levels, relative to total protein 
levels, as detected by Ponceau staining. No significant changes in CAV1 levels were detected 
after 5 days of co-culture. Results are representative of 3 independent experiments. (B) 
Representative Western analysis image. β-actin is shown as a loading control. Fre=Fre85, 
MDA=MDA-MB-231, THPD=carrier-treated THP-1, THPT=TPA-treated THP-1  
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Cytokines secreted by co-cultures 
To determine the levels of several cytokines and chemokines produced in the non-
contact and contact co-cultures, 3-day non-contact, and 5-day contact, co-cultures 
were set up in the presence of serum replacement. Conditioned medium was collected 
from the fibroblast compartment of non-contact co-cultures. Conditioned medium 
from the first set of replicates from figure 5 was assayed for the concentrations of 17 
different cytokines.  
 
CAV1 levels 
Fibroblastic CAV1 protein levels from the Fre85 and MDA-MB-231 non-contact co-
culture were 0.37 fold the monoculture control (Fig. 7A,B). Fibroblastic CAV1 
protein levels from the Fre85 and THPD non-contact co-culture were 0.36 fold the 
monoculture control (Fig. 7A,B). Fibroblastic CAV1 protein levels from the Fre85 
and THPT non-contact co-culture were 0.21 fold the monoculture control (Fig. 7A,B). 
Fibroblastic CAV1 protein levels from the Fre85 and MDA-MB-231 and THPD non-
contact co-culture were 0.39 fold the monoculture control (Fig. 7A,B). Fibroblastic 
CAV1 protein levels from the Fre85 and MDA-MB-231 and THPT non-contact co-
culture were 0.46 fold the monoculture control (Fig. 7A,B). 
 
For the contact co-culture system, conditioned medium was collected, cells were 
sorted on the FACS, and CAV1 protein levels were determined in the fibroblast 
compartment. Fibroblastic CAV1 protein levels from the Fre85 and MDA-MB-231 
contact co-culture were 1.22 fold the monoculture control (Fig. 7C,D). Fibroblastic 
CAV1 protein levels from the Fre85 and THPD contact co-culture were 0.53 fold the 
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monoculture control (Fig. 7C,D). Fibroblastic CAV1 protein levels from the Fre85 
and THPT contact co-culture were 0.70 fold the monoculture control (Fig. 7C,D). 
Fibroblastic CAV1 protein levels from the Fre85 and MDA-MB-231 and THPD 
contact co-culture were 0.77 fold the monoculture control (Fig. 7C,D). Fibroblastic 
CAV1 protein levels from the Fre85 and MDA-MB-231 and THPT contact co-culture 
were 0.79 fold the monoculture control (Fig. 7C,D). 
 
Figure 7: Co-cultures of human primary breast fibroblasts (Fre85) with a highly 
invasive (MDA-MB-231) human breast cancer cell line and an undifferentiated (THPD) 
or differentiated (THPT) monocytic cell line for cytokine assay. Results for the co-
cultures are relative to the fibroblast monoculture control. Conditioned medium from these 
co-cultures was used in a cytokine assay. (A) Non-contact co-culture. Western analysis of 
CAV1 protein levels, relative to total protein levels, as detected by Ponceau staining. (B) 
Contact co-culture. Western analysis of CAV1 protein levels, relative to total protein levels, 
as detected by Ponceau staining. Cultures were sorted using FACS. (C) Western analysis 
image of non-contact co-culture. β-actin is shown as a loading control. (D) Western analysis 
image of contact co-culture. β-actin is shown as a loading control. Fre=Fre85, MDA=MDA-
MB-231, THPD=carrier-treated THP-1, THPT=TPA-treated THP-1  
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Cytokine concentrations 
The conditioned medium from the 3-day non-contact, and 5-day contact, co-cultures, 
described in Figure 7, was screened using a cytokine assay, and the concentration of a 
number of interleukins, chemokines, and growth factors, was measured. Cytokine 
concentrations were measured in duplicate from a single (representative) sample. This 
study was unable to measure triplicate samples due to monetary constraints.  
 
Interleukins 
The interleukins detected by the assay were IL-1β, IL-1RA, IL-6, IL-8, IL-10 and IL-
13. IL-1β was secreted in concentrations that were below the threshold of the 
manufacturer-provided minimum detectable concentration plus 2 standard deviations 
of 1 pg/mL, in the 3-day monocultures of primary human fibroblasts Fre85, highly 
invasive human breast cancer cells MDA-MB-231, undifferentiated monocytes THPD 
and differentiated monocytes THPT. In the corresponding 3-day non-contact co-
cultures, Fre85 cultured with THPT resulted in IL-1β levels of 2.63 ± 0.08 pg/mL and 
Fre85 cultured with MDA-MB-231 and THPT resulted in IL-1β levels of 2.44 ± 0.25 
pg/mL in the conditioned medium (Fig. 8A). IL-1β levels in 5-day contact co-cultures 
were all below the threshold of 1 pg/mL, with the exception of the THPT monoculture 
(4.06 ± 0.15 pg/mL, Fig. 8B). 
 
The highest levels of IL-1RA were measured in the THPT monocultures: 205 ± 10 
pg/mL in conditioned medium from the 3-day monoculture (Fig. 8C), and 1476 ± 65 
pg/mL in conditioned medium from the 5-day monoculture (Fig. 8D). Non-contact 
co-cultures containing THPT also had high levels of IL-1RA, with 201 ± 15 pg/mL in 
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conditioned medium from Fre85 cultured with THPT alone, and 116 ± 0.46 pg/mL in 
conditioned medium from Fre85 cultured with both THPT and MDA-MB-231 (Fig. 
8C). The levels measured in contact co-cultures were 81.5 ± 3.35 pg/mL in 
conditioned medium from Fre85 cultured with THPT alone and 218 ± 4.55 pg/mL in 
conditioned medium from Fre85 cultured with both THPT and MDA-MB-231 (Fig. 
8D). 
 
IL-6 was detected at high concentrations in the conditioned medium from some of the 
cultures. In fact, conditioned medium from selected cultures had to be diluted and 
rescreened in order to reliably measure IL-6 concentrations. Unfortunately, not all co-
cultures were rescreened, due to limitations of the assay, and the IL-6 concentrations 
measured in the non-contact co-culture of Fre85 with THPT may be an 
underestimation.  
 
IL-6 levels were highest in non-contact co-cultures of Fre85 with both MDA-MB-231 
and THPT (triple culture), with a concentration of 21,865 ± 5,665 pg/mL (Fig. 8E). 
IL-6 levels in non-contact co-cultures of Fre85 with THPT (7,371 ± 2,289 pg/mL), 
and of Fre85 with MDA-MB-231 and THPD (3,784 ± 310 pg/mL), were also 
elevated, compared with the relevant 3-day monoculture of Fre85 (2,480 ± 242 
pg/mL, Fig. 8E). Monocultures of MDA-MB-231, THPD, and THPT, had, in 
comparison, minimal IL-6 concentrations of 2.0-8.6 pg/mL (Fig. 8E).  
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After 5 days, the IL-6 concentration in the Fre85 monoculture had increased to 9,037 
± 188 pg/mL IL-6 (Fig. 8F). Levels of IL-6 in 5-day contact co-cultures of Fre85 with 
MDA-MB-231 (3,653 ± 577 pg/mL), of Fre85 with THPD (8,499 ± 350 pg/mL), and 
of Fre85 with THPT (11,383 ± 1,677 pg/mL), were also higher, compared to the 
respective non-contact co-cultures, however the increase was not as strong as in the 
Fre85 monoculture (Fig. 8F). The 5-day contact triple cultures of Fre85 with MDA-
MB-231 and THPD (3,075 ± 328 pg/mL), and of Fre85 with MDA-MB-231 and 
THPT (7,038 ± 901 pg/mL), showed a decrease in IL-6 concentrations, compared to 
the respective 3-day non-contact co-cultures, and compared to the 5-day Fre85 
monoculture. Contact co-culture of Fre85 with THPD (8,499 ± 350 pg/mL) or THPT 
(11,383 ± 1,677 pg/mL) alone led to higher concentrations of IL-6 in the conditioned 
medium, compared to contact co-culture of Fre85 with MDA-MB-231 alone (3,653 ± 
577 pg/mL), or triple culture with THPD (3,075 ± 328 pg/mL) or THPT (7,038 ± 901 
pg/mL, Fig. 8F). 
 
Similar to IL-6, IL-8 was detected in high concentrations in some cultures. 
Concentrations of IL-8 may be underestimated in non-contact co-cultures of Fre85 
with MDA-MB-231, of Fre85 with THPD, of Fre85 with THPT, and of Fre85 with 
MDA-MB-231 and THPD (triple culture). In addition, the 3-day monoculture of 
THPT, and 5-day contact co-cultures of Fre85 with MDA-MB-231 and THPD (triple 
culture), and of Fre85 with MDA-MB-231 and THPT (triple culture), may have IL-8 
concentrations that are underestimated in the cytokine assay, due to a limited capacity 
for rescreening diluted samples. 
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The non-contact co-culture of Fre85 with MDA-MB-231 and THPT (triple culture) 
resulted in an IL-8 concentration in the conditioned medium that was higher than the 
monoculture controls; 44,618 ± 6,012 pg/mL, compared to 6,370 ± 675 pg/mL 
(Fre85), 295 ± 11 pg/mL (MDA-MB-231), and 3,141 ± 47 pg/mL (THPT, Fig. 8G). 
The remaining non-contact co-cultures had IL-8 concentrations below the 
concentration measured in the triple culture of Fre85, MDA-MB-231 and THPT, but 
the concentrations measured are likely underestimated and may lie between 6000-
44000 pg/mL. 
 
After 5 days, the IL-8 concentration in the monoculture of Fre85 was 11,513 ± 157 
pg/mL, the IL-8 concentration in the monoculture of THPD was 61.3 ± 3.90 pg/mL, 
and the IL-8 concentration in the THPT monoculture was 78,659 ± 41,389 pg/mL 
(Fig. 8H). The contact co-cultures of Fre85 with MDA-MB-231 (4,802 ± 298 pg/mL), 
with THPD (5,671 ± 191 pg/mL), and with THPT (22,175 ± 2,331 pg/mL), were 
below the average IL-8 concentrations measured in the respective monoculture 
controls (Fig. 8H). The triple cultures with Fre85, MDA-MB-231, and THPD or 
THPT, had IL-8 concentrations between 2000-4000 pg/mL, but these are likely 
underestimated. 
 
The concentrations of IL-10 measured in conditioned medium from non-contact co-
cultures, and the corresponding 3-day monoculture controls, were below the threshold 
of the manufacturer-provided minimum detectable concentration plus 2 standard 
deviations of 1.6 pg/mL, with the exception of the co-cultures of Fre85 with THPT 
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(14.5 ± 0.77 pg/mL), and of the triple culture of Fre85 with MDA-MB-231 and THPT 
(16.1 ± 0.31 pg/mL, Fig. 8I).  
 
In the 5-day monoculture controls corresponding to the contact co-cultures, 
concentrations of IL-10 were below the threshold of 1.6 pg/mL, with the exception of 
THPT (1.83 ± 0.42 pg/mL, Fig. 8J). The highest IL-10 concentrations measured in the 
contact co-cultures resulted from Fre85 cultured with THPT (4.48 ± 0.29 pg/mL), and 
from Fre85 cultured with MDA-MB-231 and THPT (triple culture, 4.78 ± 0.59 
pg/mL, Fig. 8J). The remaining contact co-cultures had IL-10 levels that were higher 
than the corresponding monoculture controls. 
 
Similar to the concentrations found for IL-10, the IL-13 concentration was highest in 
the non-contact co-cultures of Fre85 with THPT (2.19 ± 0.25 pg/mL), and of Fre85 
with MDA-MB-231 and THPT (triple culture, 3.2 ± 0.69 pg/mL, Fig. 8K). The 
remaining non-contact co-cultures and corresponding 3-day monocultures had 
concentrations of IL-13 that were below the threshold of the manufacturer-provided 
minimum detectable concentration plus 2 standard deviations of 1.9 pg/mL (Fig. 8K). 
 
IL13 concentrations in the contact co-cultures, and their corresponding 5-day 
monoculture controls, were similarly highest in the cultures of Fre85 with THPT (2.9 
± 1.0 pg/mL), and of Fre85 with MDA-MB-231 and THPT (triple culture, 4.13 ± 3.2 
pg/mL), and were below the threshold in the remaining co-cultures and monoculture 
controls (Fig. 8L). 
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Figure 8: Interleukin levels measured in conditioned medium from co-cultures of 
human primary breast fibroblasts (Fre85) with a highly invasive (MDA-MB-231) 
human breast cancer cell line and an undifferentiated (THPD) or differentiated (THPT) 
monocytic cell line, using serum replacement. Concentrations were measured using a 
Milliplex MAP human cytokine/chemokine magnetic bead panel. Error bars represent the 
standard deviation. The minimum detectable concentration plus 2 standard deviations is 
indicated with a red line, unless all measured concentrations exceed this limit. (A) IL-1β 
levels measured in the conditioned medium after 3 days of non-contact co-culture. (B) IL-1β 
levels measured in the conditioned medium after 5 days of contact co-culture. (C) IL-1RA 
levels measured in the conditioned medium after 3 days of non-contact co-culture. (D) IL-
1RA levels measured in the conditioned medium after 5 days of contact co-culture. 
Fre=Fre85, MDA=MDA-MB-231, THPD=carrier-treated THP-1, THPT=TPA-treated THP-1 
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Figure 8 continued: Interleukin levels measured in conditioned medium from co-
cultures of human primary breast fibroblasts (Fre85) with a highly invasive (MDA-MB-
231) human breast cancer cell line and an undifferentiated (THPD) or differentiated 
(THPT) monocytic cell line, using serum replacement. Concentrations were measured 
using a Milliplex MAP human cytokine/chemokine magnetic bead panel. Error bars represent 
the standard deviation. The maximum concentration that can be measured accurately is 
indicated with a purple line, unless all measured concentrations are below this limit. (E) IL-6 
levels measured in the conditioned medium after 3 days of non-contact co-culture. (F) IL-6 
levels measured in the conditioned medium after 5 days of contact co-culture. (G) IL-8 levels 
measured in the conditioned medium after 3 days of non-contact co-culture. (H) IL-8 levels 
measured in the conditioned medium after 5 days of contact co-culture. # The IL-8 levels 
measured in the non-contact co-culture and the contact triple cultures are underestimated and 
are likely to be between 5,000 pg/mL and 80,000 pg/mL. Fre=Fre85, MDA=MDA-MB-231, 
THPD=carrier-treated THP-1, THPT=TPA-treated THP-1 
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Figure 8 continued: Interleukin levels measured in conditioned medium from co-
cultures of human primary breast fibroblasts (Fre85) with a highly invasive (MDA-MB-
231) human breast cancer cell line and an undifferentiated (THPD) or differentiated 
(THPT) monocytic cell line, using serum replacement. Concentrations were measured 
using a Milliplex MAP human cytokine/chemokine magnetic bead panel. Error bars represent 
the standard deviation. The minimum detectable concentration plus 2 standard deviations is 
indicated with a red line, unless all measured concentrations exceed this limit. (I) IL-10 levels 
measured in the conditioned medium after 3 days of non-contact co-culture. (J) IL-10 levels 
measured in the conditioned medium after 5 days of contact co-culture. (K) IL-13 levels 
measured in the conditioned medium after 3 days of non-contact co-culture. (L) IL-13 levels 
measured in the conditioned medium after 5 days of contact co-culture. Fre=Fre85, 
MDA=MDA-MB-231, THPD=carrier-treated THP-1, THPT=TPA-treated THP-1 
 
Chemokines 
The chemokines detected by the assay were MCP-1 (CCL2), macrophage 
inflammatory protein-1α (MIP-1α/CCL3), and RANTES (CCL5). MCP-1 
concentrations were high in some of the undiluted samples, and the concentration 
measured in the Fre85 non-contact co-culture with THPT, and the Fre85 contact co-
culture with MDA-MB-231 and THPD or THPT (triple cultures), are likely to be an 
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underestimation. MCP-1 levels were elevated in all non-contact co-cultures, 
compared to the corresponding monoculture controls, with the highest concentrations 
measured in the non-contact co-culture of Fre85 with MDA-MB-231 and THPT 
(triple culture, 15,322 ± 1,230 pg/mL), and Fre85 with THPT (8,303 ± 135 pg/mL, 
possible underestimation, Fig. 9A). MCP-1 concentrations in the contact co-cultures 
of Fre85 with MDA-MB-231 (17,732 ± 1,634 pg/mL), and of Fre85 with THPT 
(23,585 ± 151 pg/mL), were above the corresponding monoculture controls (Fig. 9B). 
The remaining co-cultures had lower MCP-1 levels, however the concentrations in the 
triple cultures are likely to be an underestimation. 
 
MIP-1α concentrations were highest in conditioned medium from non-contact co-
cultures of Fre85 with THPT (1,656 ± 13 pg/mL), Fre85 with MDA-MB-231 and 
THPT (triple culture, 484 ± 12 pg/mL), and the 3-day monoculture of THPT (1,138 ± 
6.6 pg/mL, Fig. 9C). Concentrations in the remaining non-contact co-cultures, and the 
corresponding monocultures, were below the threshold of the manufacturer-provided 
minimum detectable concentration plus 2 standard deviations of 6.2 pg/mL. 
 
The conditioned medium from 5-day contact co-cultures of Fre85 with THPT, and 
Fre85 with MDA-MB-231 and THPT (triple culture), had lower MIP-1α 
concentrations than their 3-day non-contact counterparts; 68.9 ± 0.11 pg/mL and 55.5 
± 1.62 pg/mL respectively (Fig. 9D). The 5-day monoculture of THPT, on the other 
hand, showed a higher concentration of 4,139 ± 660 ng/mL MIP-1α, compared to the 
3-day monoculture (Fig. 9D). The 5-day THPD monoculture had a concentration of 
7.06 ± 0.54 pg/mL (Fig. 9D). Concentrations in the remaining contact co-cultures, and 
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the 5-day MDA-MB-231 monoculture, were below the threshold of the manufacturer-
provided minimum detectable concentration plus 2 standard deviations of 6.2 pg/mL. 
 
The concentration of RANTES in the 3-day non-contact co-cultures of Fre85 with 
MDA-MB-231 (6.8 ± 0.78 pg/mL), of Fre85 with THPD (168 ± 3.8 pg/mL), and of 
Fre85 with MDA-MB-231 and THPD (triple culture, 171 ± 7.3 pg/mL), was higher 
than the corresponding 3-day monocultures of Fre85 (2.45 ± 0.00 pg/mL), MDA-MB-
231 (below threshold of 1.9 pg/mL), and THPD (90.4 ± 2.16 pg/mL, Fig. 9E). The 3-
day monoculture of THPT, on the other hand, was 906 ± 2.9 pg/mL, which was 
higher than the concentrations measured in the co-cultures of Fre85 with THPT (330 
± 2.2 pg/mL), and of Fre85 with MDA-MB-231 and THPT (triple culture, 335 ± 0.00 
pg/mL, Fig. 9E). 
 
A similar pattern was seen in the 5-day contact co-cultures. The contact co-culture of 
Fre85 with MDA-MB-231 resulted in increased RANTES concentrations in the 
conditioned medium (435 ± 7.2 pg/mL), compared to the 5-day monoculture controls 
of Fre85 (17.3 ± 0.00 pg/mL), and MDA-MB-231 (48.5 ± 2.78 pg/mL, Fig. 9F). Co-
cultures of Fre85 with THPD (422 ± 28.5 pg/mL) had similar concentrations to the 5-
day monoculture of THPD (458 ± 21.3 pg/mL), however the triple culture of Fre85 
with MDA-MB-231 and THPD (792 ± 6.1 pg/mL) had increased concentrations of 
RANTES, compared with the monoculture controls (Fig. 9F). The concentrations 
were the highest in the 5-day monoculture of THPT (3,531 ± 122 pg/mL), and this 
was higher than the concentrations in the co-cultures of Fre85 with THPT (701 ± 28.7 
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pg/mL), and of Fre85 with MDA-MB-231 and THPT (triple culture, 1,055 ± 20.8 
pg/mL, Fig. 9F). 
 
 
Figure 9: Chemokine levels measured in conditioned medium from co-cultures of 
human primary breast fibroblasts (Fre85) with a highly invasive (MDA-MB-231) 
human breast cancer cell line and an undifferentiated (THPD) or differentiated (THPT) 
monocytic cell line, using serum replacement. Concentrations were measured using a 
Milliplex MAP human cytokine/chemokine magnetic bead panel. Error bars represent the 
standard deviation. (A) MCP-1 levels measured in the conditioned medium after 3 days of 
non-contact co-culture. (B) MCP-1 levels measured in the conditioned medium after 5 days of 
contact co-culture. (C) MIP-1α levels measured in the conditioned medium after 3 days of 
non-contact co-culture. (D) MIP-1α levels measured in the conditioned medium after 5 days 
of contact co-culture. # The MCP-1 levels measured in the Fre85+MDA+THPT contact co-
culture are underestimated and are likely to be between 15,000 pg/mL and 25,000 pg/mL. 
Fre=Fre85, MDA=MDA-MB-231, THPD=carrier-treated THP-1, THPT=TPA-treated THP-1 
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Figure 9 continued: Chemokine levels measured in conditioned medium from co-
cultures of human primary breast fibroblasts (Fre85) with a highly invasive (MDA-MB-
231) human breast cancer cell line and an undifferentiated (THPD) or differentiated 
(THPT) monocytic cell line, using serum replacement. Concentrations were measured 
using a Milliplex MAP human cytokine/chemokine magnetic bead panel. Error bars represent 
the standard deviation. (E) RANTES levels measured in the conditioned medium after 3 days 
of non-contact co-culture. (F) RANTES levels measured in the conditioned medium after 5 
days of contact co-culture. Fre=Fre85, MDA=MDA-MB-231, THPD=carrier-treated THP-1, 
THPT=TPA-treated THP-1 
 
Growth factors 
The growth factors measured by the assay were EGF, basic fibroblast growth factor 
(FGF-2), platelet-derived growth factor (PDGF) –AA and –AB/BB, and vascular 
endothelial growth factor (VEGF). The threshold of the manufacturer-provided 
minimum detectable concentration plus 2 standard deviations of EGF is 4.6 pg/mL. 
The concentrations in the conditioned medium from the monocultures, and co-
cultures, were below this threshold, with the exception of the 3-day non-contact co-
culture of Fre85 with THPT (4.84 ± 0.78 pg/mL), the 5-day contact co-culture of 
Fre85 with THPT (5.7 ± 0.88 pg/mL), and the 5-day monoculture of THPT (5.9 ± 
0.52 pg/mL, Fig. 10A,B). The average concentration in the 3-day monoculture of 
MDA-MB-231 (6.6 ± 4.1 pg/mL) was also above the threshold, however the standard 
deviation for this measurement was very large (Fig. 10A).  
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The concentration of FGF-2 measured in the non-contact co-cultures of Fre85 with 
MDA-MB-231 (38 ± 1.1 pg/ml), of Fre85 with THPD (56 ± 0.95 pg/mL), and of 
Fre85 with MDA-MB-231 and THPD (triple culture, 31 ± 1.9 pg/mL), was higher 
than in the 3-day monocultures of Fre85 (22 ± 2.3 pg/mL), MDA-MB-231, and 
THPD (the latter two were below the threshold of the manufacturer-provided 
minimum detectable concentration plus 2 standard deviations of 11.8 pg/mL, Fig. 
10C). Non-contact co-cultures containing THPT had a FGF-2 concentration close the 
concentration in the 3-day Fre85 monoculture; the concentration of FGF-2 in 
conditioned medium from the co-culture of Fre85 with THPT was 18 ± 3.4 pg/mL, 
and 20 ± 9.0 pg/mL in conditioned medium from the triple culture of Fre85 with 
MDA-MB-231 and THPT (Fig. 10C). The 3-day monoculture of THPT did not have a 
FGF-2 concentration above the threshold. Conversely, in the 5-day contact co-
cultures the only concentration of FGF-2 detected above the threshold was 15 ± 2.8 
pg/mL in the triple culture of Fre85 with MDA-MB-231 and THPT (Fig. 10D). 
 
High concentrations of PDGF-AA were detected in the 3-day monocultures of MDA-
MB-231 (73 ± 4.6 pg/mL), and THPT (175 ± 2.5 pg/mL), compared to the non-
contact co-cultures (Fig. 10E). The non-contact co-culture of Fre85 with THPD (4.5 ± 
0.17 pg/mL) had a PDGF-AA concentration slightly above the concentration in the 
corresponding 3-day monoculture of Fre85 (2.6 ± 0.18 pg/mL), and THPD (3.9 ± 0.52 
pg/mL, Fig. 10E). The remaining non-contact co-cultures had a concentration below 
the average of the concentrations in the corresponding 3-day monoculture controls. 
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The PDGF-AA concentration in the 5-day monocultures of Fre85 (5.33 ± 0.40 
pg/mL), MDA-MB-231 (590 ± 13.1 pg/mL), THPD (22.0 ± 2.55 pg/mL), and THPT 
(596 ± 33.8 pg/mL) was higher compared to the 3-day monocultures (Fig. 10F). This 
was, however, the case to a much lesser extend in the contact co-cultures of Fre85 
with MDA-MB-231 (13.4 ± 0.69 pg/mL for the 3-day non-contact co-culture, 
compared to 19.0 ± 0.49 pg/mL for the 5-day contact co-culture), and the triple 
cultures of Fre85 with MDA-MB-231 and THPD (9.31 ± 0.71 pg/mL, compared to 
28.5 ± 0.66 pg/mL) or THPT (10.5 ± 0.21 pg/mL, compared to 23.5 ± 0.55 pg/mL, 
Fig. 10F). Conversely, the remaining 5-day contact co-cultures showed similar or 
lower PDGF-AA concentrations, compared to the corresponding 3-day non-contact 
co-cultures; The PDGF-AA concentration in Fre85 non-contact co-culture with THPD 
was 4.49 ± 0.17 pg/mL versus 4.85 ± 0.09 pg/mL in the contact co-culture, and the 
concentration of PDGF-AA in non-contact co-culture of Fre85 with THPT was 11.6 ± 
0.59 pg/mL versus 6.97 ± 0.25 pg/mL in the contact co-culture (Fig. 10F). 
 
For the non-contact co-cultures, the only PDGF-AB/BB levels measured above the 
threshold of the manufacturer-provided minimum detectable concentration plus 2 
standard deviations of 2.7 pg/mL were found in the cultures of Fre85 with THPT 
(10.9 ± 4.61 pg/mL), and of Fre85 with MDA-MB-231 and THPT (11.8 ± 4.96 
pg/mL, Fig. 10G). The PDGF-AB/BB concentration in the 3-day monoculture of 
THPT was 4.59 ± 0.49 pg/mL, and the concentration in the 3-day monocultures of 
Fre85 and THPD was below the threshold. The average concentration in the 3-day 
monoculture of MDA-MB-231 was above the threshold, but had a very large standard 
deviation (27.0 ± 32.0 pg/mL).  
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PDGF-AB/BB levels in the contact co-cultures were the highest in the cultures 
containing THPT. The culture of Fre85 with THPT had a PDGF-AB/BB 
concentration of 18.5 ± 1.54 pg/mL, and the concentration in the triple culture of 
Fre85 with MDA-MB-231 and THPT was 14.1 ± 6.44 pg/mL (Fig. 10H). The highest 
concentration was, however, found in the 5-day monoculture of MDA-MB-231 (31.6 
± 2.63 pg/mL), whereas the concentration in the 5-day monoculture of THPT was 
10.9 ± 2.93 pg/ml (Fig. 10H). The concentration in the 5-day monoculture of Fre85 
was 5.62 ± 3.85 pg/mL, and the 5-day monoculture of THPD did not have a 
concentration above the threshold (Fig. 10H). Interestingly, the contact co-culture of 
Fre85 with MDA-MB-231 resulted in PDGF-AB/BB levels in the conditioned 
medium (3.88 ± 1.55 pg/mL) below concentrations measured in the corresponding 
monocultures (Fig. 10H). Conversely, the concentrations in contact co-culture of 
Fre85 with THPD (9.41 ± 6.96 pg/mL), and of Fre85 with THPT (18.5 ± 1.54 
pg/mL), were higher than the corresponding controls (Fig. 10H). 
 
VEGF levels were higher in all non-contact co-cultures, compared to the 
corresponding 3-day monoculture controls. The highest concentration was measured 
in the conditioned medium from the triple culture of Fre85 with MDA-MB-231 and 
THPT (2,792 ± 53.4 pg/mL, Fig. 10I). The concentrations in the 3-day monocultures 
were highest in Fre85 (1,575 ± 27.0 pg/mL), whereas 3-day monocultures of MDA-
MB-231 (226 ± 1.8 ng/mL), THPD (14.5 ± 4.71 pg/mL), and THPT (178 ± 16.3 
pg/mL), had comparatively low concentrations of VEGF (Fig. 10I). 
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The 5-day monocultures of MDA-MB-231 (2,932 ± 104.6 pg/mL), and THPD (242.1 
± 11.9 pg/mL), showed a higher VEGF concentration, compared to the corresponding 
3-day monoculture (226.18 ± 1.76 pg/mL and 14.52 ± 4.71 pg/mL, respectively, Fig. 
10J). The 5-day monoculture of THPT showed a concentration of 699.0 ± 3.1 pg/mL, 
compared to 178.04 ± 16.3 pg/mL in the 3-day monoculture, and the monoculture of 
Fre85 showed a concentration of 1,168 ± 14.4 pg/mL, compared to 1,575.22 ± 27.0 
pg/mL in the 3-day monoculture. The contact co-cultures containing THPD had 
higher concentrations of VEGF than contact co-cultures containing THPT; the VEGF 
concentration in the culture of Fre85 with THPD was 1,541 ± 143.8 pg/mL, Fre85 
with THPT was 860.2 ± 11.4 pg/mL, triple culture of Fre85 with MDA-MB-231 and 
THPD was 1,831 ± 28.6 ng/mL and triple culture of Fre85 with MDA-MB-231 and 
THPT was 1,358 ± 87.5 pg/mL (Fig. 10J). The VEGF concentration in the 5-day 
monoculture of THPD (242.1 ± 11.9 pg/mL) was, however, lower than the VEGF 
concentration in the 5-day monoculture of THPT (699.0 ± 3.1 ng/mL, Fig. 10J).  
  
	 165	
Figure 10: Growth factor levels measured in conditioned medium from co-cultures of 
human primary breast fibroblasts (Fre85) with a highly invasive (MDA-MB-231) 
human breast cancer cell line and an undifferentiated (THPD) or differentiated (THPT) 
monocytic cell line, using serum replacement. Concentrations were measured using a 
Milliplex MAP human cytokine/chemokine magnetic bead panel. Error bars represent the 
standard deviation. The minimum detectable concentration plus 2 standard deviations is 
indicated with a red line, unless all measured concentrations exceed this limit. (A) EGF levels 
measured in the conditioned medium after 3 days of non-contact co-culture. (B) EGF levels 
measured in the conditioned medium after 5 days of contact co-culture. (C) FGF-2 levels 
measured in the conditioned medium after 3 days of non-contact co-culture. (D) FGF-2 levels 
measured in the conditioned medium after 5 days of contact co-culture. Fre=Fre85, 
MDA=MDA-MB-231, THPD=carrier-treated THP-1, THPT=TPA-treated THP-1 
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Figure 10 continued: Growth factor levels measured in conditioned medium from co-
cultures of human primary breast fibroblasts (Fre85) with a highly invasive (MDA-MB-
231) human breast cancer cell line and an undifferentiated (THPD) or differentiated 
(THPT) monocytic cell line, using serum replacement. Concentrations were measured 
using a Milliplex MAP human cytokine/chemokine magnetic bead panel. Error bars represent 
the standard deviation. The minimum detectable concentration plus 2 standard deviations is 
indicated with a red line, unless all measured concentrations exceed this limit. (E) PDGF-AA 
levels measured in the conditioned medium after 3 days of non-contact co-culture. (F) PDGF-
AA levels measured in the conditioned medium after 5 days of contact co-culture. (G) PDGF-
AB/BB levels measured in the conditioned medium after 3 days of non-contact co-culture. 
(H) PDGF-AB/BB levels measured in the conditioned medium after 5 days of contact co-
culture. Fre=Fre85, MDA=MDA-MB-231, THPD=carrier-treated THP-1, THPT=TPA-
treated THP-1 
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Figure 10 continued: Growth factor levels measured in conditioned medium from co-
cultures of human primary breast fibroblasts (Fre85) with a highly invasive (MDA-MB-
231) human breast cancer cell line and an undifferentiated (THPD) or differentiated 
(THPT) monocytic cell line, using serum replacement. Concentrations were measured 
using a Milliplex MAP human cytokine/chemokine magnetic bead panel. Error bars represent 
the standard deviation. The minimum detectable concentration plus 2 standard deviations is 
indicated with a red line, unless all measured concentrations exceed this limit. (I) VEGF 
levels measured in the conditioned medium after 3 days of non-contact co-culture. (J) VEGF 
levels measured in the conditioned medium after 5 days of contact co-culture. Fre=Fre85, 
MDA=MDA-MB-231, THPD=carrier-treated THP-1, THPT=TPA-treated THP-1 
 
Other cytokines 
The cytokine assay measured the concentrations of a further 3 cytokines, a colony 
stimulating factor (GM-CSF), an interferon (IFN-γ) and a tumour necrosis factor 
(TNF-α). The highest concentrations of GM-CSF were measured in the monocultures 
of MDA-MB-231, and the co-cultures that contain MDA-MB-231. The concentration 
of GM-CSF in the 3-day monoculture of MDA-MB-231 was 89.2 ± 3.49 pg/mL, the 
concentration in the non-contact co-culture of Fre85 with MDA-MB-231 was 31.4 ± 
1.74 pg/mL GM-CSF, and the concentrations in the triple cultures of Fre85 with 
MDA-MB-231 and THPD, and Fre85 with MDA-MB-231 and THPT, were 21.5 ± 
1.02 and 56.4 ± 1.84 pg/mL, respectively (Fig. 11A). Interestingly, the non-contact 
co-culture of Fre85 with THPT (48.8 ± 0.93 pg/mL GM-CSF), resulted in a higher 
concentration than either of the corresponding 3-day monocultures; the concentration 
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in the monoculture of THPT was 17.3 ± 0.21 pg/mL and the concentration in the 
monoculture of Fre85 was below the threshold of the manufacturer-provided 
minimum detectable concentration plus 2 standard deviations of 15.0 pg/mL. 
 
The concentration of GM-CSF in the conditioned medium from the 5-day 
monoculture of MDA-MB-231 was 2,621 ± 33.2 pg/mL, compared to 89.18 ± 3.49 
pg/mL in the 3-day monoculture (Fig. 11B). The concentration of GM-CSF in the 
contact co-culture of Fre85 with MDA-MB-231 was 144.5 ± 4.9 pg/mL, the 
concentrations in the triple cultures of Fre85 with MDA-MB-231 and THPD, or 
THPT, were 58.4 ± 5.13 pg/mL and 147.0 ± 1.8 pg/mL GM-CSF respectively (Fig. 
11B). In contrast to the effect seen in the 3-day non-contact co-cultures, the 5-day 
contact co-culture of Fre85 with THPT resulted in GM-CSF concentrations that were 
below the average concentration of the corresponding monocultures; conditioned 
medium from a contact co-culture of Fre85 with THPT was 12.8 ± 0.11 pg/mL, 
conditioned medium from a 5-day monoculture of Fre85 was 8.77 ± 0.30 pg/mL and 
of THPT was 69.5 ± 1.25 pg/mL GM-CSF. 
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Figure 11: Colony stimulating factor levels measured in conditioned medium from co-
cultures of human primary breast fibroblasts (Fre85) with a highly invasive (MDA-MB-
231) human breast cancer cell line and an undifferentiated (THPD) or differentiated 
(THPT) monocytic cell line, using serum replacement. Concentrations were measured 
using a Milliplex MAP human cytokine/chemokine magnetic bead panel. Error bars represent 
the standard deviation. The minimum detectable concentration plus 2 standard deviations is 
indicated with a red line, unless all measured concentrations exceed this limit. (A) GM-CSF 
levels measured in the conditioned medium after 3 days of non-contact co-culture. (B) GM-
CSF levels measured in the conditioned medium after 5 days of contact co-culture. 
Fre=Fre85, MDA=MDA-MB-231, THPD=carrier-treated THP-1, THPT=TPA-treated THP-1 
 
The concentrations of IFN-γ measured in the non-contact co-cultures, and their 
corresponding 3-day monoculture controls, were below the threshold of the 
manufacturer-provided minimum detectable concentration plus 2 standard deviations 
of 1.1 pg/mL, with the exception of the culture of Fre85 and THPT (7.92 ± 0.30 
pg/mL), and of the triple culture of Fre85 with MDA-MB-231 and THPT (5.99 ± 0.90 
pg/mL, Fig. 12A). 
 
Similar to what was seen in the non-contact co-cultures, the highest concentrations of 
IFN-γ were measured in the conditioned medium from 5-day contact co-cultures 
containing Fre85 and THPT (4.17 ± 0.76 pg/mL), and Fre85, MDA-MB-231 and 
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THPT (2.35 ± 0.00 pg/mL), whereas the remaining cultures had concentrations below 
the threshold (Fig. 12B). 
 
Figure 12: Interferon levels measured in conditioned medium from co-cultures of 
human primary breast fibroblasts (Fre85) with a highly invasive (MDA-MB-231) 
human breast cancer cell line and an undifferentiated (THPD) or differentiated (THPT) 
monocytic cell line, using serum replacement. Concentrations were measured using a 
Milliplex MAP human cytokine/chemokine magnetic bead panel. Error bars represent the 
standard deviation. The minimum detectable concentration plus 2 standard deviations is 
indicated with a red line, unless all measured concentrations exceed this limit. (A) IFN-γ 
levels measured in the conditioned medium after 3 days of non-contact co-culture. (B) IFN-γ 
levels measured in the conditioned medium after 5 days of contact co-culture. Fre=Fre85, 
MDA=MDA-MB-231, THPD=carrier-treated THP-1, THPT=TPA-treated THP-1 
 
The concentrations of TNF-α measured in the non-contact co-cultures were the 
highest in cultures containing THPT, and in the corresponding 3-day monoculture 
control; the concentration in conditioned medium from the culture of Fre85 with 
THPT was 83.4 ± 1.75 pg/mL, from the triple culture of Fre85 with MDA-MB-231 
and THPT was 15.7 ± 0.45 pg/mL, and from the 3-day monoculture of THPT was 
132.1 ± 0.13 pg/mL TNF-α (Fig. 13A). The concentrations in the conditioned medium 
from the remaining non-contact cultures and their corresponding 3-day monocultures 
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were below the threshold of the manufacturer-provided minimum detectable 
concentration plus 2 standard deviations of 1.0 pg/mL. 
 
The concentration of TNF-α measured in the 5-day monoculture of THPT was 494.7 
± 0.46 pg/mL (Fig. 13B). In contrast, the 5-day contact co-cultures containing THPT 
showed concentrations of TNF-α that were lower than the concentrations measured in 
the corresponding 3-day non-contact co-cultures; the concentration in conditioned 
medium from the culture of Fre85 with THPT was 2.22 ± 0.08 pg/mL, and from the 
triple culture of Fre85 with MDA-MB-231 and THPT was 1.65 ± 0.48 pg/mL TNF-α 
(Fig. 13B). The conditioned medium from the remaining contact co-cultures, and their 
corresponding 5-day monocultures, had concentrations of TNF-α below the threshold 
of the manufacturer-provided minimum detectable concentration plus 2 standard 
deviations of 1.0 pg/mL, with the exception of the 5-day monoculture of MDA-MB-
231, which had a TNF-α concentration of 2.58 ± 0.09 pg/mL (Fig. 13B). 
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Figure 13: Tumour necrosis factor levels measured in conditioned medium from co-
cultures of human primary breast fibroblasts (Fre85) with a highly invasive (MDA-MB-
231) human breast cancer cell line and an undifferentiated (THPD) or differentiated 
(THPT) monocytic cell line, using serum replacement. Concentrations were measured 
using a Milliplex MAP human cytokine/chemokine magnetic bead panel. Error bars represent 
the standard deviation. The minimum detectable concentration plus 2 standard deviations is 
indicated with a red line, unless all measured concentrations exceed this limit. (A) TNF-α 
levels measured in the conditioned medium after 3 days of non-contact co-culture. (B) TNF-α 
levels measured in the conditioned medium after 5 days of contact co-culture. Fre=Fre85, 
MDA=MDA-MB-231, THPD=carrier-treated THP-1, THPT=TPA-treated THP-1 
 
Table 5 and Table 6 show the differentially secreted cytokines in conditioned medium 
from non-contact, and contact, co-cultures, respectively. 
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Table 5: Differentially secreted cytokines in 3-day non-contact co-cultures, compared to 
the 3-day Fre85 monoculture control. Fre = Fre85 primary human breast fibroblasts, MDA 
= MDA-MB-231 invasive human breast cancer cells, THPD = undifferentiated monocytes, 
THPT = differentiated monocytes. + indicates that the concentration is slightly higher, ++ 
moderately higher, and +++ much higher than in the Fre85 monoculture. - indicates that the 
concentration is slightly lower, -- moderately lower, and --- much lower than in the Fre85 
monoculture. *Likely underestimation of concentration. 
 MDA 
Mono-
culture 
THPD 
Mono-
culture 
THPT 
Mono-
culture 
Fre+ 
MDA 
Fre+ 
THPD 
Fre+ 
THPT 
Fre+ 
MDA+ 
THPD 
Fre+ 
MDA+ 
THPT 
IL-1β      +  + 
IL-1RA   +++  ++ +++ ++ +++ 
IL-6 --- --- ---   ++ + +++ 
IL-8 --- --- -- * * +* +* +++ 
IL-10      +++  +++ 
IL-13      +  ++ 
MCP-1 --- --- -- + + ++ + +++ 
MIP-1α   +++   +++ + +++ 
RANTES  ++ +++  ++ +++ ++ +++ 
EGF +     +   
FGF-2 --- --- --- + ++  + + 
PDGF-AA +++ + +++ ++ + ++ ++ ++ 
PDGF-
AB/BB 
+  +   +  + 
VEGF --- --- --- + + + + ++ 
GM-CSF +++ -- + ++  ++ + ++ 
IFN-γ      +++  +++ 
TNF-α   +++   +++  ++ 
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Table 6: Differentially secreted cytokines in 5-day contact co-cultures, compared to the 
5-day Fre85 monoculture control. Fre = Fre85 primary human breast fibroblasts, MDA = 
MDA-MB-231 invasive human breast cancer cells, THPD = undifferentiated monocytes, 
THPT = differentiated monocytes. + indicates that the concentration is slightly higher, ++ 
moderately higher, and +++ much higher than in the Fre85 monoculture. - indicates that the 
concentration is slightly lower, -- moderately lower, and --- much lower than in the Fre85 
monoculture. *Likely underestimation of concentration. 
 MDA THPD THPT Fre+ 
MDA 
Fre+ 
THPD 
Fre+ 
THPT 
Fre+ 
MDA+ 
THPD 
Fre+ 
MDA+ 
THPT 
IL-1β   +++      
IL-1RA   +++  + + + ++ 
IL-6 --- --- --- --  + -- - 
IL-8  --- +++ - - + -* * 
IL-10   + +  +++ + +++ 
IL-13 - --- - -  + - + 
MCP-1 --- --- -- + -- + -- +* 
MIP-1α   +++   +  + 
RANTES  ++ +++ ++ ++ +++ +++ +++ 
EGF   +   +   
FGF-2        + 
PDGF-AA +++ + +++ +   + + 
PDGF-AB/BB +++  +   ++  + 
VEGF ++ -- - + + - + + 
GM-CSF +++  + ++  + + ++ 
IFN-γ      +++  ++ 
TNF-α   +++   +  + 
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Discussion 
The results from this study show that the inclusion of differentiated monocytes in 
non-contact and contact co-cultures of fibroblasts with breast cancer cells leads to 
increased concentrations of cytokines that are known to play a role in CAF-tumour 
cell interactions. Additionally, the co-culture of fibroblasts with cancer cells and 
differentiated monocytes resulted in increased concentrations of cytokines associated 
with ‘alternatively’ activated (M2) macrophages.  
 
The conditioned medium from co-cultures that resulted in low fibroblastic CAV1 
levels contained several cytokines in increased concentrations. These potential 
CAV1-regulating cytokines include RANTES, MCP-1, VEGF, and GM-CSF. This 
study provides several candidates for the further investigation of fibroblastic CAV1 
regulation through secreted cytokines. Additionally, this study shows that FBS affects 
fibroblastic CAV1 levels in co-cultures, which is an important consideration for 
future investigations into the regulation of CAV1, using cell culture methods. 
 
Serum conditions 
The addition of FBS to cell culture medium provides an, often necessary, source of 
growth and adhesion factors, hormones, lipids, and minerals, to the cells in culture. 
Many cell lines require the addition of serum to grow, and many more perform less 
optimally without serum. A downside to using serum in cell culture is the introduction 
of unknown variables. There can be significant variability from one batch of serum to 
the next, significantly impacting experimental outcomes (Baker, 2016; Khodabukus 
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and Baar, 2014; Sikora et al., 2016). Additionally, many components of serum are 
unstable over time, when used in routine cell culture. 
 
As is common practice in many labs, the same batch of serum was used in all the 
experiments for the duration of this study, thereby eliminating batch-to-batch 
variability. However, serum contains many unstable proteins, such as growth factors 
and cytokines, which can lose activity over time. Manufacturers of recombinant 
growth factors and other cytokines recommend long-term storage in lyophilized form, 
and short-term storage at -80 oC. Similarly, manufacturers advise that foetal bovine 
serum be stored at -80 oC. Routine cell culture techniques, such as the thawing out of 
serum, storing and handling of serum-containing medium, including warming up 
serum-containing medium, can, therefore, potentially introduce changes to serum 
activity. 
 
Reducing, or removing, the serum content in cell culture media can improve the 
reproducibility of experiments (Van der Valk et al., 2010). To investigate whether the 
addition of FBS to co-cultures contributed to inter-experimental variability, this study 
compared co-culture of fibroblasts, cancer cells, and differentiated monocytes, at 
conventional serum levels to reduced serum levels.  
 
The comparison of non-contact co-culture of fibroblasts with cancer cells and 
lymphocytes at 10% serum conditions, with 2% serum conditions, showed a trend 
towards an increased variability in fibroblastic CAV1 protein levels, and no change in 
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the variability in fibroblastic mRNA levels, with a lower serum concentration. 
Interestingly, decreasing the FBS levels from 10% to 2% led to drastically different 
average fibroblastic CAV1 protein levels after co-culture. This suggests that FBS 
affects the fibroblastic CAV1 protein response during co-culture. 
 
Many cell lines do not respond well to culture without serum, or with reduced serum. 
Primary cells in particular, may rely on the presence of serum to be able to continue 
growing after having been removed from the extracellular matrix provided in the 
body (Baker, 2016). Removing serum from cultures may cause cells to become more 
fragile or stressed (Van der Valk et al., 2010), which is a possible explanation for 
seeing changed cell behaviour. Additionally, cells that are fragile, or behave 
differently, due to serum conditions that are suboptimal for their growth, may respond 
more strongly to variability in the serum. 
 
Heat-inactivation is commonly used to inactivate heat-labile complement in serum. 
The practice of heat-inactivation of serum is controversial, as the benefits of heat-
inactivation that once existed may no longer outweigh the disadvantages, as the 
content of heat-labile complement is significantly reduced today, and is no longer 
likely to have any measurable effect on most experimental applications. Inactivation 
of mycoplasma, another benefit of heat-inactivation, is likewise obsolete, due to 
standard filtration practices of manufacturers. 
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The disadvantage of heat-inactivation is that the procedure may inactivate proteins in 
the serum that are required for optimal cell growth. To further investigate the effect of 
serum components on inter-experimental variability, the use of heat-inactivated serum 
in co-cultures of fibroblasts, cancer cells, and differentiated monocytes, was 
compared with normal serum. No significant changes in inter-experimental 
variability, and CAV1 protein levels, were observed with the use of heat-inactivated 
serum. However, a trend towards lower average CAV1 protein levels after non-
contact co-culture with cancer cells and differentiated monocytes, using heat-
inactivated FBS, compared to using standard FBS, was observed. Heat-inactivation 
may, correspondingly, lead to changed cell behaviour, due to altered serum content. 
 
As serum reduction and inactivation were shown to have an effect on CAV1 
expression levels after co-culture, and did not improve inter-experimental variability, 
the use of a serum replacement was examined. Different serum replacement 
formulations are available from several manufacturers. This study used Serum 
Replacement 1 from MilliporeSigma (Darmstadt, Germany). All cell lines used in the 
co-culture system continued to proliferate, and no increase in cell death was observed, 
however, cells were unable to adhere to the growth surface in the absence of normal 
serum. For this reason, cells were seeded in the presence of FBS, and the medium was 
changed to serum-replacement medium, after 18-20 hours. 
 
Non-contact co-culture of primary breast fibroblasts with highly invasive breast 
cancer cells and differentiated monocytes, in the presence of serum replacement, 
resulted in significantly lower fibroblastic CAV1 protein levels, compared to a 
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fibroblast monoculture control. Parallel co-cultures in the presence of 10% FBS did 
not show this reduction in CAV1 levels, and co-cultures in the presence of FBS, or 
heat-inactivated FBS, showed larger variability between experiments. 
 
Serum replacement is a synthetic formulation, rather than a natural product like FBS, 
and is deficient of growth factors, steroid hormones, glucocorticoids, cell adhesion 
factors, detectable immunoglobulin and mitogens (manufacturer data). This study 
shows that the use of Serum Replacement 1 reduces inter-experimental variability in 
co-cultures, possibly due to the absence of labile factors in serum that influence 
CAV1 expression. 
 
Cytokine secretion profiles in co-cultures of fibroblasts, cancer cells and 
(differentiated) monocytes 
For the cytokine experiments, conditioned medium from co-cultures in the presence 
of serum replacement, rather than FBS, was used. The reasons for this were, firstly, to 
reduce inter-experimental variability, as experiments using Serum Replacement 1 
showed less variability than those using FBS, and, secondly, FBS can contain varying 
levels of cytokines, and the presence of FBS in conditioned medium could mask 
changes in concentrations, as measured in the assay.  
 
Fibroblastic CAV1 levels were measured in all the co-cultures that corresponded to 
the conditioned medium used in the cytokine array. Non-contact co-culture in the 
presence of Serum Replacement 1 led to a significant reduction in fibroblastic CAV1, 
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when primary breast fibroblasts were cultured with differentiated monocytes (double 
culture), or with both highly invasive breast cancer cells and (differentiated) 
monocytes (triple culture). A representative sample of conditioned medium from each 
of these conditions was screened in the cytokine assay. 
 
Similarly, CAV1 levels were measured in contact co-cultures in the presence of 
Serum Replacement 1. The conditioned medium for the cytokine assay was derived 
from co-cultures that were sorted into fibroblastic and non-fibroblastic cell 
populations by FACS, to be able to determine CAV1 levels in the fibroblastic 
compartment. The conditioned medium screened in the cytokine assay came from a 
set of co-cultures that showed lower fibroblastic CAV1 levels after co-culture with 
(differentiated) monocytes (double culture), or with highly invasive breast cancer 
cells and (differentiated) monocytes (triple culture). 
 
The cytokine assay has determined the concentration of a number of interleukins, 
chemokines, and growth factors, in conditioned medium from non-contact and contact 
co-cultures. The cytokines present in the screening panel were selected based on 
previous implications in fibroblast and cancer cell co-culture, fibroblast and 
macrophage co-culture, or for being secreted by cancer-associated fibroblasts, as 
reported in the literature, and within the limitations of the assay.  
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Cancer-associated fibroblasts 
Cancer-associated fibroblasts (CAFs) stimulate cancer proliferation, motility, 
angiogenesis, and inflammation (Erez et al., 2010). The co-culture of Fre85 
fibroblasts with MDA-MB-231 breast cancer cells led to the differential secretion of 
several cytokines, compared to Fre85 monoculture controls. Some of these cytokines 
were secreted by MDA-MB-231 monocultures, while others were secreted by the 
fibroblast and cancer cell co-culture only. 
 
The cytokine MCP-1 was increased in both non-contact, and contact, fibroblast and 
cancer cell co-cultures, compared to the fibroblast, and cancer cell, monoculture 
controls. The same is true for FGF-2 and VEGF in non-contact co-cultures, and IL-10 
and RANTES in contact co-cultures. This suggests that the interaction between 
fibroblasts and cancer cells resulted in the increased secretion of these cytokines.  
 
MCP-1 is a chemoattractant of monocytes that is secreted in increased amounts by 
CAFs (Yang et al., 2016). The results reported here are in line with those of others, 
who have found increases in MCP-1 secretion in fibroblast and cancer cell co-cultures 
(Li et al., 2014).  When differentiated monocytes were introduced into the co-culture 
of fibroblasts and cancer cells, the secretion of MCP-1 was further increased. MCP-1 
regulates the infiltration of monocytes/macrophages, and is produced by many cells, 
including fibroblasts, and monocytes/macrophages (Deshmane et al., 2009). 
Expression levels of MCP-1 are increased in breast cancer tissues from patients (Soria 
et al., 2011). MCP-1 levels are strongly correlated to decreased survival rates in breast 
cancer (Ueno et al., 2000), and characteristic of a tumorigenic microenvironment 
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(Svensson et al., 2015). The increased MCP-1 secretion found in fibroblast, cancer 
cell, and differentiated monocyte, co-cultures suggests that the interaction of all three 
of these tumour microenvironment components plays an important role in the high 
levels of MCP-1 that are characteristic of breast cancer. 
 
VEGF and FGF-2 are other cytokines that are secreted in increased amounts by CAFs 
(De Francesco et al., 2013; Strand et al., 2014). VEGF and FGF-2 play a role in 
tumorigenesis by promoting angiogenesis. Similar to what was seen with the secretion 
profile of MCP-1, VEGF and FGF-1 concentrations were higher in the co-cultures of 
fibroblast with cancer cells and differentiated monocytes, compared to the fibroblast 
and cancer cell co-cultures.  
 
Another cytokine that was increased in fibroblast and cancer cell contact co-cultures, 
compared to fibroblast, and cancer cell, monocultures, is RANTES. RANTES was 
secreted in high concentrations by differentiated, and undifferentiated, monocyte 
monocultures, but not by cancer cell monocultures. As concentrations were higher 
after co-culture, compared to either of the fibroblast, or cancer cell, monocultures, the 
secretion of RANTES was increased upon the interaction of fibroblasts and cancer 
cells. In addition, RANTES was secreted in increased concentrations in 5-day contact 
co-cultures, but not in 3-day non-contact co-cultures. Therefore, either direct cell 
contact is required for the secretion of RANTES to be increased, or the secretion of 
RANTES after fibroblast and cancer cell interaction increases over time. Both 
RANTES and MCP-1 are key chemokines responsible for the recruitment of 
macrophages to the tumour site (Deshmane et al., 2009; Soria and Ben-Baruch, 2008), 
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and increased levels of MCP-1 and RANTES are found in breast cancer tissue 
(Svensson et al., 2015). The expression of RANTES in stage 2 breast cancer patients 
is a predictor of disease progression (Yaal-Hahoshen et al., 2006), and inactivation of 
RANTES secreted in adipocyte and MDA-MB-231 co-cultures resulted in lower 
cancer cell motility (D’Esposito et al., 2016).  
 
PDGF-AA concentrations were higher in the fibroblast and cancer cell co-culture, 
compared to the fibroblast monoculture control. PDGF promotes cell division and 
motility in fibroblasts (Heldin and Westermark, 1999). The monoculture controls of 
MDA-MB-231, and THPT, secrete higher levels of PDGF-AA than any of the co-
cultures. It is possible that the higher concentrations of PDGF-AA in the fibroblast 
and cancer cell co-cultures is due to the presence of cancer cells, and not due to the 
interaction of the different cell populations. However, the increased levels of PDGF-
AA may contribute to the generation of a CAF-like environment in fibroblast and 
cancer cell co-cultures. 
 
Proinflammatory cytokines IL-1β, IL-6, and MIP-1α, and growth factors FGF-2 and 
VEGF, are highly expressed by CAFs (Erez et al., 2010; Giulianelli et al., 2008; Shiga 
et al., 2015). In addition, sustained low levels of TNF-α play an important role in the 
activation of CAFs (Landskron et al., 2014; Shiga et al., 2015). Interestingly, IL-1β 
and TNF-α were measured in THPT containing co-cultures only, and were 
undetectable in other co-cultures. Furthermore, MIP-1α (CCL3) and IL-6 were 
increased in THPT containing co-cultures, and not in cancer only co-cultures. This, in 
addition to the increased concentrations of MCP-1, VEGF, and FGF-2, in triple 
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cultures, compared to fibroblast and cancer cell co-cultures, suggests that the 
interaction of Fre85 fibroblasts with THPT is required for CAF-like crosstalk between 
Fre85 and MDA-MB-231 to occur. 
 
Tumour-associated macrophages 
Macrophages respond to, and generate, a broad range of stimuli, including many 
cytokines. Cues from the microenvironment stimulate macrophages to assert different 
functions, ranging from tissue repair and matrix remodelling, to proinflammatory 
immunity (Williams et al., 2016). The cytokine profiles in both the non-contact and 
contact co-culture showed an increase in the number of differentially expressed 
cytokines in the presence of macrophages (THPT), compared to co-cultures with 
monocytes (THPD), or co-cultures with cancer cells. The cytokines that were detected 
in higher concentrations in co-cultures containing THPT include macrophage 
recruiting chemokines (MCP-1, RANTES), macrophage activating cytokines (IL-1β, 
GM-CSF, IFN-γ), and cytokines secreted by activated macrophages (IL-6, MIP-1α, 
TNF-α, VEGF).  
 
Tumour-associated macrophages display a functionally distinct phenotype, belonging 
to a subset of macrophages known as M2 macrophages (Mantovani and Sica, 2010).  
M1 stimuli include GM-CSF, IFN-γ and other proinflammatory cytokines (e.g., IL-
1β, IL-6, TNF), whereas M2 stimuli include IL-10 and IL-13 (Martinez and Gordon, 
2014).  
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Crosstalk between macrophages and cancer cells can lead to M2 polarization. The co-
culture of fibroblasts with differentiated monocytes resulted in higher concentrations 
of M1 stimuli IFN-γ and TNF-α, compared to fibroblast co-culture with cancer cells 
and differentiated monocytes. Non-contact co-culture of fibroblasts with cancer cells 
and differentiated monocytes, on the other hand, resulted in slightly higher 
concentrations of M2 stimuli IL-10 and IL-13. This is in line with a study by Müller-
Quernheim et al. (2012), where the co-culture of monocyte-derived macrophages with 
A549 cancer cells resulted in an increase in the M2 phenotype marker CCL18.  
 
The co-culture of fibroblasts and cancer cells resulted in increased concentrations of 
the monocyte chemoattractants MCP-1 and RANTES. These concentrations were 
further increased when differentiated monocytes were introduced into the co-cultures, 
resulting in the co-culture of all three cell populations. Interestingly, a study by Li et 
al. (2015) found that, by blocking the interaction of MCP-1 with its receptor via a 
CCLR antagonist, the M2 macrophage polarization, and the secretion of M2 
cytokines, decreased in mouse bone marrow-derived macrophages. The high levels of 
MCP-1 in the THPT-containing co-cultures presented here could drive M2 
polarization in THPT cells. 
 
Cytokines and CAV1 expression by fibroblasts 
Several of the cytokines measured in the assay have been shown by others to affect 
CAV1 expression levels in certain contexts. The objective of the cytokine assay was 
to take inventory of the cytokines that are differentially expressed in co-cultures that 
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have decreased fibroblastic CAV1 expression, and to identify potential CAV1 
regulating cytokines for further investigation.  
 
CAV1 protein levels were decreased in all non-contact, and contact, co-cultures 
assayed for cytokine secretion, with the exception of the fibroblast and cancer cell 
contact co-culture. The only cytokines that were measured in increased concentrations 
in all but one of the co-cultures with decreased CAV1 protein levels were IL-1RA, 
RANTES and VEGF. IL-1RA and RANTES concentrations were unchanged in Fre85 
and MDA-MB-231 non-contact co-cultures, whereas VEGF concentrations were 
slightly lower in Fre85 and THPT contact co-cultures. In addition, concentrations of 
MCP-1 and GM-CSF were increased in all but two of the co-cultures with reduced 
CAV1 levels. MCP-1 concentrations were moderately lower in THPD containing 
contact co-cultures and GM-CSF concentrations were unchanged in Fre85 and THPD 
non-contact and contact co-cultures. 
 
As discussed above, MCP-1 and RANTES are chemoattractants of monocytes, and 
important regulators of the tumour microenvironment. RANTES secretion has been 
shown to be affected by altered CAV1 expression. CAV1 expression suppressed 
RANTES secretion in stably transfected RAW264.7 mouse macrophages, compared 
to vector-transfected controls (Wang et al., 2009). MCP-1 on the other hand, has been 
shown to reduce CAV1 levels in brain microvascular endothelial cells in vitro (Song 
et al., 2007).  
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Two cytokines that have been found by others to increase CAV1 levels in certain 
contexts are GM-CSF and VEGF. GM-CSF is secreted by macrophages, cancer cells, 
and fibroblasts, and differentiates and activates macrophages. Mesenchymal-like 
breast cancer cell lines, such as MDA-MB-231, secrete increased amounts of GM-
CSF (Su et al., 2014). Indeed, the levels of GM-CSF in the monoculture controls were 
high, as were the GM-CSF levels in co-cultures containing MDA-MB-231. In 
addition to being secreted in increased amounts, GM-CSF alone was found, in the 
study mentioned above by Su et al. (2014), to activate macrophages in a similar way 
to conditioned medium from MDA-MB-231 cancer cells. A study by Fu et al. (2012) 
showed that GM-CSF treatment (50 ng/mL, 7 days) simultaneously increased CAV1 
and CD68 (a macrophage marker) mRNA expression in mouse peripheral blood 
mononuclear cells. Fu et al. (2012) further demonstrated that CAV1 is an important 
regulator of monocyte-macrophage differentiation. As discussed above, VEGF is 
expressed by CAFs, and plays an important role in angiogenesis and tumorigenesis. 
VEGF treatment (50 ng/mL) upregulated CAV1 mRNA and protein levels, and 
phosphorylated CAV1 at Y14, in mesenchymal stem cells (Cipriani et al., 2014). 
 
IL-1RA may have an indirect effect on CAV1 levels, by inhibiting the action of IL-
1β. A study by Takizawa et al. (2013) showed that TNF-α (10 ng/mL) and IL-1β (1 
ng/mL) treatment of periodontal ligament cells for 24 hours increased CAV1 mRNA 
levels, and CAV1 secretion, in the culture medium. The results presented in this 
chapter show that relatively high levels of IL-1RA were secreted by monocultures of 
differentiated monocytes, and differentiated monocyte-containing co-cultures.  
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Some of the other cytokines that have been linked to CAV1 regulation include EGF, 
IFN-γ, and TNF-α. EGF treatment (100 ng/mL for 3-5 days) downregulated CAV1 
protein levels in A431 human epidermoid carcinoma cells (Lu et al., 2003), and 
combined IL-1α (2 ng/mL) and IFN-γ (10 ng/mL) treatment downregulated CAV1 
mRNA levels in human primary thyrocytes (Marique et al., 2014). However, EGF 
was secreted at relatively low concentrations in the monocultures and co-cultures, as 
shown by the results presented in this chapter.  
 
The cytokine secretion profiles of the co-cultures containing MDA-MB-231 are 
markedly different from the secretions profiles of the co-cultures containing THPT. It 
is common for cytokines to exert their effect based on the context of other cytokines, 
and additional environmental cues. Examples of this include the action of IFN-γ in the 
presence or absence of LPS (Mayo and Stein, 2006), and IL-10’s dual role in anti-
tumour immunity and tumour promoting immune suppression (Dennis et al., 2013). It 
is, therefore, possible that different CAV1 regulatory mechanisms play a role in the 
different contexts of fibroblast co-culture with cancer cells, and fibroblast co-culture 
with macrophages. The effect of the interaction between fibroblasts, cancer cells and 
macrophages in the co-culture system, as presented and discussed in this chapter, on 
the secretion of cytokines, and the proposed role of these cytokines in the tumour 
microenvironment, has been schematically represented in Figure 14. 
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Figure 14: Schematic overview of interactions between fibroblasts, breast cancer cells 
and macrophages. The interaction between human primary breast fibroblasts (Fre85), highly 
invasive human breast cancer cells (MDA-MB-231) and differentiated human monocytes 
(THPT) results in the secretion of a plethora of cancer-associated cytokines. MCP-1, VEGF 
and GM-CSF have been identified as potential CAV1 regulating cytokines in the literature. 
Blue boxes indicate effects of cytokines secreted in increased amounts after fibroblast-cancer 
cell interactions, red boxes indicate effects of cytokines secreted in increased amounts after 
fibroblast-macrophage interactions, black boxes indicate effects of cytokines secreted in 
increased amounts in monocultures. Fre=Fre85, MDA=MDA-MB-231, THPT=TPA-treated 
THP-1 
Conclusion 
Distinct profiles were seen in fibroblast and cancer cell versus fibroblast and 
differentiated monocyte co-cultures. Several cytokines, some of which have been 
previously implicated in the regulation of CAV1 expression, were secreted in 
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increased amounts in co-cultures with decreased fibroblastic CAV1 levels. The 
cytokine profiles generated by this study provide several candidates to be investigated 
further for their ability to regulate CAV1 levels in fibroblasts. Some of these 
candidates are MCP-1 (CCL2), RANTES (CCL5), VEGF, and GM-CSF.  
 
The cytokine secretion profiles of fibroblast and cancer cell, and fibroblast and 
differentiated monocyte co-cultures, showed increased levels of inflammation and 
cancer related cytokines. The inclusion of cancer cells in fibroblast and differentiated 
monocyte co-cultures resulted in the increased secretion of cytokines that are known 
to drive the polarization of macrophages to a tumour-associated macrophage (TAM) 
phenotype. Additionally, the inclusion of differentiated monocytes in the fibroblast 
and cancer cell co-cultures resulted in the increased secretion of CAF-associated 
cytokines. This further supports the important role of fibroblast, cancer cell, and 
(differentiated) monocyte, interactions in the tumour microenvironment, and the 
potential role of these interactions for the regulation CAV1 expression.  
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Chapter 6: The effect of loss of caveolin-1 in fibroblasts on 
EMT and cancer stem cell markers in PMC42-LA breast 
cancer cells 
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Introduction 
The previous chapters investigated the effect of fibroblast, cancer cell and 
(differentiated) monocyte interactions on fibroblastic caveolin-1 (CAV1) levels. The 
current chapter will investigate the effect of decreased fibroblastic CAV1 levels on 
breast cancer cells.  
 
Epithelial-to-mesenchymal transition 
An important step in the invasiveness and metastasis of carcinomas is a transition of 
epithelial cells to a less differentiated cell type, in a process known as epithelial-to-
mesenchymal-transition (EMT) (Christiansen and Rajasekaran, 2006).  
 
During EMT, a number of cellular processes occur, that result in a more motile 
phenotype. Epithelial cells associate with the basement membrane through their basal 
surface. With the progression to a mesenchymal phenotype, the epithelial cell 
undergoes changes in the expression of cell-surface proteins, the expression and 
organisation of cytoskeletal proteins, and the production of matrix metalloproteinases 
(MMPs) (Kalluri and Weinberg, 2009). Eventually, the cell disassociates from the 
degraded basement membrane and invades the stroma, an important hallmark in the 
progression of cancer. Common markers of EMT include the loss of E-cadherin, and 
the upregulation of vimentin (Sarrio et al., 2008). 
 
Cancer stem cells 
Cancer stem cells are cancer cells that display stem cell properties, and that can give 
rise to the different cell populations that are present in the tumour. Unlike other 
cancer cells, cancer stem cells are capable of sustaining the cancer, and may mediate 
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metastasis and contribute to treatment relapse. Studies in immunocompromised mice 
have shown that only certain populations of breast cancer cells are able to give rise to 
new tumours, and that these tumorigenic cancer cells can be distinguished by their 
expression of high levels of the cell surface protein CD44, and low levels of the cell 
surface protein CD24 (Al-Hajj et al., 2003). Cancer stem cells produce increased 
levels of aldehyde dehydrogenase (ALDH), and assays used to measure ALDH levels 
are used to identify cancer stem cells (Storms et al., 1999). 
 
Some studies have found an overlap between cells that have undergone EMT, and 
cells that display cancer stem cell-like properties. The induction of EMT in 
immortalised human mammary epithelial cells resulted in the expression of 
mesenchymal markers, such as vimentin, and the loss of epithelial markers, such as E-
cadherin, while simultaneously increasing the population of CD44+/CD24- expressing 
cells, in a study by Mani et al. (2008). The characterisation of cells isolated from 
primary breast tumours has revealed two overlapping populations of CD44+/CD24- 
expressing cells, displaying an EMT-phenotype, and of ALDH+ expressing cells, 
displaying a mesenchymal-to-epithelial transition (MET)-phenotype (Liu et al., 
2014b). 
 
Cancer-associated fibroblasts 
The role of cancer-associated fibroblasts (CAFs) in inducing EMT in cancer cells has 
been studied widely. CAFs secrete soluble factors, such as transforming growth factor 
β (TGF-β) and stromal cell-derived factor 1 (SDF-1) (Kojima et al., 2010), that have 
been shown to induce EMT in cancer cells (Wendt et al., 2010; Yu et al., 2014). The 
conditioned medium from patient-derived CAFs in culture, has likewise been shown 
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to increase the migration of breast cancer cells (Lebret et al., 2007). CAFs are found 
in the tumour microenvironment and are often distinguished from normal fibroblasts 
by the expression of α-smooth muscle actin (αSMA).  
 
Loss of CAV1 in mammary fibroblasts has been linked to the upregulation of 
fibroblastic αSMA (Sotgia et al., 2009), and the induction of EMT in mammary 
epithelial cells (Simpkins et al., 2012; Sotgia et al., 2009). CAV1 knockout mammary 
fibroblasts secrete the EMT-inducing hepatocyte growth factor (HGF), and 
conditioned medium from CAV1 knockout mammary fibroblasts induces the 
expression of αSMA in mammary epithelial cells (Sotgia et al., 2009). Similarly, 
treatment with conditioned medium from immortalised breast fibroblasts transfected 
with CAV1 siRNA enhances the invasiveness of breast cancer cells (Simpkins et al., 
2012). 
 
PMC42-LA breast cancer cells 
The breast cancer cell line PMC42 is a heterogeneous cell line with cancer stem cell 
properties that has been shown to have the capacity to develop into eight distinct 
morphologic subtypes in culture (Whitehead et al., 1983). The PMC42-derived cell 
line PMC42-LA is a stable variant in which only 5-10% of the cells express vimentin, 
compared to 100% of PMC42 cells (Ackland et al., 2003). The cell line PMC42-LA 
has been shown to be inducible to EMT, and is an excellent cell culture model for the 
investigation of the relationship between fibroblastic CAV1 and breast cancer EMT 
(Ackland et al., 2003; Lebret et al., 2007). 
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Aims 
The main aim of this study was to investigate the effect of decreased fibroblastic 
CAV1 levels on EMT and cancer stem cell populations in breast cancer cells. 
 
The specific aims were: 
 
• To reduce fibroblastic CAV1 levels through transfection with CAV1 siRNA. 
 
• To investigate the effect of conditioned medium from CAV1 siRNA-transfected 
breast fibroblasts on the expression of EMT markers E-cadherin and vimentin in 
PMC42-LA breast cancer cells. 
 
• To investigate the effect of conditioned medium from CAV1 siRNA-transfected 
breast fibroblasts on the expression of cancer stem cell markers CD24 and CD44 in 
PMC42-LA breast cancer cells. 
 
Results 
To investigate the effect of CAV1 downregulation in fibroblasts on the expression of 
EMT markers by PMC42-LA breast cancer cells, Fre85 primary human breast 
fibroblasts were transfected with CAV1 siRNA, and PMC42-LA cells were cultured 
in the presence of conditioned medium from these CAV1 siRNA-transfected 
fibroblasts.  
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Transfection of primary human breast fibroblasts with CAV1 siRNA 
The optimal concentration of CAV1 siRNA, and optimal exposure time to CAV1 
siRNA, were determined by measuring CAV1 protein levels in transfected Fre85 
cells. After 24 hours of treatment with 25 nM CAV1 siRNA, fibroblastic CAV1 
protein levels were 0.45 ± 0.09 fold the control (Fig. 1A). Exposure to a lower 
concentration of CAV1 siRNA (15 nM) did not results in fibroblastic CAV1 levels 
that were lower than control levels (Fig. 1A). CAV1 protein levels were at control 
levels 48 hours after transfection with both 15 nM and 25 nM CAV1 siRNA, and after 
72 hours CAV1 protein levels in the transfection samples were 4-5 fold the control 
(Fig. 2, data from 2 independent experiments). 
 
 
Figure 1: Transfection of Fre85 primary human breast fibroblasts with CAV1 siRNA 
for 24 hours. Samples were collected 24 hours after transfection. Results are relative to the 
transfection reagent-only control. Error bars represent the standard error of the mean. (A) 
Western analysis of CAV1 protein levels, relative to total protein levels, as detected by 
Ponceau staining. CAV1 levels were lower after transfection with 25 nM CAV1 siRNA, but 
not with 15 nM CAV1 siRNA. Results are representative of 3 independent experiments. (B) 
Representative Western analysis image. β-actin is shown as a loading control. Fre=Fre85 
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Figure 2: Transfection of Fre85 primary human breast fibroblasts with CAV1 siRNA 
for 48-72 hours. Samples were collected 48 and 72 hours after transfection. Results are 
relative to the transfection reagent-only control. Error bars represent the standard error of the 
mean. (A) Western analysis of CAV1 protein levels, relative to total protein levels, as 
detected by Ponceau staining. No significant changes in average CAV1 levels were detected 
48 hours after transfection with 15 nM CAV1 siRNA, or 25 nM CAV1 siRNA. Results are 
representative of 2 independent experiments. (B) Western analysis of CAV1 protein levels, 
relative to total protein levels, as detected by Ponceau staining. Average CAV1 levels were 4-
5 fold the control levels 72 hours after transfection with 15 nM CAV1 siRNA, or 25 nM 
CAV1 siRNA. Results are representative of 2 independent experiments. (C) Representative 
Western analysis image. β-actin is shown as a loading control. Fre=Fre85 
 
The expression of αSMA by transfected fibroblasts 
After CAV1 siRNA transfection, Fre85 fibroblasts were evaluated for αSMA protein 
expression, as a cancer-associated fibroblast marker. The fibroblasts showed no 
significant changes in expression of αSMA protein at 24 hours after transfection with 
CAV1 siRNA (Fig. 3A,B). In addition, no significant changes in αSMA protein levels 
were detected 48 hours and 72 hours after transfection with CAV1 siRNA (data not 
shown). 
 
	 198	
Figure 3: αSMA levels after transfection of Fre85 primary human breast fibroblasts 
with CAV1 siRNA. Samples were collected 24 hours after transfection. Results are relative 
to the transfection reagent-only control. Error bars represent the standard error of the mean. 
(A) Western analysis of α-smooth muscle actin (αSMA) protein levels, relative to total 
protein levels, as detected by Ponceau staining. No change in αSMA levels was detected. 
Results are representative of 3 independent experiments. (B) Representative Western analysis 
image. Fre=Fre85 
 
The treatment of PMC42-LA with conditioned medium from transfected 
fibroblasts 
Conditioned medium was collected from Fre85 cultures, after 24 hours of 25 nM 
CAV1 siRNA treatment, and used to treat PMC42-LA breast cancer cells. After 
treatment with conditioned medium, the PMC42-LA breast cancer cells were 
evaluated for several EMT markers. The conditioned medium used, came from Fre85 
fibroblasts that showed CAV1 protein expression of 0.72 ± 0.05 fold the control (Fig. 
4A, p<0.05). After 7 days of treatment with transfection conditioned medium, E-
cadherin protein expression in PMC42-LA breast cancer cells was 0.49 ± 0.07 fold 
control (Fig. 4B, p<0.05), vimentin protein expression was 1.51 ± 0.12 fold control 
(Fig. 4C, p<0.05) and αSMA protein expression was similar to the control levels (data 
not shown). The evaluation of E-cadherin and vimentin protein levels in PMC42-LA 
after 3 days of treatment with conditioned medium from CAV1 siRNA-transfected 
fibroblasts showed similar results to 7-day treatments (data not shown). 
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Figure 4: PMC42-LA human breast cancer cells were cultured with conditioned 
medium (CM) from CAV1 siRNA-transfected human primary breast fibroblasts. 
Results are relative to the transfection reagent-only control. Error bars represent the standard 
error of the mean. * p<0.05  (A) Western analysis of CAV1 protein levels, relative to total 
protein levels, as detected by Ponceau staining. Fibroblastic CAV1 levels were significantly 
lower after transfection with 25 nM CAV1 siRNA. Results are representative of 3 
independent experiments. (B) Western analysis of E-cadherin protein levels, relative to total 
protein levels, as detected by Ponceau staining. E-cadherin levels in PMC42-LA were 
significantly lower after treatment with CM from CAV1 siRNA-transfected fibroblasts. 
Results are representative of 3 independent experiments. (C) Western analysis of vimentin 
protein levels, relative to total protein levels, as detected by Ponceau staining. Vimentin levels 
in PMC42-LA were significantly higher after treatment with CM from CAV1 siRNA-
transfected fibroblasts. Results are representative of 3 independent experiments. (D) 
Representative Western analysis image. β-actin is shown as a loading control. 
 
In addition to the evaluation of EMT markers, PMC42-LA cells were also evaluated 
for the expression of cancer stem cell markers CD44 and CD24. PMC42-LA cells 
were treated with conditioned medium from CAV1 siRNA-transfected Fre85 
fibroblasts, and their CD44/CD24 status was determined using flow cytometry. No 
changes in the percentage of CD44+/CD24- cells, as part of the PMC42-LA cell 
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population, were observed after 3-day treatment with conditioned medium from Fre85 
cells transfected with CAV1 siRNA, compared to PMC42-LA cells treated with 
control conditioned medium (Fig. 5A-C). No changes in the percentage of 
CD44+/CD24- cells, as part of the PMC42-LA cell population, were observed after 7-
day treatment with conditioned medium from Fre85 cells transfected with CAV1 
siRNA, compared to PMC42-LA cells treated with control conditioned medium (Fig. 
5D-F).  
 
Figure 5: Flow cytometric analysis of PMC42-LA human breast cancer cells cultured 
with conditioned medium (CM) from CAV1 siRNA-transfected human primary breast 
fibroblasts. Cells were stained with CD24-PE and CD44-FITC antibodies. (A) Flow 
cytometric analysis of PMC42-LA after 3-day treatment with CM from control Fre85 cells.  
(B) Flow cytometric analysis of PMC42-LA after 3-day treatment with CM from Fre85 cells 
transfected with non-targeting siRNA.  (C) Flow cytometric analysis of PMC42-LA after 3-
day treatment with CM from Fre85 cells transfected with CAV1 siRNA. (D) Flow cytometric 
analysis of PMC42-LA after 7-day treatment with CM from control Fre85 cells.  (E) Flow 
cytometric analysis of PMC42-LA after 7-day treatment with CM from Fre85 cells 
transfected with non-targeting siRNA. (F) Flow cytometric analysis of PMC42-LA after 7-
day treatment with CM from Fre85 cells transfected with CAV1 siRNA.  
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Optimization and controls 
To ensure that the effects measured in PMC42-LA cells were due to a reduction in 
fibroblastic CAV1 expression, rather than to the transfection procedure, a control 
sample was transfected with non-targeting siRNA. As can be seen in Fig. 6A, 
transfection with the non-targeting siRNA reduced CAV1 protein levels to a similar 
extent as CAV1 siRNA. Treatment of PMC42-LA with conditioned medium from 
these reduced CAV1 fibroblasts, transfected with non-targeting siRNA, resulted in 
epithelial E-cadherin and vimentin levels that were similar to those after treatment 
with medium from CAV1 siRNA-transfected fibroblasts (Fig. 6B,C). These results 
are based on two independent experiments for CAV1 and vimentin protein levels, and 
a single experiment for E-cadherin protein levels. 
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Figure 6: PMC42-LA human breast cancer cells were cultured with conditioned 
medium (CM) from CAV1 siRNA-transfected human primary breast fibroblasts and 
non-targeting siRNA-transfected human primary breast fibroblasts. Results are relative 
to the transfection reagent-only control. Error bars represent the standard error of the mean. 
(A) Western analysis of CAV1 protein levels, relative to total protein levels, as detected by 
Ponceau staining. Results are representative of 2 independent experiments. (B) Western 
analysis of E-cadherin protein levels, relative to total protein levels, as detected by Ponceau 
staining. Results are representative of 1 experiment. (C) Western analysis of vimentin protein 
levels, relative to total protein levels, as detected by Ponceau staining. Results are 
representative of 2 independent experiments. (D) Representative Western analysis image. 
Calnexin is shown as a loading control.  
 
An alternative non-targeting siRNA from a different manufacturer (GE Dharmacon, 
Lafayette, CO, USA) was tested. Transfection with the Dharmacon non-targeting 
siRNA resulted in unstable CAV1 protein levels (Fig. 7C,D, single experiment), 
however CAV1 mRNA levels were closer to control levels (Fig. 7A,B, single 
experiment). In addition, Figure 8A and Figure 8B show an effect of transfection with 
Dharmacon non-targeting siRNA on fibroblastic CAV1 protein, but not mRNA levels 
(single experiment).  
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To investigate whether the transfection efficiency could be improved, a different 
transfection reagent was tested. CAV1 mRNA and protein levels were compared after 
transfection with CAV1 siRNA, using siPORT transfection reagent from Ambion, 
and RNAiMAX transfection reagent from LifeTechnologies. CAV1 mRNA and 
protein levels were strongly reduced after transfection with CAV1 siRNA when using 
the RNAiMAX transfection reagent (Fig. 7B,D, single experiment), but not when 
using the siPORT transfection reagent (Fig. 7A,C, single experiment).  
 
Figure 7: Transfection of primary human breast fibroblasts (Fre85), using siPORT and 
RNAiMAX transfection reagents. Error bars represent the standard deviation. (A) CAV1 
and lamin mRNA levels, relative to GAPDH levels, were detected using qRT-PCR. Results 
are representative of 1 experiment. (B) CAV1 and lamin mRNA levels, relative to GAPDH 
levels, were detected using qRT-PCR. Results are representative of 1 experiment. (C) 
Western analysis of CAV1 protein levels, relative to total protein levels, as detected by 
Ponceau staining. Results are representative of 1 experiment. (D) Western analysis of CAV1 
protein levels, relative to total protein levels, as detected by Ponceau staining. Results are 
representative of 1 experiment.  
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The RNAiMAX transfection reagent, and non-targeting and CAV1 siRNAs from 
Dharmacon, were used to generate conditioned medium from CAV1 siRNA-
transfected fibroblasts. This conditioned medium was used to treat PMC42-LA cells. 
The transfection of Fre85 fibroblasts with CAV1 siRNA resulted in a strong reduction 
in CAV1 mRNA (Fig. 8A), but a very small reduction in CAV1 protein levels (Fig. 
8B). After treatment of PMC42-LA with conditioned medium from CAV1 siRNA-
transfected fibroblasts, vimentin protein levels were 2.71 ± 1.11 fold control (Fig. 
8C).  
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Figure 8: PMC42-LA human breast cancer cells were cultured with conditioned 
medium (CM) from CAV1 siRNA-transfected human primary breast fibroblasts and 
non-targeting siRNA-transfected human primary breast fibroblasts, using Dharmacon 
transfection reagent and siRNAs. Results are relative to the transfection reagent-only 
control. (A) CAV1 and lamin mRNA levels, relative to GAPDH levels, were detected using 
qRT-PCR. Results are representative of 1 experiment. Error bars represent the standard 
deviation. (B) Western analysis of CAV1 protein levels, relative to total protein levels, as 
detected by Ponceau staining. Results are representative of 1 experiment. (C) Western 
analysis of vimentin protein levels, relative to total protein levels, as detected by Ponceau 
staining. No significant difference between treatment with control CM and CM from non-
targeting siRNA- and CAV1 siRNA-transfected fibroblasts was detected. Results are 
representative of 4 independent experiments. Error bars represent the standard error of the 
mean. (D) Representative Western analysis image. β-actin is shown as a loading control.  
 
Discussion 
EMT plays an important part in the progression of cancer from the in situ tumour to 
cancer metastasis (McCuaig et al., 2016). This study shows that the treatment of 
PMC42-LA breast cancer cells with conditioned medium from CAV1 siRNA-
transfected Fre85 primary fibroblasts results in lower E-cadherin, and higher 
vimentin, protein levels in PMC42-LA cells. The reduction of E-cadherin expression, 
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and the increase of vimentin expression, are considered markers of epithelial-to-
mesenchymal transition (EMT) (Mani et al., 2008).  
 
Cancer-associated fibroblasts play a well-described role in cancer progression, 
including the promotion of EMT (Zeisberg et al., 2007). Studies have shown that 
CAFs isolated from patient breast cancer tumours induce EMT in cancer cells, 
through secreted factors, in vitro. Breast cancer cells cultured in conditioned medium 
from patient CAFs grown in culture, showed increased expression of EMT markers, 
and greater migration and invasion (Lebret et al., 2007; Soon et al., 2013; Yu et al., 
2014). The effect of conditioned medium from CAV1 siRNA-transfected Fre85 
fibroblasts on PMC42-LA breast cancer cells presented in this chapter suggests that 
CAV1 plays a role in the CAF-driven induction of EMT in breast cancer cells.  
 
The effect of conditioned medium on EMT and cancer stem cell markers 
While the treatment of PMC42-LA with conditioned medium from transfected Fre85 
led to the increase of the mesenchymal marker vimentin, and the decrease of the 
epithelial marker E-cadherin, no changes in the cancer stem cell markers 
CD44+/CD24- were detected in the cancer cell population. Mesenchymal cancer stem 
cells express high levels of CD44, and low levels of CD24, in addition to increased 
levels of vimentin, and decreased levels of E-cadherin, compared to other cell 
populations (Liu et al., 2014b).  
 
The cell line PMC42 consists of a heterogeneous cell population, with multiple 
subpopulations that are distinguishable based on morphology, and the expression of 
markers (e.g., vimentin) (Ackland et al., 2003). This heterogeneity suggest that 
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PMC42 may be derived from a cancer stem cell origin, or has acquired stem cell 
properties (Hugo et al., 2007). PMC42-LA cells showed no increase in cell numbers 
expressing high levels of CD44, and low levels of CD24, after treatment with 
conditioned medium from CAV1 siRNA-transfected Fre85. These results suggest that 
the increased vimentin levels, and decreased E-cadherin levels, in PMC42-LA, after 
treatment with CAV1 siRNA-transfected Fre85 conditioned medium, are not linked to 
an increase in the population of cancer stem cells. However, it is possible that an 
effect on CD24 and CD44 expression levels was not measurable due to the 
conditioned medium, used for the treatment of PMC42-LA, originating from 
fibroblasts that only showed a small reduction in CAV1 protein levels. 
 
The expression of αSMA by CAV1 siRNA-transfected primary human breast 
fibroblasts 
The most commonly used marker used to distinguish different fibroblast populations 
in the tumour microenvironment is α-smooth muscle actin (αSMA) (Drake and 
Macleod, 2014). Fre85 fibroblasts did not show altered αSMA protein levels after 
transfection with CAV1 siRNA. This may suggest that the knockdown of CAV1 
alone is not sufficient to induce a CAF phenotype in Fre85 fibroblasts.  
 
These results are in contrast to others, who have found αSMA expression to be higher 
in immortalised skin fibroblasts transfected with CAV1 siRNA (Martinez-Outschoorn 
et al., 2010b). However, Goetz et al. (2011) found lower αSMA levels in MEFS from 
CAV1 knockout mice compared to WT mice. Although the study by Goetz et al. 
(2011) also found that higher CAV1 expression in fibroblasts is positively related to 
tumour growth and metastasis, and this further confirms the relationship between 
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αSMA and CAF-like properties, these results do show that the relationship between 
CAV1 expression and αSMA expression is still unclear. Additionally, the 
aforementioned studies investigated αSMA levels in CAV1 knockdown/knockout 
fibroblasts from human skin and mouse embryos, while this study used primary 
human breast fibroblasts. Therefore, the discrepancies could also be explained by 
different fibroblast sources being studied. 
 
Although there is a strong relationship between αSMA expression and CAF-like 
properties, not all CAFs display increased αSMA expression. A study by Sugimoto et 
al. (2006) on mesenchymal markers expressed in tumours originating from the 
inoculation of mouse mammary fat pads with human breast cancer cells, showed that 
CAFs are a heterogeneous cell population, and not all CAFs express αSMA. The 
transfection of primary human fibroblasts with CAV1 siRNA resulted in a small 
reduction in CAV1 protein levels. The absence of changes in fibroblastic αSMA 
expression after transfection with CAV1 siRNA can, therefore, be due to low 
transfection efficiency. It is, however, also possible that the transfected fibroblasts 
displayed CAF-like properties without an increase in αSMA expression. 
 
The transfection efficiency of primary human breast fibroblasts with CAV1 
siRNA 
The knockdown of genes by transfection with siRNA can have significant off-target 
effects. These effects include the unintentional miRNA-like regulation of genes, and 
the triggering of innate immune responses, through proinflammatory sequences in 
siRNAs binding to toll-like receptors (Jackson and Linsley, 2010). A recommended 
control, to distinguish sequence-specific from non-specific effects of transfection with 
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siRNAs, is the inclusion of a non-coding siRNA in the transfections. This study used 
non-targeting siRNA from two different manufacturers as a control in the generation 
of conditioned medium from transfected fibroblasts. 
 
When the expression of E-cadherin and vimentin in PMC42-LA treated with 
conditioned medium from CAV1 siRNA-transfected Fre85 was evaluated against 
PMC42-LA treated with conditioned medium from non-targeting siRNA-transfected 
Fre85, no changes were observed. This would suggest that the changes in E-cadherin 
and vimentin expression described in this study are a result from the transfection 
procedure in general, rather than from a specific reduction in CAV1 levels by 
transfection with CAV1 siRNA. However, when CAV1 levels were evaluated in non-
targeting siRNA-transfected Fre85 cells, CAV1 protein levels were reduced to levels 
similar to those in CAV1 siRNA-transfected Fre85 cells, while CAV1 mRNA levels 
were unaffected. It is therefore unclear whether the changes in E-cadherin and 
vimentin expression found in the non-targeting control samples were due to off-target 
effects from transfection, or due to reduced CAV1 protein levels.  
 
To address the potential miRNA-like, and immunological off-target effects, described 
above, the inclusion of a non-targeting control alone is insufficient. The CAV1 
siRNA sequence used could potentially elicit miRNA-like regulation of genes, as well 
as contain proinflammatory sequences, while the non-targeting siRNA sequence does 
not. Additionally, several commercially available non-targeting siRNAs were shown 
to alter cytokine profiles and the inflammatory response in human fibroblasts (Baum 
et al., 2010). Therefore, care should be taken with the selection of controls for 
transfection experiments. Evidence that reintroduction of CAV1 after transfection 
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would reverse changes in E-cadherin and vimentin expression in PMC42-LA cells 
treated with conditioned medium, would address these concerns, and should be 
evaluated in future experiments. 
 
Primary cell lines can be more resistant to transfection than continuous cell lines (Liu 
et al., 2007). The transfection of the primary human fibroblasts Fre85 with CAV1 
siRNA resulted in a relatively small, and inconsistent, reduction in CAV1 protein 
levels. The CAV1 protein levels in the transfected Fre85 fibroblasts were on average 
26% lower than the control. In order to optimise the transfection efficiency, different 
concentrations of CAV1 siRNA from different manufacturers were tested. CAV1 
siRNA from both Santa Cruz Biotechnology (Dallas, TX, USA) and GE Dharmacon 
(Lafayette, CO, USA) resulted in strong CAV1 mRNA reductions, but variable CAV1 
protein reductions.  
 
In addition to different sources of CAV1 siRNA, different sources of transfection 
reagent were tested. A direct comparison of siPORT transfection reagent (Thermo 
Fisher Scientific, Waltham, MA, USA) with RNAiMAX transfection reagent 
(Thermo Fisher Scientific, Waltham, MA, USA) found a stronger transfection 
efficiency, measured by CAV1 protein reduction, after the use of RNAiMAX. 
However, subsequent transfections using RNAiMAX continued to show variable 
transfection efficiency, when CAV1 protein levels were evaluated. 
 
The primary human fibroblasts showed a strong increase in CAV1 protein levels, 
following an initial decrease, after transfection with CAV1 siRNA. CAV1 protein 
levels returned to control levels, 48 hours after transfection, and after 72 hours CAV1 
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protein levels were 4-5 times fold control levels. The cell often maintains the 
expression of essential proteins, through a negative feedback mechanism. This 
feedback can be mediated by mRNA levels or by protein levels. The presence of a 
particular protein can inhibit the transcription, or translation, of its corresponding 
gene and mRNA and, similarly, the presence of transcripts from a particular gene can 
inhibit further transcription, or translation, of that gene and transcript (Singh, 2011). 
The reduction of mRNA or protein levels can relieve that inhibition, and result in 
increased transcription, or translation, of the target. Another regulatory response the 
cell can utilise to maintain stable levels of essential proteins, is enhancing mRNA or 
protein stability, when transcription or translation is impaired (Nguyen et al., 2003; 
Schwanhäusser et al., 2011).  
 
The recovery of CAV1 protein levels, 72 hours after CAV1 siRNA transfection, that 
was seen in this study, may indicate the presence of one or more of these regulatory 
mechanisms, and, as such, the importance of maintaining CAV1 protein levels in the 
cell. Likewise, the variable transfection efficiency of the primary human breast 
fibroblast with CAV1 siRNA may be due to a need of these cells to maintain CAV1 
protein levels.  
 
Conclusion 
In conclusion, the results in this study indicate that the treatment of PMC42-LA cells 
with conditioned medium from Fre85 fibroblasts that express lower levels of CAV1 
protein results in increased vimentin, and decreased E-cadherin protein expression. 
These preliminary findings suggest that the loss of CAV1 in fibroblasts may play a 
role in EMT in breast cancer cells. An increase in the transfection efficiency of 
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primary human fibroblasts with CAV1 siRNA is likely needed to properly measure 
the markers, and functional effects, of EMT, after treatment with conditioned medium 
from transfected fibroblasts. Further research is needed to rule out that off-target 
effects are responsible for the results presented in this study. To confirm whether 
fibroblastic CAV1 plays a role in driving breast cancer cell EMT, further markers of 
EMT, including measurements of cell proliferation and motility, will need to be 
evaluated.  
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Chapter 7: Summaries and conclusions 
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The data presented in this thesis contributes to the understanding of the role of 
caveolin-1 (CAV1) in the breast cancer microenvironment.  
 
CAV1 is a structural protein of caveolae, which are cup- or bulb-shaped invaginations 
of the cell membrane (Schlormann et al., 2010). Caveolae play a role in endocytosis, 
cellular signalling, cholesterol homeostasis, and mechanosensing (Parton and del 
Pozo, 2013).  
 
The role of CAV1 in breast cancer is complex. CAV1 overexpression was found to be 
correlated with the particularly aggressive basal-like breast cancer phenotype in some 
studies (Pinilla et al., 2009; Savage et al., 2007), while others have found that the 
expression of CAV1 by breast cancer cell lines was associated with reduced 
proliferation (Lee et al., 1998), and that the absence of CAV1 expression resulted in 
increased tumour burden and metastasis in a CAV1 -/- mouse model (Williams et al., 
2004). 
 
In recent years, the importance of the role of the tumour microenvironment in cancer 
progression has become clear. During the progression of cancer, the 
microenvironment undergoes many changes, including the remodelling of the 
extracellular matrix (ECM), the recruitment of immune cells, the presence of stromal 
cells with a cancer-associated phenotype, and the secretion of growth factors and 
cytokines (Bissell and Hines, 2011). Two important cell types that are well-studied 
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components of the tumour microenvironment are cancer-associated fibroblasts and 
tumour-associated macrophages (Kalluri, 2016; Williams et al., 2016). 
 
Similar to the role of CAV1 expression in breast cancer cells, the role of CAV1 in the 
tumour microenvironment appears dichotomous. The evaluation of CAV1 expression 
in breast cancer patient biopsies has shown a correlation between the loss of stromal 
CAV1 expression, and reduced progression-free survival (El-Gendi et al., 2012; Sloan 
et al., 2009; Witkiewicz et al., 2009b). A study that specifically evaluated CAV1 
expression in fibroblasts from breast cancer patient biopsies, confirmed the findings 
of the aforementioned studies, and pointed to cancer-associated fibroblasts (CAFs) as 
a key player (Simpkins et al., 2012). Additionally, the co-injection of CAV1-deficient 
fibroblasts and human breast cancer cells into nude mice has been shown to lead to 
increased tumour mass and angiogenesis, compared to co-injection of breast cancer 
cells with normal fibroblasts (Bonuccelli et al., 2010). 
 
In an apparent contradiction to the findings that the loss of CAV1 expression in the 
tumour microenvironment is correlated with unfavourable prognostic outcomes for 
breast cancer patients, others have found that an increased expression of CAV1 in 
CAFs in biopsies of breast tumours was associated with an increased mortality risk 
for breast cancer patients (Goetz et al., 2011). In support of their findings in patient 
biopsies, Goetz et al. (2011) reported that CAV1-expressing mouse embryonic 
fibroblasts (MEFs) generated an ECM, in vitro, that displayed the parallel alignment 
of fibres and increased matrix stiffness that is characteristic of a tumour stroma.   
	 216	
In addition to the controversy around the role of CAV1 in breast cancer, the 
mechanisms that result in altered CAV1 expression in CAFs are not clear. The first 
aim of this thesis was to investigate whether the co-culture of fibroblasts with cancer 
cells results in altered CAV1 expression by fibroblasts. The data presented in this 
thesis show that the co-culture of primary human breast fibroblasts Fre85 with human 
breast cancer cells does not result in significantly altered fibroblastic CAV1 
expression. Primary human breast fibroblasts Fre85 were cultured with the mildly 
invasive and the highly invasive human breast cancer cell lines MCF7 and MDA-MB-
231, respectively, in a non-contact, and a contact, co-culture system. Neither non-
contact co-culture, nor contact co-culture, resulted in significant changes in 
fibroblastic CAV1 mRNA or protein levels. In addition, the non-contact, and contact, 
co-culture of immortalised human skin fibroblasts hTERT-BJ with human breast 
cancer cells MCF7 did not result in altered fibroblastic CAV1 mRNA or protein 
levels. 
 
A study by Martinez-Outschoorn et al. (2010b), found that the contact co-culture of 
immortalised human skin fibroblasts hTERT-BJ with MCF7 breast cancer cells 
resulted in reduced fibroblastic CAV1 protein levels, in the absence of significant 
changes in fibroblastic CAV1 mRNA levels. These findings do not correspond with 
the data presented in this thesis. An important difference between the findings 
presented by Martinez-Outschoorn et al. (2010b), and the findings presented in this 
thesis, is the methods used to evaluate CAV1 expression. Martinez-Outschoorn et al. 
(2010b) evaluated CAV1 protein expression in immuno-labelled co-cultures by 
confocal microscopy only, whereas the CAV1 protein data presented in this thesis are 
primarily based on Western analysis. However, the confocal analysis of immuno-
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labelled contact co-cultures of hTERT-BJ fibroblasts with MCF7 breast cancer cells 
(Chapter 3, Fig. 4) corresponded with the results obtained with Western analysis. This 
suggests that changes in fibroblastic CAV1 expression after co-culture with breast 
cancer cells are context dependent, and not easily replicated from one culture system, 
or one laboratory, to another. 
 
As the co-culture of fibroblasts with breast cancer cells alone did not result in 
consistently and significantly altered CAV1 levels, a potential role for differentiated 
monocytes was investigated. The data presented in this thesis show for the first time 
that the addition of differentiated monocytes to non-contact co-cultures of primary 
human fibroblasts Fre85 and human breast cancer cells MDA-MB-231 reduces 
fibroblastic CAV1 mRNA and protein levels. In addition, the contact co-culture of 
primary human breast fibroblasts Fre85 with human monocytes THP-1 alone resulted 
in a reduction of fibroblastic CAV1 protein levels. 
 
Macrophages are an important part of the tumour microenvironment (Mantovani and 
Sica, 2010). Tumour-associated macrophages (TAMs) secrete a plethora of cytokines, 
and the crosstalk between TAMs and cancer cells, and between TAMs and CAFs, 
plays an important role in tumorigenesis (Comito et al., 2014; Su et al., 2014). It is 
possible that the reduction in fibroblastic CAV1 levels seen in tissue biopsies from 
breast cancer patients is in part due to the recruitment of macrophages to the tumour 
site. Further research is required to evaluate the role of macrophages in the regulation 
of fibroblastic CAV1 levels, in vivo.   
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The observation that non-contact co-culture of fibroblasts with breast cancer cells and 
differentiated monocytes lowered fibroblastic CAV1 levels, points to the involvement 
of a secreted factor in the regulation of CAV1 expression by fibroblasts. This thesis 
aimed to investigate the secretion of cytokines by co-cultures of fibroblasts, breast 
cancer cells and (differentiated) monocytes. A cytokine assay on conditioned medium 
from non-contact, and contact, co-cultures of Fre85 fibroblasts, MDA-MB-231 breast 
cancer cells, and TPA-treated THP1 cells, showed markedly different cytokine 
responses between monoculture controls, and co-cultures of fibroblasts with cancer 
cells, fibroblasts with differentiated monocytes, and fibroblasts with cancer cells and 
differentiated monocytes. The inclusion of differentiated monocytes in a fibroblast 
and cancer cell co-culture resulted in a more CAF-like response of the fibroblasts, 
compared to fibroblast and cancer cell co-culture alone. In addition, the inclusion of 
differentiated monocytes resulted in increased levels of cytokines that have been 
previously implicated in the regulation of CAV1. The data presented in this thesis 
provides several cytokine candidates that need to be investigated further, for a 
potential role in the regulation of CAV1 expression by CAFs. 
 
Studies have shown that a lower CAV1 level in CAFs affects multiple aspects related 
to cancer progression, including tumour growth, angiogenesis, and epithelial-to-
mesenchymal transition (EMT) (Bonuccelli et al., 2010; Simpkins et al., 2012). This 
thesis aimed to investigate the role of fibroblastic CAV1 in breast cancer cell EMT, 
through the treatment of breast cancer cells with conditioned medium from CAV1 
siRNA-transfected fibroblasts. The breast carcinoma cell line PMC42-LA has been 
shown to be inducible to EMT (Ackland et al., 2003), and is an excellent cell culture 
model for the investigation of the role of fibroblastic CAV1 levels in cancer cell 
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EMT. The data presented in this thesis show that treatment of PMC42-LA cells with 
conditioned medium from Fre85 fibroblasts transfected with CAV1 siRNA results in 
increased vimentin protein levels and reduced E-cadherin protein levels, important 
markers of EMT. However, changes in the expression of cancer stem cell markers 
CD24 and CD44 were not detected.  
 
Fre85 fibroblasts were highly resistant to transfection with CAV1 siRNA, and 
significant reductions in CAV1 protein levels were not consistently achieved. 
Remarkably, increased CAV1 protein levels, 72 hours after transfection, followed an 
initial decrease in CAV1 protein levels, 24 hours after transfection. In addition, non-
targeting siRNA affected fibroblastic CAV1 protein levels, and vimentin levels in 
PMC42-LA cells treated with conditioned medium from fibroblasts transfected with 
CAV1 siRNA were not significantly different from PMC42-LA cells treated with 
conditioned medium from fibroblasts transfected with non-targeting siRNA. 
Therefore, technical limitations hindered the thorough investigation of the role of 
fibroblastic CAV1 in breast cancer cell EMT. 
 
The data presented in this thesis show significant variability in fibroblastic CAV1 
levels between experiments. Several factors that could contribute to variability in cell 
culture systems were investigated for a potential effect on fibroblastic CAV1 levels. 
The synchronisation of the cell cycle of the fibroblast population, by serum starvation 
prior to co-culture, did not result in a reduction in fibroblastic CAV1 protein level 
variability between replicates. The inclusion of Serum Replacement 1, a chemically 
defined, serum-free, cell culture additive, in lieu of foetal calf serum (FBS), did, 
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however, reduce the variability in fibroblastic CAV1 protein levels after co-culture 
with cancer cells and differentiated monocytes. 
 
FBS is a source of growth- and adhesion factors, hormones, lipids, and minerals, and 
has been identified as a contributing factor to challenges with the replication of cell 
culture experiments between different laboratories (Khodabukus and Baar, 2014). 
Although the same batch of FBS was used in all co-culture experiments described in 
this thesis, it is possible that variability in FBS composition, due to the labile nature of 
many of the components of FBS, contributed to variability in fibroblastic CAV1 
levels between experimental replicates. In addition, it is possible that FBS plays a role 
in the conflicting results from the hTERT-BJ and MCF7 contact co-cultures described 
in this thesis, and by Martinez-Outschoorn et al. (2010b). 
 
The elimination of FBS from the co-culture system resulted in reduced variability 
between replicates, and the non-contact co-culture of fibroblasts with differentiated 
monocytes, with or without cancer cells, resulted in a significant reduction in 
fibroblastic CAV1 levels (Chapter 4, Fig. 5), confirming the findings in previous 
chapters that implicated differentiated monocytes in fibroblastic CAV1 regulation.  
 
It is important to note, however, that the use of the same batch of Fre85 fibroblasts 
reduced CAV1 protein variability between experimental replicates, as is shown when 
comparing Fig. 7B and Fig. 9B in Chapter 2. Moreover, some batches of Fre85 
fibroblasts responded to co-culture with cancer cells by showing higher fibroblastic 
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CAV1 protein levels after co-culture at earlier passage number, while co-culture using 
the same cells at higher passage number resulted in lower fibroblastic CAV1 levels.  
 
Other studies have provided conflicting reports on the effect of fibroblast and cancer 
cell interactions on fibroblastic CAV1 expression, and the implications of altered 
fibroblastic CAV1 expression for the progression of cancer (Goetz et al., 2011; 
Martinez-Outschoorn et al., 2010b). The evaluation of CAV1 levels in CAFs from 11 
breast cancer patients showed a significant downregulation in 8 patients, and a 
significant upregulation of CAV1 in 2 patients (Mercier et al., 2008). The data 
presented in this thesis show that the effect of fibroblast and cancer cell interactions, 
in vitro, on fibroblastic CAV1 expression is dependent on many factors, including 
fibroblast origin, the presence of differentiated monocytes, and the use of serum in 
cell culture. In addition, the observation that fibroblasts from the same batch, cultured 
under the same conditions, appear to switch their response to co-culture with cancer 
cells from higher CAV1 expression to lower CAV1 expression, suggests that changes 
in the phenotype of the cells occurring over the culture period, for example epigenetic 
changes, may play a role in the regulation of fibroblastic CAV1 levels. Combined, the 
data presented in this thesis and the data reported by others show that the regulation of 
CAV1 expression by CAFs is highly complex and context dependent. Further 
research is required to untangle the regulatory mechanisms involved. Understanding 
the regulation of CAV1 expression in fibroblasts may provide novel therapeutic 
targets for the treatments of a subset of breast cancer patients.  
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